9TH ANNUAL EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION

SACHS ASSOCIATES

9th Annual

European Life Science CEO Forum & Exhibition

Partnering & Investing in Biotech & Pharma Industry

15th – 16th March 2016

Hilton Zurich Airport Hotel • Switzerland

Conference Guide

www.sachsforum.com

Welcome

SACHS ASSOCIATES

Sachs Associates are delighted to welcome you to the:

9th Annual

European Life Science CEO Forum & Exhibition

Partnering & Investing in Biotech & Pharma Industry

15th – 16th March 2016 • Hilton Zurich Airport Hotel • Switzerland

Sachs Associates are delighted to welcome you to the 9th Annual European Life Science CEO Forum & Exhibition for Partnering & Investing in Biotech & Pharma Industry. Following its success from previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This exclusive and transactional event compliments our Annual Biotech in Europe Investor Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry, feature presentations from Big Pharma representatives demonstrating their current and future partnering strategies through thought-provoking case studies.

This year's programme features a series of panels and presentations from leading investment, pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving Finance and M&A market, Partnering activity, Vaccines, Oncology and Biomedical Investment, and includes special keynote speeches, providing an expert outlook on Europe's Biotech industry. In addition, the event holds exclusive Partnering Workshop Presentations and more than 60 exclusive company presentations from an exciting and diverse range of publicly listed and private life science companies, looking to raise finance and/or find partners.

General Information

- The registration desk is open from 8am on both days although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.
- Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.
- **The one-to-one meetings are being held in the La Place A and B**. Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Request for Presentations

Please use the agenda to mark off presentations that you are interested in and email your request to silvia@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Events Diary

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on Silvia@sachsforum.com

SACHS ASSOCIATES

2nd Annual
Immuno-Oncology: BD&L and Investment Forum
3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

4th Annual
MedTech & Digital Health Forum
for Technology & Healthcare Innovation
26th September 2016 • Congress Center Basel • Switzerland

The programme is designed to highlight the latest industry developments and showcase emerging and innovative technology companies seeking finance and partnerships. The delegates are comprised of Healthcare, MedTech, Healthcare IT, and Digital Health companies as well as consultants, bankers and corporate & financial investors. We expect over 200 delegates and 25 presenting companies plus demos.

16th Annual
Biotech in Europe Forum
For Global Partnering & Investment
27th – 28th September 2016 • Congress Center Basel • Switzerland

The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's bio industry, this event will once again be covered by our regular media partners. We expect over **600 delegates** and **100 presenting companies**.

Speakers

Anja König, *Managing Director,* **Novartis Venture Fund**

Dr. Anja König is a Managing Director of the NVF in Basel, Switzerland. She is active in the UK, Switzerland and the rest of Europe. Prior to joining NVF, she was an Associate Partner at McKinsey and Company in New York, a global consultancy, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. She currently serves on the boards of Bicycle Therapeutics, F2G and Forendo Pharma and led the investments in Covagen (sold to J&J), Heptares (sold to Sosei) and Nabriva (NASDAQ: NBRV).

Anker Lundemose, *CEO,* **MISSION Therapeutics Ltd.**

Anker Lundemose, MD, PhD, DMSc in Medical Microbiology, has extensive experience from business and corporate development as well as R&D in key therapeutic areas including oncology, diabetes and anti-infectives. He has a broad international network and experience, and has led successful mergers and acquisitions within biotech, venture investments and licensing. His background includes biotech start-ups, large biotech and big pharma, as well as an initial career in academia.

Arthur Franken, *Partner,* **Gilde Healthcare**

Arthur Franken joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche) and ProQR Therapeutics (IPO on NASDAQ). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ) and Pieris. He represents Gilde on the boards of Levicept, Moximed and Symphogen. He served as a board member for FlowCardia, MTM Laboratories and ProQR Therapeutics until the trade sales or IPO. Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Bart de Witte, *Healthcare Industry Leader DACH,* **IBM**

Bart de Witte serves as Healthcare Industry Leader for DACH at IBM. Bart de Witte served as a Healthcare Executive, part of IBM's Global Healthcare Life Science Group since 2010. He serves as a guest lecturer for the University of Applied Sciences in Business Administration Zurich on digital health, and is a founder of the Austrian Quantified Self Organization. Bart de Witte is focused on the company's investments in the healthcare industry driving growth in Europe. In this role Bart de Witte led various initiatives, closely working with Ministries of Health and executives from Health Payers and Insurers. His current top priority is to stimulate innovation in the health sector, leveraging the company's developments around cognitive solutions.

Bart De Witte has over 17 years of experience in the digital health sector, and has been involved in leading edge technologies and new IT businesses, including intimate involvement as a mentor in the formation and growth of a dozen startups within the healthcare sector.

Bart De Witte is passionate on technology and data-driven transformation of healthcare systems. His industry topics of focus are healthcare transformation and disruption.

Bart de Witte holds degrees from different universities in Belgium and has followed several other post-university tracks at national and international business schools, including Harvard Business School.

Speakers

Beat Merz, *Managing Director,* **Rockport Venture Partners**

Dr. Merz is a Managing Director of Rockport Venture Securities and Head of European Equity. Dr. Merz brings 16 years of experience in venture and growth stage equity financing and operations to Rockport, including management and leadership of over $150 million in equity financing. Prior to joining Rockport, Dr. Merz was a Partner with Ares Life Sciences. Previously, he was responsible for venture and private equity investment management as Investment Adviser of HBM Partners. Prior to joining HBM Partners, he was Managing Director of NMT New Medical Technologies, where he provided capital, professional advisory services and start-up support for early-stage medical device companies. During his career he has directed investments in the US, Europe and Israel-domiciled companies as well as Board supervision for many of them. He currently serves or has served on the Board of Directors of Micrus Endovascular (acquired by JNJ), Thommen Medical (acquired by private investors), Asthmatx (acquired by BSX), Precimed (acquired by Greatbach), Devax (acquired by BioSensors), BioControl Medical, South Eastern Technologies (acquired by Autocam Medical), Mininavident and others. Dr. Merz holds a Ph.D. in bio mechanics from ETH Zurich/Switzerland and an MBA from the University of Strathclyde, Glasgow/UK.

Bill Blair, *Director of Company Creation,* **Sunergos Innovations**

Bill began his career in the pharmaceutical industry before moving into the financial world. He was a top rated investment analyst latterly at Nomura International where he headed up the number one team in the UK healthcare sector. He joined Scottish Widows Investment Partnership in 2001 as Head of European Research where he was responsible for its €5bn European equity portfolio. Subsequently, Bill established SWIP's £150m+ venture capital portfolio investing in the UK, Europe and the US. Investments included Arrow Therapeutics, Arakis, Ambrx, Cara, Radius Pharma, Albireo and Evotec. He has board experience in the UK, Europe and the US. Bill joined Edinburgh BioQuarter as Head of Company Creation in 2011 where he and his team established over 10 companies in the last four years and then spun out Sunergos Innovations from the University of Edinburgh in October 2015. Sunergos aims to become the key commercialisation partner for universities in the north of the UK building on its continuing relationship with Edinburgh.

Carina Schmidt, *CEO,* **Athera Biotechnologies AB**

Ms Schmidt has nearly 30 years industrial experience, mainly in business development and management, international marketing and product management within the life science area. During 15 years she has worked with Pharmacia Biotech/ Amersham Biosciences (now GE HealthCare). Later she founded Grasp Bioscience AB, where positions included management consultant, board director, interim CEO and business advisor to several biotech start-ups. She joined Athera as the CEO in 2007. Former board director of Genovis AB (public), a company that develops and sells unique enzymes that facilitate development and quality control of biological drugs. Currently she is a delegate of the investment committee in ALMI Invest region Norr, a state funded seed investor. Carina Schmidt holds a MSc Chem Eng from the Royal Institute of technology, Stockholm, Sweden.

Caroline Goddeeris, *Associate,* **Gimv**

Caroline Goddeeris joined Gimv in 2014. Prior to joining Gimv, Caroline worked at UCB Pharma in several operational and strategic roles: she was active within marketing and sales for the launch of Cimzia in The Netherlands and Belgium and was involved in several licensing and M&A deals for the mid-sized biopharma player. She played a key role in defining the development strategy of several preclinical immunology products and headed UCB's late stage portfolio management. Caroline is board observer within Complix and Multiplicom and is actively involved by the management of our portfolio company Eurocept.

Caroline holds a PhD in pharmaceutical sciences from the KULeuven (2008) as well as an MBA (2009) and a Master in Corporate Finance (2013) from Vlerick Business School.

Speakers

Chandra Leo, *Partner,* HBM Partners AG

Dr. Leo has more than 15 years of experience in venture capital, clinical practice and biomedical research. He is a member of the private equity team at HBM, a healthcare-focused investment group managing >USD 1 billion in assets. Dr. Leo is currently a board member at CardiacAssist, Delenex, Gynesonics, i-Optics and Symbiomix. He previously served as a board representative at Anthera Pharmaceuticals (IPO NASDAQ), ChemoCentryx (IPO NASDAQ), ESBATech (acquired by Alcon/ Novartis) and Panomics (acquired by Affymetrix). Moreover, he managed a strategic investment collaboration between HBM Partners and a US-based biopharmaceutical company. Dr. Leo completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD. His prior roles include working as a principal at Wellington Partners, as a physician at the University Hospital Leipzig and as a postdoctoral scientist at Stanford University.

Charles Bailey, *Head of Search & Evaluation, Neurosciences,* Novartis Pharma AG

Charles is responsible for new Neuroscience business development opportunities for Novartis Pharma. Charles has worked for over ten years in Pharmaceutical business development across several major Pharma companies and has been responsible for negotiating and closing several product and diagnostic deals as well as holding alliance management responsibility.

Chris Britten, *Managing Director,* Torreya Partners (Europe), LLP

Chris is a Managing Director at Torreya Partners, a leading global investment bank focused on facilitating partnerships, M&A transactions and financings in the pharmaceutical sector worldwide. He joined Torreya from Sanofi Pasteur-MSD where he had responsibility for all business and corporate development activities. He is also a Non-executive Director at Phico Therapeutics Ltd.

Prior to Sanofi Pasteur-MSD, Chris held positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Previously, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D. He holds a PhD in Biochemistry and an MBA in Finance.

Christian Lach, *Portfolio Manager,* Bellevue Asset Management AG

- Bellevue Asset Management– BB Adamant -Team – Lead Portfolio Manager –Since October 2014
- Adamant Biomedical Investments 2008-2014 – Senior Portfolio Manager Biotech
- Bellevue Asset Management – BB BIOTECH AG Team – 2001-2008

Education:
Dr. oec. HSG (phD in Innovations management)
lic.oec.HSG (MBA),
dipl.Natw.ETH (MSc Biochemistry)

Speakers

Christophe Bonny, *CSO,* **Bicycle Therapeutics Limited**

Dr Bonny has over 20 years' experience in the field of molecular biology and signalling pathways, has authored over 70 scientific publications and is an inventor on several patents. Dr Bonny discovered D-JNKi, a cell permeable peptide inhibitor of the JNK protein, which formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery; the molecule is the first intracellular peptide currently in Phase III clinical trials. Prior to joining Bicycle Therapeutics, Dr Bonny was CSO of Xigen SA and also served as its President. He also held the position of Head of Research of the Medical Genetics unit at the University of Lausanne Hospital (Centre Hospitalier Universitaire Vaudois, Switzerland) and a prior to this was a Research Fellow at Northwestern University (US). Dr Bonny obtained a PhD from the University of Neuchâtel (Switzerland), and completed a business and entrepreneurship program at Babson College (US).

Christoph Kausch, *CEO,* **MTIP MedTech Innovation Partners AG**

Christoph Kausch has a sound knowledge in strategic management and bringing innovations to market. Before founding MTIP, he led the global strategy department of Syngenta for several years. Prior to this, he was Managing Director at Hafiba AG, a boutique investment company, where he still is a member of the board of directors. He started his career at McKinsey & Company where he had specialized in private equity and life sciences. Christoph Kausch studied mechanical engineering at the TU Munich and at the Massachusetts Institute of Technology Management (MIT). He completed his PhD in innovation & technology management at the University of St. Gallen and at Harvard Business School.

Cynthia Lavoie, *General Partner,* **TVM Life Science Management, Inc.**

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and in excess of US$1.3bn under management. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals from Munich and Montreal.

Dr. Lavoie is responsible for deal making, deal origination and execution and for the management of portfolio companies. Dr. Lavoie has led investments into Montreal-based TVM companies Kaneq Bioscience and FAAH Pharma, where she serves on the Boards of Directors. Dr. Lavoie also serves on the board of Acer Therapeutics, located in Cambridge, MA.

Prior to TVM, Dr. Lavoie was with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She served on the boards of therapeutics and device companies including Cytochroma (sold to Opko Health) and Trillium Therapeutics (NASDAQ: TRIL). Dr. Lavoie also had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc. (now Fujifilm SonoSite). Previously, Dr. Lavoie was a marketing strategy consultant with drug/device developer Vasogen (merged with Intellipharmaceutics; NASDAQ: IPCI).

Dale Dhanoa, *CEO,* **AKAAL Pharma**

Dr. Dhanoa is experienced in drug design, discovery and development of novel therapeutics for the treatment of autoimmune and inflammatory diseases, cancer, cardiovascular and central nervous system diseases. Prior to joining Akaal Pharma as CEO, he held various leadership positions at Merck (USA), Synaptic Pharmaceuticals, Alanex Corp, 3-Dimensional Pharmaceuticals, Pharmacore, Predix Pharmaceuticals and INVENT Pharmaceuticals. Dr. Dhanoa was the Senior Vice President of R&D at Predix Pharmaceuticals. Prior to that, he was the EVP/CSO at PharmaCore, Executive Director at 3-D Pharmaceuticals (dddp/nasdaq, acquired by J&J), Director of Chemistry at Alanex (acquired by Agouron, now Pfizer), Associate Director of Medicinal Chemistry at Synaptic Pharma (snap/nasdaq, acquired by H. Lundbeck A/S). Under his R&D leadership at Predix, several new small molecule drug candidates were discovered in an unprecedented short period of time. Four of these novel clinical candidates advanced through Phase I, II and III clinical trials. A novel drug candidate for the treatment of Alzheimer's Disease, PRX-03140, was partnered with GlaxoSmithKline(GSK) for $1.2 Billion. The pipeline of novel and innovative drug candidates designed by Dr. Dhanoa and his team at Predix culminated in the raising of significant venture capital prior to its M&A with Epix Pharma (epix/nasdaq).

Speakers

Dan Gelvan, *Managing Director,* **Aurum Ventures MKI Ltd.**

Dr. Gelvan is the Managing Director of Life Sciences, Aurum Ventures M.K.I. Ltd. He is a seasoned life-science executive who, before joining Aurum Ventures, was the chief executive officer and president of GammaCan International, Inc., a development-stage pharmaceutical company. Previously, Dr. Gelvan founded and managed Zetiq Technologies, a drug discovery company specializing in cell-based high-throughput screening for novel anti-cancer drugs. Dr. Gelvan founded Zetiq after leaving a senior position in Clal (Israel) Ltd., one of Israel's largest holding conglomerates. Dr. Gelvan holds a B.A. and an M.A. in Economics from the Hebrew University of Jerusalem, Israel and a Ph.D. in Business Economics from Roskilde University in Denmark.

David Cassak, *Managing Partner,* **Innovation in Medtech, LLC**

David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover's monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.

Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his business partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter. While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.

David Colpman, *Director,* **Colpman Consulting Ltd.**

David Colpman joined Shire in 1999 and was instrumental in delivering the M&A and licensing strategy which has today created a company valued at $45Bn. Reporting to the CEO he led Business Development from 2012 until leaving Shire in August 2014. During that period the BD team greatly increased its productivity, leading to the acquisition of six companies and around 30 deals completed. Notable transactions included the $4.2bn acquisition of ViroPharma, together with acquisitions of Lumena, Sarcode and Fibrotech. On the technology side collaborations with ArgenX, Tigem and Sangamo stand out.

Earlier in his career at Shire he identified and led the acquisition of TKT which went on to become the cornerstone of Shire's successful rare disease business . He also in-licensed Lialda, which has become the sector leader in ulcerative colitis.

On leaving Shire David established Colpman Consulting Ltd which is delivering strategic BD advice to Biotech and Pharma sectors. Colpman Consulting led the out-licensing of Alligator AB's immuno-oncology agent, ADC 103, identifying Johnson and Johnson as the ideal partner and securing a $700m collaboration. David has also worked extensively in 2014/15 with Purdue Pharma as Interim Head of BD and advised numerous European Biotech's in partnering and sale discussions . In April 2015 he was appointed to the Board of Orexo AB.

David is a pharmacist by training and prior to joining Shire in 1999 headed Licensing and Alliances at Novo Nordisk in Denmark and spent two years in BD at Glaxo Wellcome UK. He formerly served on the Board of ACE Biosciences and is a longstanding advisor to Sunstone Capital

Speakers

David Malek, *VP Business Development,* **BioLineRx Ltd.**

David Malek has served as our Vice President of Business Development since October 2011. Prior to joining the Company, from 2006 to 2011 Mr. Malek served at Sanofi-Aventis in a number of management positions, including Marketing, Finance and Business Development. Most recently, he served as Director of Oncology - New Products and Business Development. Mr. Malek received an MBA from the Tuck Business School at Dartmouth University and a B.A. in statistics and political science from the University of Haifa.

David Reese, *President and CEO,* **Provista Diagnostics, Inc.**

David E. Reese, Ph.D. has served as our President and Chief Executive Officer and a member of our Board of Directors since 2011. Prior to joining Provista, Dr. Reese was the Managing Director of Brencourt Advisors, LLC, where he was responsible for managing all healthcare investments for their Multi-Strategy Fund and Event Driven Fund from 2008 to 2011. From 2005 to 2007, Dr. Reese worked for Yorkville Advisors, establishing their healthcare group focused on funding early stage biotechnology, medical device and diagnostic companies. Before joining Yorkville Advisors, Dr. Reese served as an Adjunct Professor at South Mountain College after completing his postdoctoral training as a National Institutes of Health sponsored fellow. Dr. Reese has authored and published numerous peer-reviewed scientific manuscripts and abstracts, as well as successfully received multiple rounds of grant funding. Dr. Reese received his Ph.D. in biochemistry from Vanderbilt University and his B.S. from Arizona State University.

Dieter Ziegler, *Director – Search and Evaluation Europe,* **AbbVie, Inc.**

Dieter joined AbbVie (former Abbott) in 2011 through the acquisition of Solvay Pharmaceuticals. Until 2013 he was Director in Europe with the Global External Research Team. In 2013 he switched to AbbVie's Ventures & Early Stage Collaboration Team. Since July 2015 he is Director in Search & Evaluation. His primary task is to identify innovative opportunities for collaboration, mainly originating from academia.

Dieter holds a DVM degree from the Veterinary School in Hannover, Germany, and a PhD in Laboratory Animal Sciences from the Medical School Hannover, Germany. He joint former Solvay Pharmaceutical in 1986 and had various positions in Research, Development and Project Management. His last position in Solvay was Head of Scouting, Portfolio and Alliances.

Ena Prosser, *Partner,* **Fountain Healthcare Partners**

Dr Ena Prosser is a Partner in Fountain Healthcare Partners based in Dublin, Ireland. Ena was part of the team that raised Fountain Healthcare Partners Fund 1 in 2008 and Fund II in 2014. She has led investments in medtech and therapeutics and is currently a board member of gene-therapy player Genable Ltd, and anti-inflammatory company Trino Therapeutics Ltd.

Ena is a PhD biotechnologist by training and she has a broad background in international alliance and intellectual property management. For over 20 years she has led due diligence projects on technologies and products within the Specialty Pharma, diagnostic, device and biotechnology areas.

Ena was formerly Director of Enterprise Ireland BIO. In this role, she led a team to identify, fund, protect and exploit relevant Intellectual Property, commercialise lifescience technologies and review investment opportunities in R&D. Ena also held various R&D and project management roles within Elan Corporation and had extensive involvement in drug delivery development, licensing and acquisition projects over a 9-year period. Ena has a strong innovation policy background. Ena works closely with Ireland's leading ophthalmology research charities Fighting Blindness in Ireland and the USA.

Speakers

Eric de La Fortelle, *Venture Partner,* **Seventure Partners**

Dr. Eric de La Fortelle is a Venture Partner in the Life Sciences Team of Seventure Partners, a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, diagnostics and nutraceuticals. The specific 'core' of Seventure's investment strategy is 'nutrition, pharmaceuticals and connected health', with particular focus on the intestinal microbiome.

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche's global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations).

Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.

Eric Rambeaux, *CEO,* **MyoPowers Medical Technologies France SAS**

Eric Rambeaux offers more than 20 years of experience in the healthcare industry, in medical devices, in drug companies but also in the consulting space. Mr. Rambeaux holds a doctorate in pharmacy from the Paris University, and a master's degree in management and marketing from ESSEC Business School.

In his industry life, has been serving in organizations various sizes and culture. In the first part of his career, he has been leading commercial development efforts for numerous products in various therapeutic areas. He was also instrumental in the success of numerous corporate strategic projects such as design and implementation of new organizations and processes.

After in move to Business Development, Eric lead or was directly involved in a number of M&A and licensing projects (in and out licensing) either on the pharma or the consulting side.

Mr Rambeaux joined MyoPowers early 2014 to look after Business related activities and has been serving as the company CEO since December 2014 and raised a total of €6Mio for MyoPowers both dilutive and non dilutive.

Erik van den Berg, *CEO,* **AM-Pharma**

Erik has over nineteen years experience in the pharmaceutical and biotechnology industries. Previously, as a Senior Executive at Organon (currently Merck) he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, most recently the $600M alliance with Pfizer and raised more than €130M in equity and debt financing for biotechnology companies.

Ernst Hafen, *President,* **Bio-Technopark Schlieren-Zurich**

Ernst Hafen, PhD, is a Professor of Systems Genetics at ETH Zurich (Institute of Molecular Systems Biology) and former President of ETH. In addition to over 30 years of academic research, he has founded and advised several biotechnology companies and is the president of the BIO-TECHNOPARK Schlieren-Zurich. Ernst Hafen endeavors to assist scientific discovery and its efficient translation into products that help society and the economy.

As a trained geneticist, Ernst Hafen has a strong interest in human genetics and personalized medicine. He posits that an individual's control over his or her personal health data will be a key asset for better and more effective health care. In 2012 he acted as a founding member of the Association Data and Health (DatenundGesundheit.ch) whose aim it is to discuss legal, ethical and societal issues about digital self determination and the control over the secondary use of personal (health) data and to find commercial models permitting owners, not third parties, to benefit from their personal data assets. In 2015 he co-founded the personal data cooperative MIDATA.coop.

Speakers

Esteban Pombo-Villar, *Chief Operating Officer,* **Oxford BioTherapeutics, Inc.**

Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Eugen Leo, *Founder and Owner,* **LEOconsulting**

Eugen Leo, MD, PhD, MBA, is a targeted therapy development specialist with board certifications in internal medicine, hematology and medical oncology. He has over 15 years of experience in phase I-III clinical development of targeted molecules (antibodies, antibody derivatives, kinase inhibitors, vaccines, and antisense molecules), and has an outstanding track record for successful drug development in oncology, hematology, rheumatology and related fields. He was instrumental in reaching proof-of-concept for the BiTE platform (blinatumomab; Science 321 (5891): 974ff) and in developing various other first-in-class molecules. He is the founder and owner of LEOconsulting, a prime biotech and pharmaceutical industry consulting service providing rational, rapid, intelligent and creative drug development since 2009. His academic credentials include an associate professorship at the University of Heidelberg, Department of Hematology & Medical Oncology.

Prior to starting his consultancy service, Dr. Leo served in various scientific and clinical development positions with growing responsibilities up to Vice President/Global Head Early Clinical Development at the biotech firm Micromet AG and at the pharmaceutical companies Johnson&Johnson Inc. and Merck-Serono GmbH. He has substantial translational research experience and, prior to his industry career, spent three years as research fellow at the Sanford-Burnham Institute, La Jolla, CA, USA, working on signal transduction in cancer. He studied Medicine at Freiburg, Münster and Heidelberg Universities in Germany and the University of Cincinnati in the US. He is ESMO-certified and obtained an M.B.A. from Colorado State University.

Fabian Buller, *Director, New Ventures,* **Johnson & Johnson Innovation**

Fabian is Director of New Ventures at Johnson & Johnson Innovation. Fabian is based in Zurich, Switzerland, and affiliated with Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Before joining the Johnson & Johnson family, Fabian was Director of Business Development at Covagen, a company acquired by Janssen in August 2014. In this role, he helped grow a successful biotech company and was instrumental in entering a strategic research & licensing partnership and ultimately, in the sale of the company. Prior to this, Fabian led immuno-oncology discovery research at Covagen with a focus on multi-specific protein therapeutics.

Fabian holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.

Speakers

Fintan Walton, *Founder and CEO,* **PharmaVentures Ltd.**

In 1992 Dr Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures.

Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups.

In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.

Educated at Trinity College (Dublin, Ireland), Fintan subsequently gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

François Thomas, *President & Manager Partner,* **Inserm Transfert Initiative**

François Thomas has more than 25 years of experience in the life sciences sector. Before becoming President & Manager Partner Inserm Transfert Initiative in 2014, he held management positions at Ipsen (VP Clinical Development and CMO) and Genset (VP Licensing and Pharmacogenomics).

In 2002, François became Partner at Atlas Venture and in 2006 he was responsible for healthcare corporate finance at the bank Bryan Garnier. Most recently, he was CEO of Cytheris, a private biotech company.

François has been a board member of several biotech companies such as Eurogentec YMB and Gamamabs, as well as representative of Atlas and ITI in over 20 boards. In addition, in 1995 François founded a consultancy company called Bioserve Ltd.

François is medical oncologist, a former assistant professor at the Gustave Roussy Institute, and holds a Ph. D in molecular oncology and an MBA from MIT (Boston).

Guillaume Vignon, *Director BD Oncology - Global Business Development and Licensing,* **EMD Serono**

Guillaume Vignon is Director of Business Development Oncology at Merck/EMD Serono, responsible for leading business development initiatives, designing deal structures, and negotiating terms of strategic partnerships in the field of Oncology. Guillaume hold several positions within Global Business Development and Licensing with increasing responsibilities in all aspects of deal making. During his career at Merck/EMD Serono, Guillaume closed successfully several complex transactions and forged key partnerships in the fields of Oncology, Companion Diagnostic, and Antibody Discovery, strengthening Merck/EMD Serono's portfolio of innovative products and enhancing R&D capabilities in the field of Biologics. Recently, Guillaume was the business development lead of the collaboration between Merck and BeiGene, which has received the 2013 BayHelix Elsevier Alliance of the Year Award recognizing a ground breaking pharmaceutical collaboration agreement involving a Chinese entity. Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.

Speakers

Hakan Goker, *Senior Investment Director,* **MS Ventures**

Hakan Goker (Ph.D.) is a senior investment director at MS Ventures, the corporate venture capital fund of Merck Serono. Hakan joined MS Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK), Nimbus Discovery (US) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Asceneuron, Forendo Pharma, Raze Therapeutics, Tocopherx, Synaffix, and Progyny Inc.

Heinz Lubenau, *Co-Founder and General Manager,* **VAXIMM GmbH**

Heinz Lubenau has 21 years of hands-on experience in drug development and regulatory affairs in pharma and biotech companies. At VAXIMM, Heinz Lubenau is Co-Founder and General Manager of the German VAXIMM GmbH responsible for all development aspects of an oral T-cell immunotherapy platform. Before joining VAXIMM, he held positions of increasing responsibility at BioGeneriX and Servier in Paris and Munich. At BioGeneriX, Dr. Lubenau was Head of Preclinical and Clinical Development. He was Global Project Leader for the development of the first biosimilar G-CSF up to the EMA approval and market launch and Project Manager for the company's long-acting second generation G-CSF development program lipegfilgrastim from implementation of the project up to clinical phase II. Both drugs have been approved in various countries worldwide in the meantime. At Servier, Dr. Lubenau was Clinical Research Manager Internal Medicine after holding several positions of increasing responsibility. He was involved in the clinical development of the company's drugs in cardiology, diabetes and hypertension. Heinz Lubenau is a pharmacist by training, and has received his Ph.D. from the University of Mainz.

Heinz Schwer, *CEO,* **Lanthio Pharma B.V.**

Heinz Schwer is a highly experienced CEO and a successful biotech entrepreneur. As CEO of Lanthio Pharma, he sold this company just recently to the German stock listed MorphoSys AG. Before that, he was Senior Director at MorphoSys, responsible for the company's corporate venture activities. At MorphoSys he started as Strategic Advisor where he was involved in several technology based deals and the company's M&A activities. He joined MorphoSys in 2010 after he has sold his first biotech company Sloning Biotechnology to MorphoSys. Heinz Schwer co-founded Sloning in 2000 and managed the company as CEO from 2005 until 2010. In the years before, he held the positions as Chief Operating Officer and Head of R&D. Heinz Schwer spent several years as postdoc at the Harvard Institute of Medicine and the Dana-Farber-Cancer Institute in Boston. In this time, he has received numerous awards, including a fellowship for his research in the field of leukemia disease and the biogenesis of blood platelets. He obtained his Ph.D. in clinical chemistry from the University of Regensburg and holds an MBA from Henley Management College in UK. He is also a founding member and Vice President of the International Association of Synthetic Biology.

Ittai Harel, *Managing General Partner,* **Pitango Venture Capital**

Ittai Harel is a Managing General Partner with Pitango Venture Capital. His investment focus is in Healthcare, and includes digital health, medical devices, diagnostics, and specialty pharma.

Before joining Pitango, Ittai headed up Corporate Development at Nektar Therapeutics (NASDAQ: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals. He also served as head of business development at IDEXX Laboratories (NASDAQ: IDXX).

Ittai currently serves on the Board of directors of Inotek Pharmaceuticals (NASDAQ: ITEK), LifeBond, EarlySense, Medisafe, Valeritas, and Vertos Medical, and serves as Chairman of the Board at LifeBond and EarlySense

Ittai holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an MBA from the MIT Sloan School of Management.

Speakers

Ivo Staijen, *Investment Advisor/Portfolio Manager,* **HBM Partners AG**

HBM Partners' Ivo Staijen has over four years of experience in the pharma industry and fifteen years of experience in investment analysis and portfolio management in the healthcare sector. He was senior biotechnology analyst at Bank Sarasin and a former department head at MDS Pharma Services. Ivo obtained a Master of Science degree in chemistry from the University of Groningen, the Netherlands, and a PhD in biology from the Swiss Federal Institute of Technology (ETH), in Zurich, Switzerland. He also was a visiting scholar at the Department of Biology at the MIT, Cambridge, Massachusetts USA.

James Sapirstein, *CEO,* **ContraVir Pharmaceuticals, Inc.**

James Sapirstein, R.Ph., brings over thirty years of pharmaceutical industry experience to ContraVir Pharmaceuticals, Inc.. Mr. Sapirstein spent 17 years in large pharmaceutical companies (Eli Lilly, Hoffmann-LaRoche, BMS) in various commercial positions both in the US and overseas.

Mr. Sapirstein started his career in smaller biotech companies when he joined Gilead Sciences, Inc. (GILD), Mr. Sapirstein served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread. In 2002, he accepted the position of Executive Vice President for Serono Laboratories. He co-founded Tobira Therapeutics as CEO in 2006. Most recently, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua, Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization. Mr. Sapirstein developed the growth strategies for the organization and was responsible for several key licensing opportunities which lead to an increased return on investment for all of the shareholders.

Mr. Sapirstein holds board positions on Panther Biotechnology (PBYA.OB), Cortex Pharmaceuticals (CORX), BioNJ, BIO (Emerging Companies Board) and Clinical Supplies Management

Jason Slingsby, *Head of Business Development,* **Oxford BioMedica Plc.**

Jason Slingsby is Head of Business Development at Oxford BioMedica. He was awarded a 1st class degree in Biochemistry from Oxford University and has a PhD in genetics from Imperial College. He was also awarded an MBA with distinction from London Business School. Jason has held a number of business development positions, and was also co-founder and CEO of ProtAffin AG, a biotech in Austria and the UK.

Jennifer McMahon, *Associate,* **Seroba Life Sciences**

Jennifer McMahon joined the team of Seroba Life Sciences in 2011. She graduated from University College, Dublin with an honours degree in Pharmacology in 2010. Jennifer then entered a Master's degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her Master's degree in 2011, Jennifer then joined Seroba's Investment Team as an Investment Analyst. Jennifer is a member of and Dublin-hub Ambassador of the Thousand Network (formerly the Sandbox network), a global community for 'exceptional innovators'. In October 2015 Jennifer was recognised as one of Ireland's 'Top 30 Under 30', shaping the future of business in the country. She guest-lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons, Ireland. Jennifer was promoted to Associate in 2016.

Seroba Life Sciences is a European life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide. Headquartered in Ireland, we work with some of Europe's best entrepreneurs developing innovative medical devices, diagnostics and therapeutic drugs.

Speakers

Jenny Laird, *Senior Director, Search & Evaluation,* **Eli Lilly & Co.**

Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly's European Headquarters near London. The Search & Evaluation team complements Lilly's internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and early development. Dr. Laird joined Lilly in 2012; prior to that she spent 10 years at AstraZeneca as Executive Director heading Translational Science and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, holds an honorary appointment as Professor of Pharmacology at McGill University, Canada and serves an Editorial Board member of Neuropharmacology and the European Journal of Pain.

Joern-Peter Halle, *SVP, Head of External Innovation, Biopharma, Global Research & Development,* **Merck KGaA**

Peter is leading the External Innovation function in Merck Biopharma. Most recently, he was Head of the President's Office and of Strategy and Business operations in Merck Serono. Prior to this, he was responsible for the program leaders of the oncology portfolio, part of the cross-functional oncology leadership team, and Head of Early Stage Licensing of Merck Serono. He started his carrier in Merck 10 years ago as a member of the corporate development team and was member of the Serono acquisition and integration team. Prior to joining Merck, he co-founded a biotech company focusing on R&D in dermatology where he served as a Chief Business Officer.

Peter holds a PhD in molecular biology from the University of Konstanz and began his carrier as a postdoc in biochemistry at the Gene Center Munich.

Jonathan Tobin, *Principal, Healthcare Ventures,* **Imperial Innovations**

Jonathan joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with antibacterial drug discovery company Auspherix, and diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica, Psioxus and Inivata. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.

Klaus Mendla, *Global Head, BD and Licensing CNS,* **Boehringer Ingelheim Pharma GmbH & Co. KG**

Dr. Mendla received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship in Neuropathology at the University of Heidelberg.

Since joining Boehringer Ingelheim (BI) in 1985, he has held several positions in Research and Development within the corporation. Before joining BI's international Business Development and Licensing organization, Dr. Mendla was director of the company's neurodegenerative diseases research unit.

Dr. Mendla currently acts as Global Head, Business Development & Licensing CNS at Boehringer Ingelheim. He is member of BI's CNS Therapeutic Area Leadership Team and heads up the cross-functional CNS Licensing Advisory Team which is responsible for BI's global partnering and licensing activities in the therapeutic area CNS Diseases.

The strategic partnering focus of Dr. Mendla and his team is on compounds and novel therapeutic approaches for the treatment of neuropsychiatric diseases (including Alzheimer's disease, schizophrenia and depression).

Speakers

Lars Gredsted, *Senior Business Analyst,* **Wellcome Trust**

Lars Gredsted is a Senior Business Analyst at the Innovations division at the Wellcome Trust in London where his responsibilities include sourcing of new investment opportunities, contract negotiations and management & oversight of funded projects/ companies including board level representation. Lars previously worked in biotech with in-licensing of early stage research projects at Union Life Sciences and as management consultant with BCG. Lars gained his PhD from EMBL/Heidelberg University in addition he holds an MPhil in Bioscience Enterprise from Cambridge University and a Master of Biochemistry from the University of Copenhagen.

Laurence Barker, *Dementia Discovery Fund CBO,* **SV Life Sciences**

Laurence recently joined SV Life Sciences as Chief Business Officer of the Dementia Discovery Fund (DDF). Prior to this, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible for managing GSK's venture investment portfolio. In addition, he led licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys. Laurence holds an MBA from Cambridge and a PhD in Biochemistry from the University of Tübingen, Germany.



Laurent Audoly, *SVP, Head of R&D, Managing Partner, Global Head of Drug Development and Translational Medicine,* **Pierre Fabre Fund for Innovation**

Dr. Laurent Audoly is Senior Vice President and heads Research and Development at Fabre Pharmaceuticals for both novel medicines and consumer healthcare products. Laurent is also Managing Partner and Founder of the Pierre Fabre Fund for Innovation. In addition, Laurent is president of the Orphan Diseases and the Medical Devices units within Pierre Fabre.

Prior to this role, Laurent was Chief Scientific Officer in biotech focused on next generation therapeutic proteins where he led the growth of the pipeline from no drug candidates prior to his arrival to a high value pipeline and multiple strategic partnerships with big pharma ultimately leading to a successful exit.

Laurent has held positions of increasing leadership responsibilities in the pharmaceutical industry (Pfizer, Merck, MedImmune) contributing to the identification of new projects and the development of five approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology as well as leading large teams across the pharma value chain.

Throughout his career, he has championed high impact collaborations and established a world-wide network of academic and company-based partnerships. Many of these collaborations have resulted in drug development projects. Laurent is focused on strategic and business growth and has also established strong connections with internal and external commercial and manufacturing organizations. He studied medicine and chemistry for his Bachelor's degree and graduated with a Ph.D. in Pharmacology from Vanderbilt University. Laurent was awarded a fellowship from the American Heart Association during his post-doctoral training at Duke University. Laurent has maintained strong ties with the academic world as an Associate Professor (Adj) at Duke NUS Graduate Medical School. He has also served on NIH study sections, given seminars at universities across the world, and published > 70 papers and patents. He is on the board and an advisor for multiple healthcare organizations across the world aimed at improving healthcare and accelerating the discovery and advancement of novel therapies for patients and their families.

Speakers

Laurent Choppe, *Managing Partner,* **Cukierman & Co. Life Sciences**

Laurent leads Cukierman & Co. Life Sciences since 2008 and has been involved in more than 50 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture-backed and middle market companies for fund raising, licensing deals and M&A transactions as well as strategic projects for key life sciences industry players.

Laurent brings an extensive international life sciences experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, medical device, biotechnology, nutraceuticals, animal health and direct-to-consumer markets.

After a veterinary practice and a new venture management experience, he worked 10 years in Schering-Plough (today Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, General Manager in Israel and Vice President, Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE, dedicated to Alzheimer's disease and AA amyloidosis).

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3 and lives in Lausanne (Switzerland).

Lionel Carnot, *Managing Director,* **Bay City Capital**

Lionel Carnot, MS, MBA, is a Managing Director of Bay City Capital, joining the firm in 2005 after having been extensively involved in the firm's activities as part of The Pritzker Organization since 2000. Mr. Carnot is based in Bay City Capital's office in Basel, Switzerland, where he manages the firm's European activities.

Mr. Carnot is currently a member of the board of directors of Interleukin Genetics, Merus B.V., and Madrigal Pharmaceuticals. He is a former member of the board of several companies, including Reliant Pharmaceuticals, which was sold to GlaxoSmithKline in 2007 marking the single largest all-cash transaction for a venture-backed biotech company at that time.

Prior to The Pritzker Organization, Mr. Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly as well as several sales and marketing positions at Sanofi-Aventis. Mr. Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services. Mr. Carnot holds an MBA with Distinction from INSEAD and an MS with honors in Molecular Biology from the University of Geneva.

Lubor Gaal, *Head of Licensing and External Innovation,* **Almirall, S.A.**

Lubor is the Head of External Innovation and Licensing for Almirall, responsible for leading global scouting, diligence and negotiating transactions to secure external innovation for Almirall. Almirall is a European Specialty Pharma company based in Barcelona, Spain with a strong presence in the US and Europe focused on Dermatology with prescription pharmaceuticals and Aesthetics devices.

Lubor has extensive international business development experience having worked for small and large companies in Europe and the U.S. for almost 20 years. Prior to joining Almirall, Lubor held various senior global BD positions for Bristol-Myers Squibb such as Head of Europe, Search and Evaluation and Global Head of Fibrosis, Neuroscience and Immunoscience.

Before that, he was the Head of Business Development for CNS company Neuro3d in France and Chief Business Officer for Immuno-oncology company Vectron Therapeutics AG in Germany. In the U.S., Lubor was the Global Head of CNS and CV Licensing for Schering AG based in New Jersey. He started his professional business development career at Burrill & Co. in San Francisco. Lubor received his Ph.D. from the University of California at Berkeley, and his B.Sc. in Neuroscience from the University of Sussex in Brighton (UK) having studied biology at the Universities of Mainz and Tubingen in Germany.

Speakers

Luisa Henk, *Senior Manager Business Development,* **Drooms AG**

Luisa has been developing international teams for the last ten years and has been responsible for rolling out business-models in different sectors. Prior to that, she studied languages in Seville (ES), Bogotá (COL) and Mainz (GER). After finishing her studies, she worked for four years as Client Care Manager in Istanbul, Dubai and Johannesburg. Being based in Turkey, Luisa implemented the company's European structure to the entire CEMEA area, while reporting to the HQ in Paris. For the last four years, she has been working as Senior Manager Business Development for the secure-cloud-provider Drooms and has been building up the life-science sector ever since.

Margarita Chavez, *Director, Ventures & Early Stage Collaborations,* **AbbVie, Inc.**

Margarita Chavez has over 15 Years of dealmaking experience. She has been in her current role since June 2010 (then Abbott Biotech Ventures), leading investments and managing portfolio companies in the US and Europe. Before joining AbbVie Ventures, Ms. Chavez was a Director in Abbott's Global Pharmaceutical Licensing & Acquisitions Division. Prior to that, Margarita was Senior Counsel in Abbott's Legal Division. Margarita started her career as a corporate and securities lawyer in Silicon Valley and practiced with the firm of Brobeck Phleger & Harrison. Santa Clara University JD 1997; BS 1994 .

Mark Beards, *Corporate Development Director,* **Cell Therapy Ltd**

Mark Beards is the Corporate Development Director at Cell Therapy Limited. He brings over 20 years' experience in the life sciences and financial sectors. He has worked in sales, marketing and R&D roles at Abbott Laboratories and GlaxoSmithKline. He also brings a significant amount of life science strategic consulting experience, from McKinsey & Company, and as co-lead for life sciences strategy at Charles River Laboratories. Mark was the Head of Healthcare Equity Research where he built a new team focused on the European pharmaceutical, biotechnology and medical technology sectors. He was most recently Director of Life Sciences Strategy at KPMG. Mark holds a BA(Hons) and MA in Mathematics from The Queen's College, Oxford University. He is a qualified Chartered Management Accountant.

Mark Carnegie-Brown, *CEO,* **Glide Pharmaceutical Technologies Limited**

Mark is CEO of Glide Pharmaceutical Technologies Limited, based in Oxfordshire, which is focused on the delivery of patient-friendly healthcare solutions, including its proprietary Glide SDI® (the Solid Dose Injector) system for the easy, safe and convenient delivery of solid dose therapeutics and vaccines. He has 25 years' experience of the life sciences sector and was previously CEO of Evolutec, a biological drug development business, where he led a successful IPO and established the company's clinical and manufacturing programmes. He was also CEO of Aenova, a pharmaceutical tablet and capsule manufacturer, where he led the integration of the Swisscaps and Dragenopharm organisations. Dr. Carnegie-Brown started his career in R&D at ICI and subsequently held a number of commercial roles before becoming General Manager of Zeneca's UK and Eire business.

Speakers

Mark Vaeck, *CEO,* **Complix N.V.**

Mark Vaeck has more than 25 years of experience in the biotech and pharma industry and has raised over 70 million Euro in equity financing for his companies. In 2008 he co-founded the biopharmaceutical company Complix (Belgium) and was elected as its CEO in May 2010. From 2006 until 2010 he has been the founding CEO of ActoGeniX (Belgium), and from 2001 until 2006 CEO of Ablynx (Belgium), which he co-founded in June 2001. Prior to that, Mark was COO of Ceres Inc (US), a NASDAQ listed company engaged in the development of innovative technologies for biofuel production. From 1993 until 1998 he served as Director Business Development and thereafter as CEO of Keygene (The Netherlands). Between 1983 and 1993 he held several management positions in the biotech and pharma industry, including Director Business Development at EuroCetus (Chiron Corp.), Manager Licensing at UCB Pharma, and Manager Business Development at Plant Genetic Systems. Currently he is also Board member of InteRNA, a drug discovery and development company focused on novel cancer therapies.

Education: Mark received his PhD in Immunology in 1982 from the Free University of Brussels.

Markus Goebel, *Managing Director,* **Novartis Venture Fund**

Markus Goebel started his career in the Health Care Industry in 1990. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters to include a worldwide alliance with Amgen. He joined Novartis in 2000 and first worked as Global Head Nervous System BD&L Pharma and later as Global Head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US, moving back to Europe in 2009. Previously he received an MD and a PhD from the Ludwig Maximilian's University in Munich and an MBA from Henley Management College. Markus serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx, EraGen, Intellikine and LigoCyte.

Markus Hosang, *General Partner and Managing Director,* **BioMedPartners AG**

Dr. Markus Hosang is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and personalized medicine/diagnostics. Before joining BioMedPartners in 2005, Dr. Hosang was a Venture Partner at MPM Capital, where he managed the firm's European office in Munich, was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions of increasing importance in the Pharma R&D organization, including Head of Vascular Diseases Research, Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, member of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Pharma Portfolio Board, and most recently, as the Deputy Head and Chief Scientific Officer of Roche Pharma Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee.

Dr. Hosang obtained his Ph.D. in Biochemistry from the ETH in Zurich with summa cum laude and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular diseases. He was on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) from 1994-2002. He currently serves on the boards of Aleva Neurotherapeutics AG, Anergis SA, Biotectra AG, Genkyotex SA, Hookipa Biotech and Imevax GmbH. Earlier he was a member of the boards of SuppreMol GmbH (until its acquisition by Baxter in March 2015), Okairos (until its acquisition by GSK in May 2013), Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents.

Speakers

Markus Kalousek, *Global BD&L Franchise Head, I&D, S&E,* Novartis Pharma AG

Markus has 20 years leadership experience in various countries and functions (BD&L, M&A, Drug Development), with proven track record of successful development and in-licensing of innovative drugs.

He is currently heading the search & evaluation function for Novartis' Immunology, Dermatology, Nephrology & Transplantation Franchise (Novartis Pharma Global BD&L).

Before joining BD&L, he was responsible to build Novartis' Development function in China and was global team leader for some of Novartis' most successful drug development programs (e.g. Lucentis).

Prior to that he had roles of increasing responsibility in a CRO and in small and mid-sized Biotech companies.

Markus studied Biochemistry, Molecular Biology & Pharmaceutical Medicine and did his PhD and PostDoc in Oncology research before joining the Pharma industry.

Martin Judge, *Innovation Sourcing Director,* Novo Nordisk

Martin Judge is an Innovation Sourcing Director at Novo Nordisk A/S, a global pharmaceutical company headquartered in Denmark. He is responsible for the evaluation of partnering opportunities related to potential new protein-based therapeutics and related technologies in Novo Nordisk's strategic focus areas of diabetes, obesity, and hemophilia. He is from New York City, received his Ph.D. in 1985 at NYU, and relocated to Copenhagen in 1987 for a research position in pharmacology at Novo Nordisk. In 1998 he transferred to Business Development and now devotes his time to the search for new projects and technologies of interest for Novo Nordisk's drug discovery and early development activities.

Martin Pfister, *Senior Investment Manager,* High-Tech-Gruenderfonds Management GmbH

Martin Pfister joined the High-Tech Gruenderfonds (HTGF) Medtech/LifeSciences team in Bonn in 2010. HTGF is the largest Seedfonds in Europe with about 580 Mio EUR under management and an active portfolio of about 230 technology-based portfolio companies, about 85 of which are in life sciences.

- Studied a combination of Medicine, Pharmacy and Biology in Germany and New York University, Medical School with a PhD in Immunology
- Started his career in the hospital/laboratory
- Moved to the life sciences industry 14 years ago.
- Held several management positions in start-up companies and a healthcare consultancy in Germany/UK
- Co-founded two companies in the molecular Dx field (VC backed, sold) and healthcare services (still shareholder)
- @ HTGF manages a portfolio of 13 life science companies including Biotech, Medtech and ehealth



Matthew Foy, *Partner,* S.R.One Limited

Mr. Foy joined SR One's London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications. His portfolio companies include Asceneuron, Atopix, AtoxBio, Progenitor, PsiOxus, Puridify and VHSquared.

Speakers

Matthias Bünte, *Head Operational Transaction Services,* **Ernst & Young AG**

Matthias joined EY recently to build the Operational Transaction Services (OTS) and Lifescience Strategy Team in Switzerland.

He brings extensive management consulting and industry experience from 8 years at BCG and 8 years at Booz Allen Hamilton with a focus on life sciences

He also gained line management experience at Amgen developing and implementing their strategy for Central & Eastern Europe and managing Poland and the Baltic States.

Before joining EY he was General Manager Middle East & Africa for Celgene.

Michal Silverberg, *Senior Director, External Innovations, Israel and Europe,*
Takeda Pharmaceuticals International GmbH

Michal Silverberg is a Senior Director for External Innovation, Europe and Israel at Takeda Ventures. She has been involved in the life science space since 1998, in various sectors, government, venture capital and global pharmaceutical, biotech companies. Most recently she worked for Novo Nordisk as Senior Director Business Development and New Product Commercialization and a member of the BioPharm leadership team. Prior to Novo Nordisk she worked in Business Development for OSI Pharmaceuticals.

Prior to joining OSI Pharmaceuticals, she held various positions in a biotech company (MGVS), an investment group (Ofer Brothers Hi tech) and the Office of the Chief Scientist of Israel (The Incubator program).

She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University and M.A. in Biotechnology from Columbia University in the US.

Michele Ollier, *Co-Founder,* **Medicxi Ventures**

Prior to co-founding Medicxi Ventures, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Epsilon 3 Bio, Minerva Neuroscience (Nasdaq: NERV), LinguaFlex, Encare, Gadeta, and Human Antibody Factory. She was also a Director at OncoEthix (Sold to Merck Pharmaceuticals) and Aegerion (Nasdaq: AEGR).

Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Gencell/Aventis International and Serono International.

She currently serves on the board of directors of Ipsen Pharmaceuticals(Euronext:IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord. She advises the Robertson Therapeutic Development Fund at the Rockfeller University in New York City.

Michèle earned an MD from Paris-Ouest University.

Speakers

Nanna Lüneborg, *Principal,* **Novo Ventures**

Nanna is a Principal with Novo Ventures in the Copenhagen office. She joined Novo A/S in 2012, and spent the first four years as part of the Novo Seeds team, where she helped build a strong portfolio of seed and Series A stage companies, primarily in Scandinavia. She led the initial investments and served on the Boards of MinervaX, IO Biotech, Glionova and Inthera Bioscience. She also served on the Boards of Pcovery and Affinicon, and as an Observer with Forendo and Galecto. She joined the Ventures team in 2016.

From 2008-2012, Nanna was an Associate with Apposite Capital, a London-based venture fund, where she was part of the life science investment team and participated in both primary and secondary investments, with multiple portfolio companies leading to highly successful exits for the fund. Earlier in her career, she worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA.

Nanna holds a PhD in Neuroscience from University College London, where she was a Wellcome Trust Scholar, an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar, and a 1st class BA from University of Oxford.

Naveed Siddiqi, *Partner,* **Edmond de Rothschild Investment Partners**

Naveed joined the life sciences team of Edmond de Rothschild Investment Partners in 2013. Most recently he was a Partner at Phase4 Ventures in London. Prior to this Naveed worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as medical doctor in the UK's National Health Service. He has 22 years of venture capital, investment banking, private equity advisory and accountancy experience in life sciences and other sectors. Naveed graduated in medicine from Guy's and St Thomas's Hospital Medical School at the University of London. Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales. Naveed has previously served or observed on several company Boards in both Europe and United States at Nomura and Phase4 Ventures. Naveed is a Director of Laboratoris Sanifit SL.

Norbert Steinbach, *Director Business Development Western Europe & Canada,* **AbbVie, Inc.**

Norbert started his career in the pharmaceutical industry back in the late 70´s. He holds a Bachelor degree in business administration from the University of Applied Sciences of Rhineland Palatinate/Germany. At the beginning of his personal development he spend some years in the Brazilian affiliate of a German pharma company and as Commercial Director for Latin American countries. Thereafter he has been named General Manager of the company´s Portuguese subsidiary in Lisbon/Portugal. In the mid 90´s he accepted to move into a more strategic role and developed a core strategy for building own operational structures for BASF Pharma in Japan, which culminated in the acquisition of a majority shareholding of a mid-sized Japanese pharma company. In 2001 Norbert joined Abbott Germany as Division Director Primary Care and became member of the affiliate management team. Successively he held various functions in the German affiliate of Abbott and AbbVie and became member of the company´s European Business Development team in 2004, which he started to head from mid 2013.

Oliver Middendorp, *Co-CEO & CBO,* **Numab AG**

Oliver Middendorp is the CBO and co-CEO, as well as a founder of Numab. Prior to this role, he served as Head of Alliance Management at Esbatech. In this function Oliver negotiated and concluded various collaboration and license agreements and managed the resulting alliances. Furthermore, he was responsible for managing Esbatech's patent portfolio, as well as for analyzing Esbatech's freedom to operate. After Esbatech was acquired by Alcon in September 2009, Oliver took over additional responsibilities in Alcon's R&D Alliance Group, where he became responsible for search, evaluation, negotiations and alliance management of collaborations in the fields of external diseases and drug delivery. Oliver studied molecular biology and immunology at the University of Zurich and received his PhD in biochemistry from the University of Basel in 2004. In the same year he was offered the position as Esbatech's business developer and became a member of the Esbatech Management.

Speakers

Oliver Schacht, *CEO,* **Curetis N.V.**

Following a long-standing career with Epigenomics AG (1998–2011), Oliver Schacht, an expert in the diagnostics industry, has been CEO of Curetis N.V. since 2011. He was a co-founder and CFO of Epigenomics AG in Berlin and CEO of the US subsidiary Epigenomics Inc. (Seattle, USA). Oliver has extensive experience in developing and implementing commercial strategies and financing measures (including an IPO), as well as in finance, M&A transactions and alliance negotiations. Oliver obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a master's degree and a PhD at the University of Cambridge (UK). During his time at Mercer Management Consulting (1995–1999), he worked on projects in the fields of M&A, growth strategies and reorganization in the pharmaceutical, biotechnology and other industries.

Patrick Benz, *Senior Director Alliance Management,* **Johnson & Johnson Innovation - JJDC, Inc.**

Patrick Benz, Senior Director Alliance Management, Janssen Business Development.

In this role Patrick manages all global commercial and R&D key alliances for Neuroscience in all different global regions.

Patrick joined Johnson & Johnson Family of Companies in 1998 at Janssen Switzerland. He progressed through several commercial roles into the board of the Swiss Operating Company as Business Unit Director CNS, then he moved to Italy, holding several commercial roles at board level, advancing to EMEA Franchise Leader for Neurology, overseeing the entire EMEA Neurology Franchise. Since October 2008, Patrick has been a member of the Janssen Business Development team. In this group he was holding the position of Senior Director, Business Development & Licensing for the Neuroscience Franchise until 2013, where he was negotiating several transactions for commercial as well as R&D assets.

Patrick holds a Master Degree in Pharmacy and a PhD in Organic Chemistry. Before joining Janssen Switzerland in 1998, Patrick did work for Gebro Pharma AG, Switzerland, and for Boehringer Mannheim/Roche.

Paul Hermant, *Partner,* **Bird & Bird LLP**

Paul Hermant is a corporate & finance partner at Bird & Bird LLP, based in Brussels. He also heads the firm's corporate life sciences practice.

Paul assists clients in their corporate and financial transactions and provides the full range of advice in these fields. He has particular expertise in mergers and acquisitions, private equity, joint ventures, securities offerings, take-over bids, as well as project and acquisition finance. Paul also represents clients in corporate and financial litigation, including shareholders disputes, directors' liability and cases relating to financial products and services.

Paul is one of our leading corporate and finance partners. He joined us in 2000 with his team, coming from another leading international law firm.

Paul speaks English, French, Dutch and German and, besides his legal education, also holds a masters' degree in business administration from the Solvay Business School (University of Brussels).

Paul has written and spoken widely on corporate and financial law topics and teaches at the University of Brussels and at the Cooremans Institute. He also serves on the Board of the Solvay Alumni.

Peter Hoang, *Senior Vice President, Business Development & Strategy,* **Bellicum Pharmaceuticals, Inc.**

Peter Hoang is the Senior Vice President, Business Development & Strategy at Bellicum Pharmaceuticals, where he is head of business development, corporate development and business strategy. He has over 18 years of finance and deal experience in investment banking and venture capital. Prior to Bellicum, he was the Managing Director, Innovations, for The University of Texas MD Anderson Cancer Center where he headed the institution's new venture formation and development effort.

Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and Head of Healthcare Mergers & Acquisitions advisory for CIT Group, a New York corporate and investment banking firm with over $65 billion in assets (NYSE: CIT). Previously, he also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank. He earned high honors distinction with an M.B.A. from the Anderson School of Management at UCLA and a B.A. from Yale University.

Speakers

Peter Langkafel, *Founder and CEO,* **HCB Healthcubator GmbH**

Peter Langkafel MD PHD MBA is CEO and founder of healthcubator – enable digital solutions in healthcare GmbH. He is president for the Berlin / Brandenburg region of the Association for Medical Informatics in Germany. Since more than 20 years he works at the interface between medicine, business and information technology. Until mid of 2015 he was general manager healthcare for Europe at SAP AG. Before he was part of the management team of the Charité, Medical Faculty of the Humboldt University in Berlin. He recently edited the book "big data in medicine: diagnosis, treatments, side-effects. (available in English and German).

Rainer Metzger, *VP Global Business Development Pharma,* **QIAGEN GmbH**

Since 2013 Dr. Metzger works for QIAGEN where he is leading the QIAGEN Pharma Partnership and Precision Diagnostics program. Dr. Metzger joined QIAGEN from a Danaher company, Leica Biosystems, where he has worked for 2 years as Vice President, Head Pharma Partnerships, with responsibilities Pharma collaborations in the field of advanced staining and histogenetics. Prior to joining Danaher Dr. Metzger has worked for Roche Diagnostics as Vice President, Head BD Oncology and for Roche Pharma / Genentech as Vice President, Head of Clinical Biomarkers for more than 10 years. Dr. Metzger has founded several biotech companies and has worked in the Biotech field for more than ten years.

Rao Movva, *Novartis Distinguished Scientist,* **Novartis Institutes for BioMedical Research**

Rao was born in India and pursued his studies leading to M.Sc degree from Nagpur university in India. He completed my Graduate studies with a Ph.D degree in Molecular Biology at SUNY at StonyBrook, New York in 1980. Subsequently,he joined Biogen S.A , then , a novel start-up biotech company in Geneva, Switzerland as a research scientist in 1980 and worked there until 1987 in various capacities as Project leader, Program executive and Senior research scientist focusing on cloning of novel genes and the expression of recombinant protein He moved to Sandoz AG in Basel, Switzerland in 1987 and have been with the organization since in several research environments and in various capacities. As a group leader in the Biotechnology (1987-92), he had developed methods for successful production of various recombinant proteins, including lymphokines IL-3, IL-6 and LIF from E.coli. From 1992-1996, as the head of Signal transduction Biology group, he contributed to elucidate the of Mechanism of action of action of immunesuppressive drugs, including , notably the identification of TOR protein as the target of Rapamycin, the active component of Novartis transplant (Certican) and cancer(Affinitor) drug. As the Head of Molecular biology and Gene therapy unit in the (1996-2004), he led very early efforts to evaluate the gene therapy technologies and developed screening strategies for small molecules to identify tool and lead compounds for drug development. In the past 10 years, he focused his efforts in chemical biology to connect the chemicals with their biological targes toaccelerate drug discovery. In addition he is involved in setting up multiple collaborations between Novartis and the various leading academic instituitions of the world by acting as a scout to identify and initiate new drug discovery projects including the Human microbiome efforts in Novartis Institute for Biomedical research (NIBR). Overall, Rao has more than 30 years of biotech and large pharma research and drug discovery experience and has authored several peer reviewed publications.

Speakers

Regina Hodits, *General Partner,* **Wellington Partners**

Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Themis, Rigontec, Middle Peak Medical, Ayoxxa, and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm, until January 2010. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo, Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, which was acquired by SciClone (NASDAQ SCLN) in 2010.

Regina also worked for Apax Partners and was closely involved in investments such as Genmab and Silence Therapeutics. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. In the 90s, Regina gained insights into the fast-growing biotech sector as university lecturer and post-doctoral researcher at the University of Vienna and the MRC Cambridge, where she collaborated with emerging UK biotech companies.

Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.

Reza Halse, *Head of MSD European Innovation Hub,* **MSD**

Rez serves as head of the European Innovation Hub in London, leading business development and licensing activities, with a focus on early-stage therapeutics for MSD, i.e. pre-clinical to proof-of-concept, and novel technology platforms.

He is also a partner in the MRL Venture Fund with responsibility for European investments. The European Innovation Hub offers a range of partnering constructs to match the interests of European innovators: collaborations, licensing and independent venture investments.

Previously, Rez was a partner with the corporate venture capital arm of Partners HealthCare, a large academic medical center and Harvard Medical School affiliate, based in Boston, US. In this role, he led investments and had Board responsibility for a number of therapeutics and technology platform companies, spanning infectious disease, oncology, neurology, inflammation and genome editing. Prior to this, he was a founding member of a US-based product development company, BioMed Valley Discoveries, that in-licensed and advanced a number of oncology assets into clinical trials. He also had management roles of increasing responsibility at Novartis, based in the US, initially in the diabetes and metabolism group, and then in an internal incubator with a mandate to develop programs outside the core disease areas. Earlier in his career, he led research at Xcellsyz Ltd, a venture-backed start up in the UK. Rez holds a B.Sc. and Ph.D. from Newcastle University, UK

Richard Godfrey, *CEO,* **BerGenBio AS**

Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008.

He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles.

He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.

Speakers

Ruth Ben Yakar, *CEO,* **BioSight Ltd.**

Dr. Ben Yakar has over 22 years of experience in the biomedical field, including 15 years of management in the biotech industry, leading diverse corporate, business, operational, financial, clinical development, and research activities.

Dr. Ben Yakar serves as the CEO of BioSight, a clinical-phase biotech company, a Director at SHL Telemedicine and Cellect Biomed, a business consultant to several biomed companies, and a lecturer at Lahav, the Recannati Business School of Tel-Aviv University, presenting the Israeli biomed industry to investors and business groups. Dr. Ben Yakar formerly served as the CEO of Procognia, a biotech company traded on the TASE, where she established the company as a leader in biopharmaceutical analytics. Prior to that, Dr. Ben Yakar was the CEO of Thrombotech, where she led a multi-center phase II clinical trial and led the company towards acquisition. Prior to that, Dr. Ben Yakar served as the Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, responsible for the commercialization of the WIS technologies, and a Vice President in several Biotech companies where she led diverse product development activities and clinical and pre-clinical R&D projects.

Dr. Ben Yakar holds a PhD Cum Laude in molecular cell biology from the Weizmann Institute of Science. Her research, in the field of oncology, yielded several prestigious publications and awards.

Sarah Holland, *Head of Europe, External Science and Partnering,* **Sanofi**

Sarah Holland is Head of External Science & Partnering, Europe at Sanofi. She responsible for cultivating relationships and bringing forward innovative external opportunities from key stakeholders located across Europe.

Sarah joined Sanofi from Roche where she was the Life Cycle Leader for alectinib, an ALK inhibitor licensed from Chugai. The Life Cycle Team she led was responsible for all aspects of the program, including manufacturing, development and marketing.

Previously, Sarah was Global Head of Strategic Partnering at Roche and a member of the Partnering Leadership Team. Her team's projects included pharma M&A transactions, including rapid company integrations, spin-outs and major strategic partnerships. Sarah championed Roche's entry into rare diseases and re-entry into anti-bacterials. Prior to that, Sarah was the Global Head of CNS Partnering, responsible for all Partnering activities across neurology and psychiatry. Her first role at Roche was as Oncology Finder, when Sarah led the deal with Plexxikon that resulted in the launch of 'Zelboraf'.

Prior to Roche, Sarah was Global Brand Director at AstraZeneca during US and EU launch. This followed roles in strategic planning, pricing and health economics. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies.

Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D. Phil. and first degree at the University of Oxford.



Simon Blake, *Senior Director, Scientific Licensing for Immunology,* **Johnson & Johnson**

My PhD in Biochemistry was obtained whilst at the Kennedy Institute of Rheumatology, London, UK. I then served multiple Post-Doctoral Research appointments, where I continued to study the pathogenesis of inflammatory joint disease, focusing on the role of the cytokines IL-1 and TNF. I moved into industry in 1994 spending 5yrs each at Celltech Therapeutics and GlaxoSmithkline respectively, leading small and large molecule discovery research teams. In 2004 I joined Centocor and was appointed Director of Cardiovascular and Metabolic Diseases team in 2005. I am currently Senior Director for Scientific Licensing in Janssen Business Development, supporting the Immunology and Janssen Biotherapeutics teams within Janssen Pharmaceuticals R&D.

Speakers

Simon Kerry, *Chief Executive Officer,* **Karus Therapeutics Ltd.**

Simon is a business professional with two decades' experience of creating and developing innovative life science companies. Before he joined Karus as the Company's CEO in 2006, he was Director of Business Development at Ablynx NV (Ghent, Belgium), where he secured a number of research, development and licensing agreements with major pharmaceutical companies including Wyeth (now Pfizer) and Novartis. During this time, he played a key role in Ablynx's growth from early-stage to one of Europe's most promising antibody companies.

Prior to Ablynx, Simon was Director of Business Development at Active Biotech AB (Lund, Sweden), where he spun-out the molecular evolution company, Isogenica Ltd (Cambridge, UK), later joining the spin-out as Vice President of Business Development.

Simon has held other key commercial appointments at Actinova Ltd (Cambridge, UK), and Actigen Ltd (Cambridge, UK). He has also occupied senior commercial roles at the Health Protection Agency (Salisbury, UK) and within the Jasmin group of companies. Simon has a degree in Medicinal Chemistry, a Life Science PhD and an executive MBA from Loughborough University Business School.

Simon is on the Advisory Board of MedCity (http://www.medcitylondon.com/), an initiative that positions London and South-East England as a world leading, interconnected region for life science research, development, manufacturing and commercialisation. Simon is also a co-founder of Angels4LifeSciences (http://www.a4ls.com), an angel investment community committed to early-stage UK-based life science companies.

Stephanie Léouzon, *Partner and Head of Europe,* **Torreya Partners (Europe), LLP**

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over

$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

Stephen Levin, *Managing Partner,* **Innovation in Medtech, LLC**

Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company's editorial coverage of the medical device industry, following Elsevier's acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the IN3 medical device partnering conference series. Stephen joined Windhover Information in 1997, where as Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company's General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.

Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law).

Speakers

Stewart Kay, *Director, Business Development,* **GlaxoSmithKline Plc.**

Stewart started his career at Amersham International (now part of GE) and held various sales, marketing and business development positions in the Life Science and Technology Platforms division. He joined Evotec in 2002 as SVP Business Development for Europe and was part of the operational management team. In 2005 he joined Pharmagene as VP Commercial Development and as a member of the Executive Management team took the company into a merger with Asterand. Stewart joined GSK in 2008 and is currently Director Transactions in Worldwide Business Development, Pharma R&D. Stewart hold s Bsc in Biochemistry and a MBA from Warwick Business School.

Thierry Chignon, *Senior Partner,* **Merieux Developpement**

Thierry Chignon has more than 25 years of experience in Quality Assurance, Regulatory Affairs, Clinical Trials with particular focus on the medical device sector, including a first experience as Head Pharmacist with Institut Mérieux (10 years).

As Director with Quintiles Consulting, between 1997 and 2006, he defined and participated in the implementation of business development strategies for innovative products in Europe. Thierry also worked for 5 years as an expert of the Commission of the European Union drafting Guidelines and Regulations for medical devices. He has chaired standardization working groups in CEN and ISO, as well as a Eucomed Task Force on Tissue engineering.

In 2006, Thierry joined Matignon Investissement to raise and deploy the first French fund dedicated to European medical technologies (Matignon Technologies II, 80M€).

After several positive exits (trade sale and IPOs), Thierry joined Mérieux Développement in 2014.

Thierry holds a Pharmacy Degree, PharmD, a Master Degree from IEP Paris (Sciences Politiques), and an executive MBA from HEC Paris.

Thomas Stockman, *Director, Healthcare Investment Banking,* **Royal Bank of Canada**

Tom is a Director in RBC's European Healthcare team, with over 14 years of investment banking experience, focusing on Life Sciences. He recently joined from Citi, where he had been part of their EMEA Healthcare team since 2002. Tom holds an MA in Biological Sciences from Oxford University.

Capital markets transactions include: Santhera's follow-on on SIX, Shire's financing for the acquisition of Baxalta, Biotie's directed issue of convertible notes and warrants and US listing on Nasdaq, Abivax's IPO on Euronext Paris, GSK on the increase in ownership of its Nigerian listed subsidiary GSK Consumer Nigeria, DBV Technologies on its US IPO, Huvepharma's syndicated loan financing, Prosensa on its US IPO, GSK's selldown in Aspen Pharmacare, Merck on its rights issue in relation to the Serono acquisition, Shire's issue of convertible bonds, Hikma's Accelerated Equity Offering, Gambro's syndicated loan acquisition financing, Bayer on its equity offering in relation to the Schering acquisition, Hikma on its UK IPO.

Select M&A experience: Shire's defence following an unsolicited approach by AbbVie, GSK on its three-part deal with Novartis (sale of oncology, acquisition of vaccines, consumer JV), Hikma on the acquisition of Bedford Laboratories from Boehringer Ingelheim, Permira's acquisition of Norwegian animal health player Pharmaq, Nabriva on its structured sale agreement with Forest Labs, Roche on its hostile offer for Illumina, Hikma on the acquisition of Promopharm, Roche on its acquisition of Anadys, Huvepharma on the sale of a stake to CVCI, Solvay on the sale of its pharmaceutical business to Abbott, Numico on is sale to Danone, BUPA on the sale of its hospital business to Cinven, Savient Pharmaceuticals on the sale of Rosemont to Close Brothers Private Equity.

Speakers

Thomas Wilckens, *CEO,* **InnVentis Ltd.**

Thomas Wilckens is an MD and a serial entrepreneur. InnVentis' focus is on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable PRECISION MEDICINE. Thomas is also the founder of the LinkedIn group PRECISION MEDICINE & Big DATA. Before InnVentis he was an associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. In 1998 he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in biomedicine and Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. "Symbiotic Innovation". With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in nano- and biotechnology; i.e. Precision Medicine will ultimately be supported by algorithms for diagnostics and therapeutic decision making and become available anywhere 24/7.

Tim Dyer, *CEO,* **Addex Therapeutics Ltd.**

Mr Dyer serves as CEO/CFO of Addex Therapeutics Ltd, a Swiss biopharmaceutical company listed on the SIX Swiss exchange under the ticker symbol, ADXN. Mr Dyer is also founder and managing partner of TMD Advisory Ltd, a CFO & finance function services company which provides services to technology based start-up companies. In addition, Mr Dyer is co-founder and serves on the board of Qwane Biosciences SA, a private drug development tool company focused on commercializing microelectrode array technologies, and serves on the board of Abionic SA, a private medical device start-up company focused on allergy diagnostics. He also serves as a member of the Swiss government innovation promotion agency coaching team (CTI startup) as a specialty advisor, is a member of the EPFL-MOT advisory board, member of the EPFL alumni start-up mentoring program and a co-founder of the ExpertNetwork, a Swiss Romandie technology start-up entrepreneurial network.

Mr Dyer has extensive experience in finance, corporate development, business operations and the building and management of high growth start-up technology companies. Mr Dyer co-founding Addex Therapeutics in 2002 and served as CFO until May 2013, head of business development until April 2008 and head of human resources until October 2008. In June 2013, Mr Dyer was appointed as CEO/CFO of the Addex group under a management mandate entered into by TMD Advisory. Mr Dyer has raised more than CHF300 million in private and public financings and has extensive experience in structuring financing transactions including VC investments, PIPEs, convertible notes and IPOs. He also has executed life science collaboration and licensing deal of more than $1 billion of upfront and milestones.

Mr Dyer is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton. Prior to co-founding Addex, Mr Dyer worked at Price Waterhouse (PW) & PricewaterhouseCoopers (PwC) in the UK and Switzerland as part of the audit and business advisory group for more than 10 years. At PW in the UK, Mr Dyer spent two years performing inward investment due diligence on local financial institutions in the Ex-Soviet Union.

Tim Herpin, *Vice President, Head of Transactions (UK),* **AstraZeneca**

Timothy Herpin heads a group of business development professionals involved in all aspects of transactions negotiation and execution at AstraZeneca. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Speakers

Ulrich Muehlner, *Global Head Outcomes Technologies Incubator (NOVAE),* **Novartis Pharma AG**

Ulrich Muehlner is currently Global Head Outcomes Technologies Incubator (NOVAE) at Novartis. In this Corporate role, he is – in close collaboration with the Novartis' businesses – leading or supporting programs and partnerships aiming at increasing the value of the Novartis portfolio through "beyond-the-drug" (digital) technologies that enable or enhance the real-world outcomes performance of Novartis products.

Examples of such initiatives include the "smart lens" licensing deal with Google(x) Life Sciences (Verily), the collaboration with the "smart pill" company Proteus Digital Health, and various projects together with the Novartis' Cardio Metabolic franchise to develop outcomes solutions for Entresto (e.g., "Heart Partner" App to support Heart Failure caregivers and patients).

Ulrich joined Novartis in August 2009 as Director Corporate Strategy, leading key Group initiatives in areas such as emerging markets, digital health, innovation driven growth opportunities and venturing. From August 2012 – April 2013, Ulrich was Global Head Corporate Strategy (a.i.) and co-led the team to develop the portfolio strategy that resulted in the fundamental transformation of the Novartis business portfolio.

Prior to Novartis, Ulrich was a Principal at BCG and worked primarily in the healthcare / biopharma industry, studied Biochemistry and earned a PhD in Biochemistry and Molecular Biology.

Uwe Schoenbeck, *SVP & Chief Scientific Officer, External R&D,* **Pfizer, Inc.**

Uwe Schoenbeck leads Pfizer's Worldwide Research and Development (WRD) External R&D Innovation (ERDI) team which seeks to identify and establish partnerships with outstanding Pharma and Biotech companies and key academic centers to gain first access to cutting edge science and innovative disease targets, drug candidates as well as technologies. His team works closely with colleagues across Pfizer, including WRD's key therapeutic research units, business development, business units, and Pfizer country organizations to harness these opportunities for the company. He is a member of the WRD Leadership Team and sits on Pfizer's Senior Leadership Council.

Prior to joining Pfizer in 2009, Uwe was Vice President, External R&D Innovation for Wyeth Pharmaceuticals and was a member of the Wyeth's R&D Executive Committee where he was responsible for developing and implementing Wyeth's External R&D strategy and operations. As continued in his current role, the function involves integration of exploratory to clinical Proof of Concept drug candidates as well as technologies addressing high unmet medical needs and covers both small and large molecule therapies, including those within WRD's core therapeutic areas of Cardiovascular Metabolic Disease, Immuno-Oncology, Inflammation & Immunology, Neuroscience, Oncology, Rare Disease, and Vaccines. Uwe leads several small research units that prosecute high quality clinical assets mostly through external partnerships in indication areas complimentary to Pfizer WRD's innovative core including Gene Therapy.

Preceding his time at Wyeth Uwe served for five years as Vice President, Cardiovascular Research for Boehringer Ingelheim ("BoehringerI") in Ridgefield, CT, and was responsible for the global cardiovascular research strategy and drug discovery program from target identification to Pre-Development including life cycle management for marketed and advanced pipeline products. Prior to joining BoehringerI in 2003, he held the position of Assistant Professor of Medicine, Brigham & Women's Hospital, Harvard Medical School.

Uwe received his degree from the University of Kiel, Germany, and completed postdoctoral training in the Division of Cardiovascular Medicine, Brigham & Women's Hospital, Harvard Medical School, before joining as a faculty member. Uwe has served as a reviewer for multiple peer-reviewed journals (incl. Circulation, Circulation Research, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of the American College of Cardiology (JACC), Nature Medicine, and the Proceedings of National Academy of Sciences U.S.A.) and has published more than 100 peer-reviewed articles, review articles/book chapters and abstracts with particular contributions in areas such as molecular & cell biology, cardiovascular research, immunology and metabolism.

Speakers

William Watson, *Head of European Business Development,* **Teva Pharmaceutical Industries Ltd.**

William P. Watson is a member of the Global Business Development and Corporate Strategy team at Teva Pharmaceuticals, with responsibility for the commercial stage Speciality (non-generic) Business Development activities in the European region.

His previous roles at Teva involved sourcing early stage opportunities (Discovery to Phase 1) from Academic groups, start up and early stage companies.

Prior to joining Teva in 2008 he was based in Copenhagen at H. Lundbeck A/S, initially as Head of Neuropharmacology in the Drug Discovery area , and then as Head of Scientific Licensing within the Business Development group. For the last 2 years of that role he was also an employee-elected member of the company's Board.

A PhD Pharmacologist by training, with particular expertise in drug discovery and early stage drug development, CNS pharmacology, and translation of academic work to the commercial environment, he has also worked in consultancy roles for several smaller and start -up companies.

He holds a Diploma in Management and an MBA from the Open University Business School, is a Member of the Chartered Management Institute, a Fellow of the British Pharmacological Society, and a Fellow of the Royal Society of Biology.

Yves Decadt, *CEO,* **Medimetrics Personalized Medicine**

Yves Decadt is CEO of Medimetrics and CEO and of Co-Founder of BioLingus.

Yves has More than 25 years of global pharmaceutical experience in technical/scientific, business development roles and as CEO.

Yves has been CEO of Stragen Pharma and VP Business Development at SkyePharma, both in Switzerland.

Before that, Yves worked almost 20 years at Johnson and Johnson, in different roles and countries. In his role in the JNJ Global Businesss Development Group, he covered a broad spectrum of deal types, from early stage discovery deals to late-stage co-promotion deals.

Yves Decadt holds a Masters Degree in Bio-Engineering, a Masters Degree in industrial Business Administration (both from the University of Ghent in Belgium) and a Masters Degree in Pharmacology and Pharmaceutical Medicine (from the Medical Faculty at the Free University of Brussels). He also followed an executive business program at IMD in Lausanne, Switzerland.

Yves is Board member of the Swiss Health Care Licensing Group and Member of the Advisory Board of mHealth in the Benelux

Abzena Plc.

www.abzena.com

CONTACT
Dr Sally Waterman
SVP Corporate Development

ADDRESS
Babraham Research Campus
Babraham
Cambridge CB22 3AT
United Kingdom

TEL
+44 (0) 1223 903498

YEAR FOUNDED
2014

SECTOR

• Biotechnology • CMO • CRO

COMPANY PROFILE

Abzena offers a suite of complementary services and technologies to enable the selection, development and manufacture of better biopharmaceuticals which will have a greater chance of reaching the market.

OPPORTUNITIES

Anti-CD52 mAb (humanised)
A novel humanised and deimmunised mAb that binds CD52 which has the potential to be a biobetter version of alemtuzumab. Proof of efficacy has been demonstrated in an animal model of cancer.

Anti-CTLA4 mAb (humanised)

A novel humanised and deimmunised mAb that binds CTLA4 which has the potential to be a biobetter version of ipilimumab. Proof of efficacy has been demonstrated in an animal model of cancer.

Anti-PSMA mAb and ADC
A novel humanised and deimmunised mAb that binds PSMA which has been produced as an ADC. Proof of efficacy has been demonstrated in an animal model of cancer.

MANAGEMENT

Dr John Burt, *CEO*
Dr Sally Waterman, *SVP Corporate Development*
Dr Neil Butt, *VP Business Development*
Dr Mathew Baker, *CSO*
Dr Campbell Bunce, *SVP Scientific Operations*
Julian Smith, *CFO*
Nareshkumar Jain, *SVP (ADC Biomanufacturing) & Global Head of Chemistry*
Donna Hackett, *VP IP, Commercial and Legal Affairs*
Leigh Pierce, *CTO (Biomanufacturing)*
Gary Pierce, *President PacificGMP*
Dr Jim Mills, *VP Technical Operations*

ADDEX Therapeutics Ltd.

www.addextherapeutics.com

CONTACT
Tim Dyer,
Chief Executive Officer

ADDRESS
12, chemin des Aulx
1228 Plan-les-Ouates,
Geneva
Switzerland

TELEPHONE
+41 22 884 1555

EMAIL
investor.relations
@addextherapeutics.com

YEAR FOUNDED
2002

SECTOR

- Biotechnology

COMPANY PROFILE

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and has been granted orphan drug status by the US FDA for PD-LID. Dipraglurant is currently being prepared to enter phase III for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start phase I and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM for neurodegenerative diseases, mGluR7NAM for psychosomatic disorders and TrkBPAM for neurodegenerative disorders and mGluR3PAM, which is being advanced in collaboration with Pierre Fabre Pharmaceuticals. Allosteric modulators are an emerging class of small molecule drugs, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

MANAGEMENT

Tim Dyer, *Chief Executive Officer*
Sonia Poli, *Chief Scientific Officer*
Robert Lutjens, *Head of Discovery*

Adivo

CONTACT
Dr Kathrin Ladetzki-Baehs,
Associate Director, Alliance Management

Dr Markus Waldhuber,
Project Team Leader, Discovery Alliances & Technology

SECTOR

• Biotechnology
Other Sector • Veterinary Medicine

COMPANY PROFILE

Translating expertise in developing human therapeutic antibodies to the veterinary market. Offering service to develop antibody therapeutics as well as developing proprietary antibody therapeutics.

Adivo is a spin-out of leading antibody discovery company MorphoSys AG, which has:
• The most successful antibody library technology,
• A proven antibody development expertise,
• A successful track-record of partnering with pharmaceutical companies
• A deep pipeline of proprietary and partnered human therapeutic programs

MANAGEMENT

Dr Kathrin Ladetzki-Baehs, *Associate Director, Alliance Management*
Dr Markus Waldhuber, *Project Team Leader, Discovery Alliances & Technology*

Akaal Pharma Pty Ltd.

www.akaalpharma.com

CONTACT
Dr Dale Dhanoa
CEO & Managing Director

ADDRESS
Thomas Cherry Building,
#301 E & F
Chemistry Department, La Trobe University,
Bundoora, VIC – 3086,
Australia

TELEPHONE
+61 (3) 9479 2584 (AUS)

EMAIL
info@akaalpharma.com

YEAR FOUNDED
2007

SECTOR

• Biotechnology • Pharmaceuticals/Licensing
Other Sector: • Biotech/Pharmaceuticals

COMPANY PROFILE

Akaal Pharma is a clinical-stage biopharmaceutical company focused on developing novel drugs for the treatment of autoimmune and inflammatory diseases. Akaal Pharma has created a pipeline of novel small molecule drugs for the treatment of Psoriasis, Atopic Dermatitis, Multiple Sclerosis (MS), Ulcerative Colitis (UC) and others. Akaal Pharma has completed a Phase-1 clinical trial of its First-in-Class Topical drug AKP-11 for mild-to-moderate Psoriasis. Two Phase-2 clinical trials for the topical treatment Psoriasis and Atopic Dermatitis (Eczema) are underway.

Akaal Pharma is also developing its Best-in-Class oral drug candidate AKP-210 for the treatment of Multiple Sclerosis (MS), Psoriasis and Ulcerative Colitis (UC).

Akaal Pharma's business strategy is to partner its drug candidates with pharmaceutical and biotech companies for further clinical development, manufacturing and commercialization in exchange for upfront fees, research and development funding, milestone payments and potential royalties on product sales.

PIPELINE

AKP-11/ Phase 2 Clinical Trials for the Treatment of Dermatological Conditions including Psoriasis and Atopic Dermatitis (Eczema)
AKP-11 is a novel Sphingosine 1-Phosphate (S1P) receptor-1 (S1P1) modulator undergoing Phase 2 clinical trials for the treatment of Skin/dermatological diseases including Psoriasis and Atopic Dermatitis (Eczema)

AKP-210 is a novel, safer and effective oral drug candidate in development for the treatment of autoimmune and inflammatory diseases including:
• Multiple Sclerosis
• Ulcerative Colitis
• Psoriasis
• and other diseases

AKP-210 is a potent and highly selective S1P1 receptor modulator in development for the treatment of Multiple Sclerosis, Ulcerative Colitis, Psoriasis and other immune and inflammatory diseases.

OPPORTUNITY

Both the First-in-Class Topical Drug AKP-11 and the Oral Drug AKP-210

MANAGEMENT

Dale S. Dhanoa, PhD, *Chief Executive Officer*
B. S. Sandhu, *Chairman*
Damian W Grobelny, PhD, *Senior Scientist*
Gurmit S. Gill, PhD, *Vice President R&D*
Inderjit Singh, PhD, *Scientific Advisory Board Member*

Akinion Pharmaceuticals AB

www.akinion.com

CONTACT
Dr Richard Jones
CEO

ADDRESS
Karolinska Institutet Science Park
Nobels väg 3
SE-171 65 Solna
Sweden

TELEPHONE
+46 (0)8 524 869 65

EMAIL
info@akinion.com

YEAR FOUNDED
2009

SECTOR

- Pharmaceuticals/Licensing

COMPANY PROFILE

Akinion Pharmaceuticals AB is a privately owned Swedish biotech company with a UK subsidiary focused on the discovery and development of signal transduction inhibitors for the treatment of acute myeloid leukemia (AML).

PIPELINE

Akinion's discovery program has yielded a lead drug candidate, AKN-028 a dual mechanism of action inhibitor of tyrosine protein kinase, FLT3, and a downstream DNA repair target.

AKN-028 is in Phase I/II clinical development and has the potential to be an important new class of drug for the treatment of AML.

OPPORTUNITY

Investment
Akinion is seeking £12m; $17m to complete the ongoing phase Ia/Ib clinical program to translate drug with novel mechanism of action into signs of clinical activity and preparations for POC in phase II.

The next value inflection point will be achievement of signs of clinical activity by late 2018.

MANAGEMENT

Dr Richard Jones, *CEO*
Birgitta Stahl, *COO*
Mikael von Euler, *CMO*
Lars Abrahmsen, *CSO*

amcure GmbH

www.amcure.com

CONTACT
Klaus Dembowsky, MD PhD
CEO

YEAR FOUNDED
2012

SECTOR

- Biotechnology

COMPANY PROFILE

amcure, a spin-off from the Karlsruhe Institute of Technology, develops a first-in-class approach for the treatment of metastatic cancer. Peptide-based compounds target the tumor specific co-receptor CD44v6 and function as allosteric RTK inhibitors. They show significant efficacy in relevant POC animal models against highly metastatic epithelial cancers.

Complex formation with CD44v6 is a prerequisite for the activation of several receptor tyrosine kinases (RTKs) that are critical for tumor growth, angiogenesis and metastasis (e.g. VEGFR-2 and c-Met).

The objective is to show a proof-of-concept in man in a Phase I/Ib study for the treatment of CD44v6-expressing metastatic cancers.

PIPELINE

AMC303 - preclinical development

MANAGEMENT

Klaus Dembowsky, MD PhD, *CEO*
Matthias Klaften, PhD, *COO/CFO*
Alexandra Matzke-Ogi, PhD, *CSO*

APIM Therapeutics AS

www.apimtherapeutics.com

CONTACT
Kostas Alevizopoulos, PhD,
Chief Executive Officer

ADDRESS
c/o NTNU Technology Transfer AS
Sem Sælandsvei 14
Kjemiblokk 1, 3etg
N-7491 Trondheim
Norway

TELEPHONE
+47 73 49 4002

EMAIL
contact@apimtherapeutics.com

YEAR FOUNDED
2009

SECTOR

- Biotechnology

FINANCIAL SUMMARY

APIM Therapeutics has raised more than 5.5M EUR from public and private sources since its creation in 2009 (latest transactions concluded in March 2015 and a bridge transaction in January 2016).

Current investors include Sarsia Seed (www.sarsiaseed.com), NIK III (www.televenture.no) and Birk Venture (www.birkventure.com), among others.

COMPANY PROFILE

APIM Therapeutics is a VC-financed, Norwegian biotechnology company developing first-in-class peptide drugs for various oncology indications. Currently at the CTA-stage, we are seeking investments and/or collaboration opportunities to bring our lead drug ATX-101 to the clinic.

We target a novel therapeutic intervention point offering strong potentiation of the action of 29 different chemotherapeutic and targeted drugs across multiple cancer indications. Consequently, ATX-101 has shown proof-of-efficacy in multiple in vivo and ex vivo cancer models of solid tumors and blood cancer (e.g. breast, bladder, prostate, multiple myeloma, leukemia) in combination with several clinical drugs.

Having concluded GLP toxicology studies, the company will be submitting two clinical trial applications to regulatory authorities in early 2016. Two Phase I/IIa clinical trials in advanced cancer (intravenous administration) and non-muscle invasive bladder cancer (localized treatment) are planned for 2016.

PIPELINE

ATX-101/CTA-stage (2 Clinical Trial Applications ready to file)
ATX-101 is a first-in-class peptide drug targeting a yet unexploited therapeutic intervention point highly relevant for cancer escape in multiple cancer indications.

Briefly, ATX-101 abrogates protein protein interactions between a master cell regulator/organizer called PCNA (Proliferating Cell Nuclear Antigen; involved in the regulation of cell cycle, DNA repair, apoptosis, epigenetics and immune system responses) and client proteins containing a specific PCNA-binding recognition motif during stress (e.g. stress induced by several families of chemotherapeutic agents). As such, ATX-101 prevents correction of damages introduced in cancer cells by chemotherapy pushing them to death. In addition, ATX-101 interferes with the capacity of PCNA to regulate key signaling pathways such as PI-3K, MAPK and AKT. This property affords strong combinatorial action with several targeted agents. Observed in: i) cancer cells of different origins and ii) regulating responses to 29 different drugs, we believe that this mechanism of action brings significant therapeutic and market potential.

Our clinical plans (2016) include the following 2 trials:

1. A Phase I/IIa clinical trial of intravenous ATX-101 in advanced cancer patients

2. A phase I/IIa clinical trial of intravesical ATX-101 co-administered together with Mitomycin-C in superficial bladder cancer patients. As this study involves early stage patients and a marker-lesion design (i.e. dose escalation in the presence of a single tumor lesion), it could offer a preliminary but relevant efficacy endpoint already in phase I/IIa.

OPPORTUNITIES

ATX-101 Investment)
We are interested in identifying investors wishing to lead and/or co-invest with the existing investor syndicate in order to finance the planned clinical program of ATX-101 (two clinical phase I/IIa trials). Current funding requirements are estimated at 4.5-5M EUR over the next 24 months.

continued...

APIM Therapeutics AS

www.apimtherapeutics.com

CONTACT
Kostas Alevizopoulos, PhD,
Chief Executive Officer

ADDRESS
c/o NTNU Technology Transfer AS
Sem Sælandsvei 14
Kjemiblokk 1, 3etg
N-7491 Trondheim
Norway

TELEPHONE
+47 73 49 4002

EMAIL
contact@apimtherapeutics.com

YEAR FOUNDED
2009

...continued

ATX-101 Partnering/Licensing

We are interested in exploiting partnering/licensing synergies with pharmaceutical companies developing targeted agents for various indications aiming to prevent cancer escape and resistance and prolong responses of their inhibitors.

Our data support a role of ATX-101 in increasing the efficacy and prevent escape in rsponse to targeted agents such as HER1/2 and other receptor tyrosine kinase pathway inhibitors.

MANAGEMENT

Kostas Alevizopoulos, PhD, *Chief Executive Officer.*
Senior biomedical executive with >15 years development and commercialization experience in the biotech/pharma sector.

Prof. Marit Otterlei, *Chief Scientific Officer.*
Professor at the Norwegian Institute of Science and Technology, company founder and primary inventor APIM APIM's IP.

Athera Biotechnologies AB

www.athera.se

CONTACT
Carina Schmidt
CEO

ADDRESS
Athera Biotechnologies AB
Sankt Eriksgatan 117, 4th floor
113 43 Stockholm,
Sweden

TELEPHONE
+46 76 1938 190

EMAIL
c.schmidt@athera.se

YEAR FOUNDED
2002

SECTOR

- Biotechnology

COMPANY PROFILE

Athera is a clinical stage biotech company with its origin from Karolinska Institutet. The Company is developing targeted anti-inflammatory bio-therapeutics and companion diagnostics with the primary focus on secondary prevention and treatment of cardiovascular disease ("CVD"). Athera initiated the current programs in 2005, and today has a its lead project, PC-mAb, in clinical development, supported by an approved proprietary companion diagnostic kit, CVDefine® kit. PC-mAb, is currently in a Phase I clinical study in PAD patients undergoing revasculaization interventions. The plan is that proof-of-activity data will drive an exit to a pharmaceutical partner that will pursue later clinical development and commercialization.

MANAGEMENT

Carina Schmidt MSc, *CEO*
Knut Pettersson PhD, *CSO*
Gunilla Ekström MD, PhD, *VP Operations/Clinical*
Anders Bergman PhD, *VP IP/Legal*
Karin Wåhlander MD, PhD, *Senior Advisor clinical development*
Tommy Abrahamsson PhD, *Senior Advisor pharmaceutical development*
Gunnar Olsson, MD, PhD ,*Chairman, former head of CV/GI in AstraZeneca*
Jonas Brambeck PhD, *Board Director, Investment Manager Industrifonden*
Otto Skolling, MSc, *Board Director*
Svein Mathisen, MSc, *Board Director, former CEO of Bioinvent International AB (publ)*

ATRIVA Therapeutics GmbH

www.atriva-therapeutics.com

CONTACT
Dr. Rainer Lichtenberger, MBA
CEO

YEAR FOUNDED
2015

SECTOR

• Biotechnology • Pharmaceuticals/Licensing

FINANCIAL SUMMARY

Founded April 2015

Founders Seed Round November 2015

Convertible Loan January 2016

COMPANY PROFILE

Atriva Therapeutics GmbH stands for new antitviral therapies.

We are primarily focusing on influenza, but have also strongly encouraging data against other viruses. Most recently we discovered a significant activity of MEK-Inhibitors against selected bacterial targets of commercial relevance as well.

Due to repurposing of existing and nearly off-patent, clinically-proven MEK inhibitors, we are able to prepare for clinical challenge studies still in 2016 in our first indication.

The inventors, all internationally renowned KOL's in viral research, have build a strong global patent portfolio on usage and formulation for a variety of indications and compounds.

The founders teams comprises a wealth of relevant research & development, business and commercial experience..

PRODUCT PIPELINE

ATR-001: Small molecule, MEK-Inihibitor, Indication: Influenza, Stage: Clinical Candidate

ATR-003: Small molecule, MEK-Inihibitor, Indication: Influenza, Stage: Clinical Candidate

ATR-004: Small molecule, Indication: not disclosed, Stage: Lead

ATR-005: Small molecule, Indication: not disclosed, Stage: Lead.

MANAGEMENT

Dr. Rainer Lichtenberger, MBA, *CEO*
Prof. Dr. Oliver Planz, *CSO (design.)*
Dr. Sebastian Canisius, MD, *CMO*
Dr. Henrik Luessen, *CBO*
Emilie Hofstetter, *Chief Strategy Officer*

Avexxin AS

www.avexxin.com

CONTACT
Scott B. Woodward
CBO

ADDRESS
Department of Biology
Norwegian University of Science and Technology
Høgskoleringen 5
N-7491 Trondheim
Norway

TELEPHONE
+47 73 59 61 07

EMAIL
eh@avexxin.com

YEAR FOUNDED
2005

SECTOR

- Biotechnology

COMPANY PROFILE

AVEXXIN HAS COMPLETED PHASE IIB AS OF JUNE 2015 for Psoriasis. We are seeking additional investment to move our programs forward. We recently raised $2.5M in 2015 and are looking for an additional $5-6M investment. We are would also be interested in discussing potential licensing deals.

Avexxin AS is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders. With our target cPLA2, we feel we can target a range of inflammatory conditions.

(1) AVX001 is being developed for the topical treatment of psoriasis (and other dermatological inflammatory disorders). The small molecule targets the group IVA phospholipase A2 (cPLA2) enzyme regulating the cytokine-induced activation of the proinflammatory nuclear transcription factor-kappa B (NF-kappa B). AVX001 is a clinical stage asset undergoing an ascending-dose phase I/IIA trial in patients.

(2) AVX002 and AVX235 are pre-clinical stage assets that also target cPLA2. They are being developed for the treatment of rheumatoid arthritis and glomerulonephritis, respectively. In preliminary animal testing, AVX235 has also exhibited significant anti-cancer activity. AVX001, AVX002 and AVX235 are lead compounds from two distinct chemical families being developed by Avexxin.

OPPORTUNITIES

We are looking to license all assets

MANAGEMENT

Scott B. Woodward, *CBO*
Berit Johansen, *CSO and Founder*
Mikael Oerum, *President and CEO*
Peter Damsbo, MD, *Chief Medical Officer*
Anders Ljungqvist, M.Sc. (Pharm), *Head Regulatory Affairs*
Dennis B. Henriksen, PhD, *Quality Assurance Manager*

BerGenBio AS

www.bergenbio.com

CONTACT
Mr Richard Godfrey
Chief Executive Officer

ADDRESS
BerGenBio AS
Jonas Lies vei 91
5009, Bergen,
Norway

TELEPHONE
+47 535 01 564

EMAIL
post@bergenbio.com

YEAR FOUNDED
2008

SECTOR

- Biotechnology

COMPANY PROFILE

BerGenBio is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers.

The Company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), which is widely recognised as a key pathway in immune evasion, acquired cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of first-in-class EMT inhibitors.

BerGenBio intends to develop its drug candidates to proof of concept stage; further clinical development and subsequently commercialisation will be through strategic alliances and partnerships with appropriate global bio-pharma oncology businesses.

PRODUCT PIPELINE

BGB324 Phase II
First-in-class orally bioavailable small molecule inhibitor of AXL.
• BGB101 preclinical • mAb against AXL

BGB002 preclinical
First-in-class, orally bioavailable small molecule
• Proprietary target.



OPPORTUNITIES

BGB324
Out licening opportunity to forward develop in multiple oncology positions.
BGB324, lead compound, back up molecules and companion diagnistics

BGB101
Out license opportunity to forward develop into clinical development

MANAGEMENT

Mr Richard Godfrey, *Chief Executive Officer*
Prof James Lorens, *Chief Scientific Officer*
Dr Murray Yule, *Clinical Development Officer*
Mr Petter Nielsen, *Chief Financial Officer*
Dr Anthony Brown, *Research Director*
Dr Endre Kjærland, *Associate Director of IP and Contracts*
Dr Julia Schölermann, *Business Support Manager*

Bicycle Therapeutics Limited

www.bicycletherapeutics.com

CONTACT
Christophe Bonny
CSO

ADDRESS
Meditrina Building
Babraham Research Campus
Cambridge CB22 3AT
United Kingdom

TEL
+44 (0)1223 497 415

EMAIL
info@bicycletherapeutics.com

YEAR FOUNDED
2009

SECTOR

- Biotechnology

COMPANY PROFILE

Bicycle Therapeutics is a UK biotech developing highly constrained bicyclic peptides (bicycles) as a novel class of therapeutic

Bicycles have the affinity and specificity associated with antibodies, but are much smaller in size and can be chemically synthesised. They have been shown to address targets not easily tractable with small molecules (e.g. protein-protein interactions).The company is exploring applications in a number of areas where these advantageous features have the potential to show significant benefit.

Bicycle Therapeutics is backed by top-tier VC investors and is seeking to realise the full potential of Bicycle technology by developing an internal pipeline of bicycles into the clinic, as well as allowing partners access to the technology platform through selected R&D collaborations.

MANAGEMENT
Kevin Lee, *CEO*
Christophe Bonny, *CSO*
Edward Garmey, *CMO*
Alan Watt, *VP Therapeutics*
Robert Lutz, *Oncology lead*

BioLineRx Ltd.

www.biolinerx.com

CONTACT
David Malek, MBA
Vice President of Business Development

ADDRESS
Modi'in Technology Park
2 HaMa'ayan Street
Modi'in 7177871
Israel

TELEPHONE
+972-8-642-9100

EMAIL
info@BioLineRx.com

YEAR FOUNDED
2004

SECTOR

- Biotechnology

COMPANY PROFILE

BioLineRx (NASDAQ: BLRX) identifies, in-licenses and develops innovative biopharmaceutical projects, both in preclinical and clinical stages. Our company currently actively develops two clinical-stage projects: BL-8040 (CXCR4 antagonist against several liquid and solid tumors) and BL-7010 (for the treatment of celiac disease).

We are actively looking for new projects for our pipeline and for our partnership with Novartis.

PRODUCT PIPELINE

BL-8040/Phase II

BL-8040 is a novel synthetic peptide which acts as a CXCR4 antagonist and inverse agonist, and is being investigated for the treatment of multiple indications:AML (consolidation treatment as well as r/r AML), Stem Cell Mobilization and pancreatic cancer. CXCR4 is over-expressed in more than 70% of human tumors and has been shown to directly stimulate tumor outgrowth, invasion and formation of blood vessels. In addition, it regulates stromal cell adhesion-mediated drug resistance to chemotherapy.

Studies have demonstrated BL-8040's efficacy by utilizing two distinct attributes: first, it allows for the mobilization of stem cells and cancer cells from the bone marrow to the peripheral blood stream, resulting in increased sensitivity to anti-cancer agents such as antibodies and chemotherapy. In parallel, BL-8040 blocks survival and angiogenic signals, subsequently leading directly to the apoptosis of cancer cells. In a phase I/II clinical study conducted with multiple myeloma patients, BL-8040 showed a good safety profile and an outstanding capability in the mobilization of cancer cells from bone marrow to plasma. BL-8040 expansion stage of a Phase II clinical trial in relapsed/refractory AML is ongoing, after successfully completing its dose escalation stage. Additional Phase II clinical trial has been initiated for AML consolidation treatment. Moreover, a Phase I clinical trial for stem cell mobilization has been successfully completed and several other studies are planned in hematological malignancies.

In January 2016 BioLineRx has announced a clinical collaboration with Merck to investigate the combination of BL-8040 with Keytruda in metastatic pancreatic cancer patients.

BL-5010

BL-5010 is a novel formulation composed of approved components for non-surgical removal of benign skin lesions such as warts, Seborrheic Keratosis and AK. BL-5010 offers an alternative to painful, invasive and expensive removal treatments including surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and eliminates the need for anesthesia or bandaging. BL-5010 is applied topically to the lesion, using a unique device, for a few minutes and causes the lesion to gradually dry out and slough off.

The OTC rights for this product in Europe and several other terriotries have been licensed to Omega Pharma (now Perrigo).

BL-7010 / Phase II

BL-7010 is a novel, non-absorbable, high-molecular-weight polymer investigated for the treatment of celiac disease and gluten sensitivity. It has a high affinity for gliadins, the immunogenic peptides present in gluten that cause a pathological reaction in celiac disease patients. Preclinical studies have shown that BL-7010 prevents pathological damage to the small intestine, helps to preserve the integrity of the intestinal mucosa and reduces inflammation. In addition, a clinical study in celiac patients has shown BL-7010 to be safe following multiple administrations.

MANAGEMENT

Kinneret Savitsky PhD, *Chief Executive Officer*
Philip A. Serlin, CPA, MBA, *Chief Financial & Operating Officer*
David Malek, MBA, *Vice President of Business Development*
Arnon Aharon, MD, *Vice President of Medical Affairs*

BioSight Ltd.

www.biosight-pharma.com

CONTACT
Dr Ruth Ben Yakar
CEO

ADDRESS
Hanapach 34, Industrial Park,
Karmiel 21653,
P.O.B 6372,
Israel

EMAIL
contact@biosight-pharma.com

YEAR FOUNDED
2000

SECTOR

- Biotechnology

COMPANY PROFILE

BioSight is a clinical stage drug development company, developing Astarabine™, a Breakthrough Therapy Designation candidate for treatment of acute leukemia, addressing severe unmet medical needs and multi-billion dollar markets.

BioSight lead product Astarabine™ targets world-wide sales of several billions of dollars and rapid market penetration rate, as it addresses severe unmet needs in the treatment of leukemia, aiming to replace the AML first-line chemotherapy drug, cytarabine, which conveys major, life-threatening side effects that limit its use and leave most of the patients with no adequate treatment.

Astarabine™ is a non-toxic, cancer-targeted novel drug under clinical development for the treatment of leukemia (AML & ALL), now completing a successful Phase 1/2a trial for treatment of leukemia. Results to date demonstrate excellent safety profile and high response rates in patients otherwise unfit for conventional intensive chemotherapy.

BioSight completed a successful Pre-IND meeting with the FDA for a Phase 2b trial in AML. FDA agreed that Astarabine™ will be considered as a 505(b)(2) application and is suitable for a Fast Track Designation, as well as for a Breakthrough Therapy Designation pending clinically-meaningful results in the Phase 2b trial. Moreover, the FDA referred to AstarabineTM as a “potentially transformative treatment”.

Hence, Astarabine™ addresses multi-billion dollar markets, with a potential for a shorter time-to-market due to the clear unmet medical need it addresses, the promising clinical data, and FDA’s position.

PRODUCT PIPELINE

Astarabine™ : Clinical stage: Completing Phase 1/2a

BioSight lead product Astarabine™ targets world-wide sales of several billions of dollars and rapid market penetration rate, as it addresses severe unmet needs in the treatment of leukemia, aiming to replace the AML first-line chemotherapy drug, cytarabine, which conveys major, life-threatening side effects that limit its use and leave most of the patients with no adequate treatment.

Astarabine™ is a non-toxic, cancer-targeted novel drug under clinical development for the treatment of leukemia (AML & ALL), now completing a successful Phase 1/2a trial for treatment of leukemia. Results to date demonstrate excellent safety profile and high response rates in patients otherwise unfit for conventional intensive chemotherapy.

BioSight completed a successful Pre-IND meeting with the FDA for a Phase 2b trial in AML. FDA agreed that Astarabine™ will be considered as a 505(b)(2) application and is suitable for a Fast Track Designation, as well as for a Breakthrough Therapy Designation pending clinically-meaningful results in the Phase 2b trial. Moreover, the FDA referred to AstarabineTM as a “potentially transformative treatment”.

Hence, Astarabine™ addresses multi-billion dollar markets, with a potential for a shorter time-to-market due to the clear unmet medical need it addresses, the promising clinical data, and FDA’s position.

OPPORTUNITIES

Investment

BioSight is in a financial round to raise $10m to fund a Phase 2b study.

This investment would be sufficient to bring the company to an exit: IPO/M&A/licensing

Licensing

BioSight is looking for a strategic partner for the late clinical stage development of Astarabine™ and its marketing.

Continued...

BioSight Ltd.

www.biosight-pharma.com

CONTACT
Dr Ruth Ben Yakar
CEO

ADDRESS
Hanapach 34, Industrial Park,
Karmiel 21653,
P.O.B 6372,
Israel

EMAIL
contact@biosight-pharma.com

YEAR FOUNDED
2000

...continued

BioSight lead product Astarabine™ targets world-wide sales of several billions of dollars and rapid market penetration rate, as it addresses severe unmet needs in the treatment of leukemia, aiming to replace the AML first-line chemotherapy drug, cytarabine, which conveys major, life-threatening side effects that limit its use and leave most of the patients with no adequate treatment.

Astarabine™ is a non-toxic, cancer-targeted novel drug under clinical development for the treatment of leukemia (AML & ALL), now completing a successful Phase 1/2a trial for treatment of leukemia. Results to date demonstrate excellent safety profile and high response rates in patients otherwise unfit for conventional intensive chemotherapy.

BioSight completed a successful Pre-IND meeting with the FDA for a Phase 2b trial in AML. FDA agreed that Astarabine™ will be considered as a 505(b)(2) application and is suitable for a Fast Track Designation, as well as for a Breakthrough Therapy Designation pending clinically-meaningful results in the Phase 2b trial. Moreover, the FDA referred to AstarabineTM as a “potentially transformative treatment”.

Hence, Astarabine™ addresses multi-billion dollar markets, with a potential for a shorter time-to-market due to the clear unmet medical need it addresses, the promising clinical data, and FDA’s position.

MANAGEMENT

Dr Ruth Ben Yakar, *CEO*
Dr Stela Gengrinovitch, *Founder, Chief Scientist*

Canbex Therapeutics Ltd.

www.canbex.co.uk

CONTACT
Jesse Schulman
CEO

ADDRESS
London BioScience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

TELEPHONE
+44 (0) 20 7554 5872

EMAIL
enquiries@canbex.co.uk

YEAR FOUNDED
2006

SECTOR

- Biotechnology

FINANCIAL SUMMARY

In early 2015, Canbex entered an option agreement with Paris-based global specialty pharma firm Ipsen. Under the deal, Ipsen has the option to acquire Canbex for up to €90m ($103m) and royalties. The Ipsen deal is specific to VSN16R and the Canbex shareholders retain a portfolio of novel lead molecules.

Canbex raised a $3.2m Series A led by Merck Serono Ventures which closed April 2013 and has successfully attracted grant and foundation funding, including from the Wellcome Foundation, the US and UK National Multiple Sclerosis Foundations, and the UK government's Biocatalyst program. Equity funding to date is approximately $6m.

COMPANY PROFILE

Best-in-class potassium channel openers for neurological disorders

Lead compound in Phase II, partnered with Ipsen

Seeking partners for follow-up compounds

Latest news: Fragile X Syndrome validated in animal model

Canbex is developing its validated VSN small molecule compounds that selectively regulate nervous system excitability via the BKCa potassium channel. The VSN series has potential applications in movement disorders, glaucoma, epilepsy, neuropathic pain and others including the orphan paediatric disorder Fragile X Syndrome.

The VSN compounds are activators of the BKCa large conductance potassium channel. The company's lead BKCa activator, VSN16R, is in Phase II for the treatment of spasticity in people with multiple sclerosis, an important and poorly served indication. The Phase II trial of VSN16R for spasticity in MS is being carried out under an option agreement with Ipsen SA, which aims to add VSN16R to its growing portfolio of spasticity treatments.

The VSN compounds counter hyper-excitability without causing sedation. The Canbex proprietary VSN compounds are the only known BKCa activators that are selective, and in addition are highly soluble drug-like compounds.

Canbex is currently seeking investment and partnerships for its extensive suite of BKCa activators in a range of indications.

Canbex believes that it has a potentially high value class of assets which are validated by the successful Phase I of VSN16R and the Ipsen deal.

PRODUCT PIPELINE

VSN16R: Phase II
VSN follow-up compounds: lead optimisation
VSN16R is a potassium channel opener in Phase II for the treatment of spasticity, a movement disorder, in patients with multiple sclerosis.

VSN follow-up compounds: lead optimisation

OPPORTUNITIES

Fragile X Syndrome
Canebx has recently validated the VSN series in the fmr1 knockout mouse model of Fragile X Sydrome, a genetic disorder leading to mental retardation. The VSN follow-up compounds are in lead optimsation with therpeutic potential in Fragile X Syndrome, glaucoma, epilepsy, neuropathic pain, neurodegenration and other disorders involving excess excitability in nervous and endothelial tissues.

Continued...

Canbex Therapeutics Ltd.

www.canbex.co.uk

CONTACT
Jesse Schulman
CEO

ADDRESS
London BioScience Innovation Centre
2 Royal College Street
London NW1 0NH
United Kingdom

TELEPHONE
+44 (0) 20 7554 5872

EMAIL
enquiries@canbex.co.uk

YEAR FOUNDED
2006

...continued

Glaucoma

Canbex has animial model data from multiple models demonstrating that the VSN compounds lover intraocular pressure. Moreover, the VSN compound class is known to be neuroprotective, which is currenlty seen as essential for new glaucoma treatments.

Canbex is seeking corporate partners and investors for its glaucoma program.

MANAGEMENT

Jesse Schulman, *CEO*
Keith Powell, *Chariman*
Miroslav Ravic, *CMO*
Jill Makin, *CMC*
Allison Morgan, *Clinical Operations*

CELLTHERAPY
REGENERATIVE MEDICINE FOR LIFE

Cell Therapy Ltd.

www.celltherapyltd.com

CONTACT
Mark Beards
Corporate Development Director

ADDRESS
The Maynard Centre
Forest Farm Industrial Estate
Longwood Drive
Cardiff
CF14 7YT
United Kingdom

EMAIL
info@celltherapyltd.com

YEAR FOUNDED
2009

SECTOR

- Regenerative Medicine

COMPANY PROFILE

Cell Therapy Limited (CTL) is a Cardiff-based pharmaceutical company focused on the discovery and development of regenerative medicines in areas of high unmet patient need. CTL was founded in 2009 by Novel prize winner Professor Sir Martin Evans and Ajan Reginald, former Global Head of Emerging Technologies at Roche, and includes world-class scientists and clinicians led by experienced management, an active Board and a scientific advisory committee of world experts.

CTL has developed a novel and proprietary platform, based on the stem cell discoveries of Sir Martin Evans, which can isolate tissue-specific stem cells from donor blood, and is developing a range of allogeneic therapies for different indications. Its lead product, Heartcel™, has demonstrated unprecedented survival rates in patients with advanced heart failure in a Phase II clinical trial. Cell Therapy's heart failure product franchise also includes Myocardion™, and targets the 20 million patient heart failure market. Cell Therapy is also developing Tendoncel™, a topical regenerative medicine for tendon repair, and Skincel™, a regenerative dermatology therapy.

MANAGEMENT

Prof. Sir Martin Evans, *President & Chief Scientific Officer*
Mr. Ajan Reginald, *Chief Executive Officer*
Mark Hughes, *Chief Financial Officer*
Dr. Sabena Sultan, *Research & Development Director*
David Preston, *Chief Operating Officer*
Mark Beards, *Corporate Development Director*

Cellestia Biotech AG

www.cellestiabiotech.com

CONTACT
Dr Michael Bauer
CEO

ADDRESS
Technology Park Basel
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland

EMAIL
michael.bauer
@cellestiabiotech.com

YEAR FOUNDED
2014

SECTOR

- Biotechnology

FINANCIAL SUMMARY

Cellestiabiotech AG is a privately owned company, which has attracted non-dilutive funding (CTI) as well as private equity funding in a recently closed SEED A financing round. The SEED B financing round is open for investment, targeting a total of up to 3.295 mCHF, to bring the company to clinical stage within the next 12-18 months.

COMPANY PROFILE

Cellestia Biotech AG is a spin-off from Swiss Institute for Experimental Cancer Research at University Lausanne, EPFL, Switzerland.

Cellestia is developing a first-in-class, pan-NOTCH inhibitor for the treatment of NOTCH pathway activation dependent cancer. It is the first compound targeting NOTCH centally in the cell nucleus (transcription complex), thereby controlling NOTCH activation regardless of its cause. In contrast to all competitors, Cellestia´s lead compound can also control NOTCH constitutive activation, a currently unmet medical need.

For the lead compound, preclinical proof of efficacy has been demonstrated in vitro, animal models and, most importantly, leukemia patient derived blood samples, demonstrating selective killing of leukemic cells.

PIPELINE

CB-103, a small molecule inhibiting the NOTCH transcription complex in the cell nucleus.

OPPORTUNITY

Investment
Cellestia Biotech is seeking private equity and/or VC investment to advance the project to clinical stage.

MANAGEMENT

Dr Michael Bauer, *CEO*
Dr Dirk Weber, *CMO*
Dr Rajwinder Lehal, *CSO*

Cellply s.r.l.

www.cellply.com

CONTACT
Massimo Bocchi
CEO & co-founder

ADDRESS
Via Giuseppe Massarenti 61
I-40138 Bologna
Italy

TELEPHONE
+39 051 0397670

EMAIL
info@cellply.com

YEAR FOUNDED
2013

SECTOR

• Biotechnology • Medical Devices • Diagnostics

COMPANY PROFILE

Cellply develops an in-vitro diagnostic platform for personalization of cancer treatment and patient stratification through a Companion Diagnostic model. Patient's response to anticancer drugs is defined by measuring ex-vivo cell death induced on clinical samples obtained from blood, bone marrow or fine-needle aspirates. Supported drugs are by cytotoxic and cytolytic drugs, including targeted therapies and chemotherapies, with direct or mediated mechanisms of action. The test is performed at the bedside, in contrast with existing services available remotely, thanks to a proprietary microfluidic technology automating sample preparation and the entire analysis. Clinical pipeline includes hematologic and solid tumors, with a first focus on leukemias.

MANAGEMENT

Massimo Bocchi, *CEO & co-founder*
Roberto Guerrieri, *co-founder*
Laura Rocchi, *Head of Assay Development*
Andrea Faenza, *Head of Microsystem Engineering*
Luca Giulianelli, *Head of Software Engineering*

ContraVir Pharmaceuticals, Inc.

www.contravir.com

CONTACT
James Sapirstein
CEO

ADDRESS
399 Thornall Street, 1st Floor
Edison, NJ 08837
USA

TELEPHONE
+1 (732) 902-4000

EMAIL
info@contravir.com

YEAR FOUNDED
2013

SECTOR

- Biotechnology

COMPANY PROFILE

ContraVir is developing targeted antiviral therapies with two drug candidates in clinical studies. FV-100, now in Phase 3 trials, is being developed for the treatment of herpes zoster, or shingles, and shingle pain. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®).

PRODUCT PIPELINE

FV-100 / Phase 3
ContraVir is initiating a pivotal Phase 3 trial in to further explore FV-100's potential to reduce the incidence of shingles pain and post-herpetic neuralgia.

CMX157 / Phase 2 Ready
Having demonstrated favorable safety and efficacy in Phase 1 trials, ContraVir is planning to initiate a Phase 2 study in Hepatitis B ("HBV").



MANAGEMENT

James Sapirstein, *CEO*
John Sullivan-Bolyai, *CMO*
Terri Matkovits, *VP, Product Development*

Curetis N.V.

www.curetis.com

CONTACT
Oliver Schacht
CEO

ADDRESS
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany

TELEPHONE
+49 (0)7031 / 49195-10

EMAIL
contact@curetis.com

YEAR FOUNDED
2007

SECTOR

- Diagnostics

FINANCIAL SUMMARY

See company's investor website for public filings

COMPANY PROFILE

Founded in 2007, Curetis is a molecular diagnostics company which focuses on thedevelopment and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

PIPELINE PRODUCT

Unyvero Platfom / commercial stage
Unyvero is a platform that allows rapid detection of highly multiplexed panels pf pathogens and antibiotic resistance markers in a cartridge based sample to answer format.

Unyvero P55 Pneumonia Cartridge / commercial
Comprehensive panel covering around 40 analytes from lower respiratory tract samples (sputum, aspirates, BAL)

Unyvero ITI application cartrige / commercial
Application cartridge for implant and tissue infections (inc PJI,, SSI, SSTI, diabetic foot ulcers, burn wounds, catheters etc.) covering 80 analytes.

OPPORTUNITIES

Commercial distribution partnerships in certaiu nEU countries and RoW countries

Pharma partnering for Unyvero use in clinical trials of novel antibiotics

MANAGEMENT

Oliver Schacht, *CEO*
Dr. Achim Plum, *CCO*
Johannes Bache, *COO*
Andreas Boos, *CTO*
Heiko Schorr, *Director Finance*

DC4U B.V.

www.dc4u-technologies.nl

CONTACT
Antoine Wellink MSc
CEO

ADDRESS
Joop Geesinkweg 167,
1114 AB Amsterdam -Duivendrech
The Netherlandst

TELEPHONE
+31 (0)20 7 234 412

EMAIL
antoine.wellink
@dc4u-technologies.nl

YEAR FOUNDED
2006

SECTOR

- Biotechnology

COMPANY PROFILE

DC4U develops new generation glycan-antigen conjugate based immunotherapeutics

DC4U is a life science company with a technology platform applied to develop better drugs for allergy, autoimmune diseases and cancer. DC4Us glycan-antigen conjugate based products are the new generation immunotherapeutics, either boosting or suppressing responses of the human immune system to disease.

The GlycoDC technology of DC4U is unique. It uses specific and proprietary glycan structures, which are covalently linked to antigen peptides or proteins. The glycans are naturally occurring human oligosaccharides which form recognition elements for specific antigen presenting cell receptors. The glycan-antigen conjugate products:

1. targets the antigen peptide directly to the relevant immune (dendritic) cell receptor,
2. improves uptake of the antigen peptide and
3. instructs the immune system to induce either antigen-specific tolerance or immunity.

DC4U has shown proof-of-principle for its dendritic cell targeting technology via the development of a pipeline of products with highly promising preclinical in-vivo efficacy results. Two of these products are being developed in collaboration with pharma / food companies. DC4U intends to develop its proprietary 2,6 sia-myelin Multiple Sclerosis product and its 2,3 sia-grass pollen Allergy product up to Phase IIa clinical Proof of Concept. At that point the company will seek a licensing partner for further development and marketing. In parallel, DC4U seeks to apply its technology in additional areas in collaboration with industrial partners with proprietary antigen based products.

DC4U is looking for investors in its multiple sclerosis and allergy pipeline and co-development partners in the pharmaceutical industry for application of the GlycoDC technology in auto-immune diseases, allergy and therapeutic cancer vaccines.

PRODUCT PIPELINE



2,6 sia-myelin peptide conjugate / preclinical

The 2,6 sia-myelin conjugate product is a new generation immunotherapeutic to treat Multiple Sclerosis. The product is composed of a mixture of 3 glycan-autoantigen conjugates. The selected auto-antigens are T-cell epitope peptides derived from the 3 major myelin auto-antigens: Myelin Oligodendrocyte Glycoprotein (MOG), Myelin Basic Protein (MBP) and Proteolipid Protein (PLP). The applied glycan structure, '6 sialyl N-acetyllactosamine ("2,6 sia"), is a naturally occurring human oligosaccharide which specifically binds to dendritic cell siglec receptors. The glycan and peptide are conjugated via a linker.

Continued...

DC4U B.V.

www.dc4u-technologies.nl

CONTACT
Antoine Wellink MSc
CEO

ADDRESS
Joop Geesinkweg 167,
1114 AB Amsterdam -Duivendrech
The Netherlandst t

TELEPHONE
+31 (0)20 7 234 412

EMAIL
antoine.wellink
@dc4u-technologies.nl

YEAR FOUNDED
2006

...continued

The Siglec receptor recognizes the sialic acid glycans as being part of a "self" protein. This results in:
1. DC specificity of the sia-myelin;
2. Increased DC uptake and MHC presentation of the myelin derived peptides
3. Suppression of unfavourable CD4+ and CD8+ effector T cell responses
4. Induction of favourable MOG/MBP/PLP specific regulatory T-cells for long-term tolerance
5 Tolerance induction in the brain. DC Siglec receptors are also present on microglia, i.e. brain antigen presenting cells that persist the severity of MS. Sia-myelin may tolerize brain resident microglia as well, and therefore may dampen MS both systemically as well as in the brain.
6 Low & local dosing requirement

Proof-of-Principle for the technology in MS treatment has been established with one of the components of the vaccine, 2,6 sia-MOG35-55. Experiments demonstrated that the glycation of an antigen changes the program of dendritic cells towards a tolerogenic, suppressive stage on multiple levels. Results show that the 2,6 sia-MOG35-55 peptides generate a higher percentage of CD4+FoxP3+ T (T-reg) cells compared to non-glycated peptides. Furthermore, compared to the non-modified peptide, the 2,6 sia-MOG35-55 peptides showed a lower IFN-y+ production, a measure of CD4+ effector T-cell activation. Further in vivo testing in EAE models is ongoing.

We have chosen Multiple Sclerosis as a first indication for the application of our technology in auto-immune diseases. The approach may as well be used for the treatment of other autoimmune diseases.

OPPORTUNITY

DC4U multiple sclerosis
DC4U is looking for investors and a pharmaceutical co-development partner for its multiple sclerosis product (see "Product 1").

DC4U Allergy
DC4U is looking for investors in its allergy pipeline and co-development partners in the pharmaceutical industry for new applications of the GlycoDC technology in allergen specific immunotherapy.

DC4U Therapeutic Cancer Vaccines
DC4U is looking for investors and co-development partners in the pharmaceutical industry for application of the GlycoDC technology in therapeutic cancer vaccines.

MANAGEMENT

Antoine Wellink MSc, *CEO*
Prof. Yvette van Kooyk, *CSO*

EMTensor GmbH

www.emtensor.com

CONTACT
Serguei Semenov
CEO

ADDRESS
Tech Gate Vienna -
Wissenschafts- u
Technologiepark GmbH
Donau-City-Straße 1,
1220 Wien
Austria

TELEPHONE
+43 189 066 12

EMAIL
office@emtensor.com

YEAR FOUNDED
2012

SECTOR

• Diagnostics • Medical Devices

COMPANY PROFILE

EMTensor GmbH is a young privately owned Vienna based medical device/technology company specializing in the research and development of novel 4D electromagnetic imaging devices, unifying anatomical and functional capabilities in a single technology.

MANAGEMENT

Serguei Semenov, *CEO*

Eos Biosciences, Inc.

www.eosbiosciences.com

CONTACT
Dr Omar Haffar
Founder, President and CEO

ADDRESS
1999 Avenue of the Stars
Suite 1100
Century City, CA 90067
USA

TELEPHONE
+1 (415) 314-7542

EMAIL
omar@eosbiosciences.com

YEAR FOUNDED
2013

SECTOR

• Biotechnology • Drug Delivery

FINANCIAL SUMMARY

To date, Eos has raised oapproximately $5M in two rounds of preferred financing (Seed & SeriesA)..

COMPANY PROFILE

Eos Biosciences Inc., is a privately-held nanomedicines company developing a unique targeted drug delivery platform, the Eosome.

Eosomes are self-assembling, non-liposomal nanoparticles (<50 nm in diameter) initially developed at Cedars-Sinai Medical Center in Los Angeles and now being advanced by Eos under an exclusive worldwide license. These non-immunogenic nanoparticles are composed of multifunctional recombinant polypeptides designed to incorporate three elements that define their target and payload specificity; 1) Cell targeting peptide, 2) Endosomal lysis and penetration peptide, 3) Therapeutic capture peptide.

The modular design of the polypeptides allows rapid and efficient substitution of the targeting and therapeutic capture peptides. As such, Eosomes represent a versatile nanoparticle platform that can be adapted for the delivery of a wide variety of therapeutic payloads (e.g. small molecules, nucleic acids) for multiple disease indications.

PRODUCT PIPELINE

Eos-001: Preclinical

Eos-001: HER3-targeted Eosomes carying doxorubicin payload.

In in vitro and in vivo (animal models) preclinical studies using human HER2+/HER3+ breast cancer cells, including refractory or drug-resistant lines, Eos-001 has shown greater than 10-fold improvement in doxorubicin efficacy compared to free doxorubicin, and a substantial reduction if not total disappearance of related cardiac and hepatic toxic side effects. In addition to human breast cancer, Eos-001 is highly effective on gastric cancer, prostate cancer, and glioma.

Eos-001 is entering IND-enabling studies that are expected to be completed in 2016. Phase 1 clinical study is anticipated to begin in 1Q 2017.

Eos-002: Preclinical

Eos-002: HER3-targeted Eosomes with a proprietary a small molecule therapeutic payload.

The small molecule therapeutic payload is from a novel class of compounds that induce disruption in the mitochondrial membrane potential and elevation in superoxide.

Eos-002 has shown high level of efficacy against a variety of tumor cell lines in vitro and in vivo (animal models).

Eos-002 will follow Eos-001 into IND-enabling studies mid-2016. Phase 1 clinical study is anticipated to begin in 2Q/3Q 2017.

Eos-003/Validation

Eos-003: c-Met-targeted Eosomes carying doxorubicin payload.

Similar to HER3, c-Met is overexpressed on many metastatic and drug-resistant tumors. Although HER3 and c-Met overexpression overlaps on some solid tumors, many others show differential expression of one or the other receptor. Therefor, Eos-003 will be developed against solid tumors that Eos-001 or Eos-002 may not address.

OPPORTUNITIES

Equity Investment

Eos will be intiaitng a series B preferred financing to raise $15M-$20M that will enable the company to complete

Continued...

Eos Biosciences, Inc.

www.eosbiosciences.com

CONTACT
Dr Omar Haffar
Founder, President and CEO

ADDRESS
1999 Avenue of the Stars
Suite 1100
Century City, CA 90067
USA

TELEPHONE
+1 (415) 314-7542

EMAIL
omar@eosbiosciences.com

YEAR FOUNDED
2013

...continued

the GMP manufacturing and progress two pipeline products into clinical development.

The investment opportunity in Eos is based not only on our proprietary pipeline of products, which allow for broad applications for treating cancers that are either underserved or represent an unmet medical need, but also based on the versaitlity of our Eosomes platform technology that enables the packaging of many types of therpaeutic payloads and can be adapted to multiple disease indications. The unique and differentiated properties of the Eos platform compared to other drug delivery technologies in development, has already generated interest from potential Corporate partners. Eos is presently involved in two joint proof of concept studies.

Eos-001/Eos-002

Eos would be interested in entering into licensing/co-development discussions for Eos-001 and Eos-002.

Expansion of Platform Technology

In addition to advancing its proprietary product pipeline, Eos is interested in establishing collaborations for expanding the application of the Eosomes platform technology to indications other than oncology such as, cardiovascular disease, virology, immune disorders, metabolic diseases and genetic disorders.. These collaborations could be structured as either licensing agreements or co-development partnerships.

To that end, Eos has ongoing projects for testing the delivery of specific RNAi molecules, and is in discussions with additional potential collaborators for the delivery of other nucleic acid therapeutics.

MANAGEMENT

Omar K. Haffar, Ph.D, *President & CEO:*
CFO: Recruitment to be completed by March 15 2016

Genetics Microdevices Ltd.

www.genetic-microdevices.co.uk

CONTACT
Dr Dimitrios Sideris
CEO

ADDRESS
104 Friars Avenue
London
SW15 3DW
United Kingdom

TELEPHONE
+44 (0) 20 8417 4781

EMIAL
info@genetic-microdevices.co.uk

YEAR FOUNDED
2005

SECTOR

• Biotechnology • Diagnostics • Laboratory Equipment • Medical Devices

FINANCIAL SUMMARY

The company has developed it's technology based on Angel Funding and Government Grants (London Development Agency, Innovate UK SMART Awards). It has recently closed a $0.5M round and is currently raising $15M to expand it's product pipeline.

COMPANY PROFILE

Genetic Microdevices Ltd (GMD) is a London based business that has developed a disruptive disposable chip that analyses blood, DNA, RNA proteins and small molecules with ultra-high performance and sensitivity. The underlying microfluidic technology encompasses a unique concept that allows molecular separations with 100x the resolution compared to other competing devices, 10,000x sample concentration and 270x faster analysis.

GMD is looking for end-users in biotechnology to enhance their development efficiency and for investors to provide funding for the next stage of expansion of the company.

PRODUCT PIPELINE

DNA chip: Looking for end-users for fragment analysis, high throughput sequencing. Chip has demonstrated significantly higher resolution than competitors and 270x higher speed per lane compared to commercial sanger sequencers. Other competitive advantages are High Readlength (~1000bases) and 10,000x sample concentration.

Small molecule analysis chip: We have demosntrated very high resolution analysis carbohydrates and miRNA. We are looking for end-users who find it very difficult to perform small molecule separations/ purity analysis and fingerprinting of samples, with current technology.

Protein chip: Under development. GMD technology is the only known technology that can shift the high throughput DNA analysis paradigm to Proteomics. Unlike other protein chips, our technology can analyse the majority of the proteins and peptides with high resolution and speed. We are looking for collaboration of opportunities with interested end-users in diagnostics, cancer research and drug development, to shape our product to their needs.

OPPORTUNITY

Raising $15M bridge funding

GMD technology is a platform technology, however its chips are application specific. This means that GMD can follow a flexible market entry strategy based on key consumables, the application specific DNA/RNA/Protein & Small Molecule analysis chips. This is an oportunity and a challenge simultaneously. We are currently focussed in serving the existing end-user customers in three application areas. In the next stage of funding we plan to enter the wider market and expand the product pipeline through a $15M bridge investment and a subsequent IPO.

MANAGEMENT

The Company is headed by the i*nventor of the technology and CEO* Dimitrios Sideris. He has a PhD in Particle Physics from Imperial College and 12 years of experience in developing and bringing award winning high tech products to market.

Professor Andreas Manz is *Scientific Advisor*. He is a pioneer in the field of Microfluidics. He founded the Journal Lab-on-a-Chip and has been a Founding member of Calliper Technologies a NASDAQ listed company.

Kenneth Freeman is *acting CFO*. Ken is an experienced venture capitalist, CFO (biotech and vc) and Board Member (biotech, software and non profit) and cofounded a biotech company in Germany. He has a MBA Harvard, MPA Harvard and Ph.D. KCL and has been co founder of, CFO of biotech companies in Germany, and has extensive consulting and due diligence experience in technology related industries.

Glide Pharmaceutical Technologies Limited

www.glide-technologies.com

CONTACT
Dr Mark Carnegie-Brown
CEO

ADDRESS
45B/C Western Avenue,
Milton Park,
Abingdon,
Oxfordshire
OX14 4RU
United Kingdom

TELEPHONE
+44 (0) 1235 577 120

EMAIL
enquiries@glide-technologies.com

SECTOR

- Biotechnology

COMPANY PROFILE

Glide is a clinical stage development business based in Oxford in the UK. Glide has its own unique proprietary formulation and device platform in which the solid dose replaces the needle so enabling sub-cut delivery. Glide is focussed on the development of peptides and vaccines through its SDI® platform. The solid dosage formulation avoids the need for refrigeration and cold chain. The device itself is simple, intuitive and has only 4 steps to injection; so improving patient experience and compliance.

Glide intends to license initial peptide technology following proof of concept clinical studies next year and enter development collaborations with novel peptides and vaccines. Glide's pipeline includes octreotide, teraparatide, exenatide and vaccine partner programmes on anthrax and recombinant flu. Glide is currently manufacturing clinical material in a GMP environment for the 2016 study.

Early clinical work has shown patient preference for the Glide SDI® over injection with a standard needle and syringe. Market research has shown an appetite for the Glide system.

MANAGEMENT

Dr Mark Carnegie-Brown, *CEO*
Ms Imogen Collis, *CSO*
Dr Tony Mills, *CBO*

GreenBone Ortho s.r.l.

www.greenbone.it

CONTACT
Dr. Lorenzo Pradella
CEO

ADDRESS
Via Albert Einstein 8,
48018 Faenza
(RA)
Italy

YEAR FOUNDED
2014

SECTOR

• Medical Devices • Regenerative Medicine

FINANCIAL SUMMARY

Round A 3,0M EURO closed mid 2015, covering all activities up to first patient recruitment (1Q17)

Round B 4,0M EURO by end 2016

COMPANY PROFILE

GreenBone Ortho develops a patented innovative bamboo-derived, bone regenerative, load-bearing implant for extensive bone damages. Unique properties needed for large implants in different skeletal segments such as pseudoarthrosis and non-unions fractures, spinal damages, trauma and cancer induced bone loss. Reduction of hospitalization - rehabilitation periods and costs expected. Bone formation demonstrated in vitro and in vivo. Scaled up manufacturing, suitable for GMP validation. Clinical study planned 1Q 2017 in patients with non-union critical size fractures from trauma. Global Orthopedic Biomaterials market forecasted US$11,2 billion by 2018 (CAGR 10.78%). GreenBone use in different skeletal applications can target >40% of GOB market. Estimated annual sales in long bone critical size defects only, > US$250M. Round A of EURO3,0M successfully closed in 2015. GreenBone is at TEDxBinnenhof 2016, being selected among the 10 very best 'Ideas from Europe' (March 31, The Hague http://tedxbinnenhof.com).

PRODUCT PIPELINE

GreenBone, end of non-clinical development

GreenBone is a patented bamboo derived, bone regenerative, load-bearing implant for extensive bone loss caused by trauma and tumours.Scaffolds with porosity > 60% able to regenerate long load-bearing bones supported by the adequate vascular network and suitable to become a platform technology for different skeleton disease applications do not exist. New bioactive large scaffold under development belong to metallic and/or polymeric materials with well-known limitations, including 3D printing. Large quantity, lower costs, easily shaped by surgeons before implantation. No risk of diseases transmission or rejection.

OPPORTUNITY

GreenBone

- New bone formation demonstrated in vitro and in vivo.
- Scaled up manufacturing line suitable for GMP validation.
- Clinical study planned 1Q17.
- Reduction of hospitalization - rehabilitation periods.
- Reduction health care and social costs.
- World class team (multiple orthopaedic products from bench to market)
- Exit 2019

MANAGEMENT

Dr. Lorenzo Pradella, *CEO*
Anna Tampieri, PhD, *CSO*
Dr. Elena Venturelli, *Senior Regulatory & QA*
Dr. Angela Palumbo, *Regulatory & QA*
Simone Sprio, PhD, *Project Coordinator*
Andrea Ruffini, PhD, *Senior Scientist*
Dr. ALberto Ballardini, *Researcher*

Helsinn Healthcare SA

www.helsinn.com

CONTACT
Roberto De Ponti,
Senior Director,
Head of Corporate Business Development

ADDRESS
Helsinn Healthcare SA
Via Pian Scairolo 9
6912 Lugano/Pazzallo
Switzerland

TELEPHONE
+41 (0) 91 985.21.21

EMAIL
info-HHC@helsinn.com

YEAR FOUNDED
1976

SECTOR

• CMO • Investor - Private • Investor - VC • Medical Devices • Pharmaceuticals/Licensing

COMPANY PROFILE

Helsinn is a privately owned cancer supportive care pharmaceutical group, with a proprietary portfolio of marketed products and a broad development pipeline. For 40 years, Helsinn has been improving the everyday lives of patients, guided by its core family values of respect, integrity and quality, through a unique integrated licensing business model working with long-standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is committed to searching for high quality cancer care development phase compounds and marketed products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the United States, a representative office in China and product presence in about 90 countries.

MANAGEMENT

Riccardo Braglia, *Group Chief Executive Officer, Board Member & US Chairman*
Giorgio Calderari, *Group General Manager & Chief Operating Officer & US Board Member*
Waldo Mossi, *Local General Manager, Chemical Business, Helsinn Advanced Synthesis, Switzerland*
Padraig Somers, *Local General Manager, Pharma Business, Helsinn Birex Pharmaceuticals, Ireland*
William Mann, *Local President & CEO & Board Member US Pharma Business, Helsinn Therapeutics (U.S.), Inc*
Andrea Meoli, *Corporate Chief Commercial Officer*
Sergio Cantoreggi, *Corporate Chief Scientific Officer*
Konrad Wilson, *Chief Financial Officer*
Matteo Missaglia, *Senior Director, General Counsel, Corporate Legal Affairs*
Roberto De Ponti, *Senior Director, Head of Corporate Business Development*
Daniele Bonadeo, *Senior Director, Head of Corporate Technical Affairs*

ImmunID

www.immunid.com

CONTACT
Bernhard Sixt, PhD
Chairman and CEO

ADDRESS
BHT 52,
7 parvis Louis Néel,
CS 20050
38040 Grenoble Cedex 09,
France

TELEPHONE
+33 (0) 438 785 770

EMAIL
contact@immunid.com

YEAR FOUNDED
2005

SECTOR

- Biotechnology

FINANCIAL SUMMARY

$5m investments, several $ millions in grants.

COMPANY PROFILE

ImmunID adds precision to the immuno-oncology revolution by personalizing immunotherapy for cancer patients. With its decade-long experience in immune molecular diagnostics, ImmunID provide doctors with clinically meaningful data on the highly complex immune system to select the right therapy for individual patients and to monitor their response. ImmunID's flagship CE-marked product, ImmunTraCkeR®, evaluates the patient's immune status based on the T lymphocyte diversity, from a simple liquid biopsy. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic assay for immune checkpoint inhibitors and other immunotherapies. In addition, ImmunID collaborates with pharma and biotech companies to optimize the development of their next-generation immunotherapies. ImmunID is ISO 9001 and ISO 13485 certified and runs a CAP-accredited laboratory in the MINATEC high-tech campus in Grenoble, France.

MANAGEMENT

Bernhard Sixt, PhD, *Chairman and CEO*
Sébastien Weisbuch, PhD, *Delegate Managing Director, Chief Operating Officer & Co-Founder*
Nicolas Pasqual, PhD, *Chief Scientific Officer & Co-Founder*
Nadia Plantier, *Vice President, Business Development & External Collaborations*

Inflamalps SA

www.inflamalps.com

CONTACT
Dr. Vincent Mutel
CEO and co-founder

ADDRESS
Route de l'Ile-au-Bois 1A
1870 Monthey,
Switzerland

YEAR FOUNDED
2012

SECTOR

- Pharmaceuticals/Licensing

FINANCIAL SUMMARY

Inflamalps raised CHF1.85 million in 2015 through private investors. We are now looking to raise CHF8 million to bring INF101 at the end of one phase Ib clinical trial in Sjogren's disease associated dry eye and one phase Ib in non-infectious anterior uveitis.

COMPANY PROFILE

Inflamalps' mission is to discover and develop novel medicines to treat inflammatory diseases of the eye in particular uveitis and dry eye. Inflamalps has one molecule, INF101, which is a specific inhibitor of IL-17 production for the topical treatment of Sjogren's associated dry eye and non-infectious anterioir uveitis, two ophthalmological indications where the existing therapies have serious side effects preventing their long term use. INF101 is in preclinical development and we are actively looking to elucidate its mechanism of action and develop new chemical scaffolds keeping the unique profile of the parent molecule.

PRODUCT PIPELINE

INF101, topical drug for the treatment of dry eye and uveitis in pre-clinical development
INF101 is a small molecule which specifically inhibits the production of IL-17 from Th-17 cells, a cytokine which is largely responsible of the occurrence and maintenance of uveitis and dry eye. Inflamalps is actively working to unravel its precise mechanism of action. In addition we are building up structural knowledge around the parent molecule in order to create a novel IP and we already identify novel molecules which share the same specific activity profile of INF101..

OPPORTUNITY

Investment
Inflamalps is looking to raise CHF8 million to complete the pre-clinical development of INF101 and to bring it at the end of one phase Ib clinical trial in Sjogren's disease associated dry eye and one phase Ib in non-infectious anterior uveitis.

MANAGEMENT

Dr. Vincent Mutel, *CEO and co-founder*
A seasoned biotechnology entrepreneur. He was co-founder and CEO of Addex Pharmaceuticals Ltd, where Dr. Mutel completed three rounds of venture financing, an IPO and a PIPE and signed three major drug development partnerships with large pharmaceutical companies.

Dr. Andrea Cesura, *Chief Scientific Officer*
A pharmacologist with more than 20 years R&D experience in large Pharmaceutical and Biotech companies. Dr. Cesura has previously worked as SVP Preclinical Research at Evotec, Associate Director at Serono and Senior Scientist at Roche.

Dr. Eduard Vidovic, *Chief Medical Officer:*
A medical doctor with 25 years of experience and a specialty in Pharmaceutical Medicine. Dr. Vidovic has previously worked as Chief Medical Officer both at Creabilis SA and Microscience PLC and he was also Head, Medical Affairs, at Sanofi-Aventis SA.

Dr. Cyril Portmann, Head of Chemistry
An expert in Natural Product Chemistry holding a Ph.D. from Ecole Polytechnique Federale in Lausanne (EPFL) and Post-Doctoral training at Harvard Medical School in Boston. During his career, Dr. Portmann acquired several years of experience in the area of discovery of new bioactive small molecules from natural origins.

InGeneron GmbH

www.ingeneron.com

CONTACTS
Michael Coleman, Ph.D.
CEO and President

Christoph Neyer
Director Business Development

ADDRESS
Sonnenstraße 24 - 26
München, Germany 80331

TELEPHONE
+49 157 7398 7679

EMAIL
contact@ingeneron.com

YEAR FOUNDED
2006

SECTOR

• Biotechnology • Medical Devices • Pharmaceuticals/Licensing • Regenerative Medicine

FINANCIAL SUMMARY

Currently, EUR2.5M in revenue.

COMPANY PROFILE

InGeneron is a US and Germany based biotech company. Basic research started in 2001 and InGeneron was officially founded in 2006 as a spin-off from Tulane University and MD Anderson Cancer Center of the University of Texas and is

(i) a leading provider of medical devices for the point-of-care preparation of adult stem cells within 1 hour for autologous treatment

(ii) aiming to build up the largest biobank of stem cells derived from umbilical cord tissue – the richest source of stem cells – for allogeneic treatment

Having already received CE marks and EMA designation as non-ATMP for subcutaneous indications, InGeneron will roll out its point-of-care system in the $3bn EU wound care and aesthetics markets in Apr-2016. US trials are currently designed and in discussion with the FDA (under IDE for PMA approval) for the orthopedic and wound care market, which extends the addressable market in the mid-term to $11bn.

They are preparing a Series D Preferred Stock financing in Q2 2016. 40% of the investment amount is already soft commited.

PIPELINE

Progress to Date: 4 divisions ready for application



Medical Devices:

- **Aesthetics & Reconstruction:** Market entry phase
- **Wound care:** Market entry phase (EU)
- **Animal Health:** Market entry phase
- **Bio-orthopedics:** Clinical trial phase
- **Cardiovascular:** Preclinical phase

Medical devices for the point-of-care preparation of adult stem cells within 1 hour for autologous treatment.

Continued...

InGeneron GmbH

www.ingeneron.com

CONTACTS
Michael Coleman, Ph.D.
CEO and President

Christoph Neyer
Director Business Development

ADDRESS
Sonnenstraße 24 - 26
München, Germany 80331

TELEPHONE
+49 157 7398 7679

EMAIL
contact@ingeneron.com

YEAR FOUNDED
2006

...continued

Biobanking & Biopharmaceuticals:
- **Biobaking:** Market entry phase
- **Biopharmaceuticals:** Preclinical phase

Building up the largest biobank of stem cells derived from umbilical cord tissue – the richest source of stem cells – for allogeneic treatment

OPPORTUNITIES

Series D Preferred Stock Financing
Series D Preferred Stock financing in Q2 2016. A verbal soft-commitment by a large US hospital chain exists for 40% of the volume.

The use of proceeds will be (i) marketing our point-of-care system in the EU, (ii) clinical trials for FDA approval and (iii) building up of stem cell biobank from umbilical cord tissue.

AMPLIVANT® conjugates mediate direct dendritic cell targeting with the TLR ligand-coupled antigen and activation of these dendritic cells, leading to long-term, effective antigen presentation and T cell response induction.

Licensing Deal
- **Aesthetics/Reconstruction**
- **Wound Care**
- **Orthopedics**
- **Animal Health**

Licensing Cardiovascular Devision
Licensing our patents and medical devices for the point-of-care preparation of adult stem cells within 1 hour for autologous treatment and development of cardiac pacemaker cells.

MANAGEMENT

Michael Coleman, Ph.D., *CEO and President*
Fabian Alt, *CFO*
Ron Stubbers, MBA, *VP Operations and Secretary*
Christoph Neyer, *Director Business Development*

InnVentis Ltd.

www.innventis-pharma.com

CONTACT
Dr. Thomas Wilckens
CEO

ADDRESS
c/o Brooks Keret
Hamaalit 6
Kadima 6092000
Israel

EMAIL
thomas.wilckens@innventis.com

YEAR FOUNDED
2015

SECTOR

• Biotechnology • CRO • Diagnostics • Pharmaceuticals/Licensing • Bioinformatics

COMPANY PROFILE

InnVentis will enable Precision Medicine to treat and eventually cure chronic inflammatory diseases —or even prevent them entirely. Their unique science and technology, along with their business leadership, is looking to create a new ecosystem for diagnostics and health management of inflammatory diseases with a major socioeconomic impact. InnVentis primary focus is on arthritis (including rheumatic diseases) which is the major cause for disablity which and costs the US 128B US$ annually. Of note, there is currently no molecular difinition of disease resulting in a trial and error treatment approach which misses the window of opportunity to drive disease in full remission; a patient stratification enginge like InnVentis would allow companies to find their patients early on, i.e. allow first line treatment and reduce costs to payer based on better outcome.

The InnVentis technology platform combines data with cutting-edge algorithms to create actionable insights by way of:
– Cost-efficient sourcing of extremely high quality multi-omics analytics and clinical analytics.
– Proprietary knowledge in machine learning and algorithm development.
– Access to patient cohorts with well curated EMRs over decades via HMOs in Israel
– Stringent control of sample and data collection with proprietary standard operation procedures.

In order to harvest reliabe, valid and comparable data InnVentis will partner with Pharma companies in early clinical development for "biomarker" discovery and also initiate proprietary clinical trials to build the reference database.

Ultimately this ecosystem will enable precise diagnostics as well as treatment and intervention in very early preclinical stages. InnVentis's goal is to enable disease-free remission or even prevention of major chronic inflammatory diseases.

PRODUCT PIPELINE

"Patient stratification engine" to support clinical development and "biomarker" development.
InnVentis is in the process of building its proprietary technology and data integration platform as well as generating algorithms for patient stratification.

Acess to patients has been secured

InnVentis has generated proproprietary SOPs and a coherent logistics chain to secure highest data quality that weill eventually generate the best reference database patient stratificiation.

Real-time disease diagnostics, treatment decision and monitoring ecosystem (including a B2C disease management product to enable patients to optimally manage their health jointly with the support of their specialist or GP.)

OPPORTUNITIES

Series A
InnVentis seeks a staged series A financing of 19M Euro

Delivarables & Goals
1: Minimal viable Product as defined by customer feedback
2: Integrated omics data analytics & machine learning platform
3: Joint venture with HMO re biobanking
4: Partner with at least 3 Pharma/Biotech companies for clinical development support
5: Prepare to scale to other regions for extended data harvesting supported by a series B

Continued

InnVentis Ltd.

www.innventis-pharma.com

CONTACT
Dr. Thomas Wilckens
CEO

ADDRESS
c/o Brooks Keret
Hamaalit 6
Kadima 6092000
Israel

EMAIL
thomas.wilckens@innventis.com

YEAR FOUNDED
2015

...continued

MANAGEMENT

Dr. Thomas Wilckens, MD, *Chief Executive Officer*
Founder Precision Medicine & Big Data in Life Science on LinkendIn; Associate GLORAD Institute on R&D management St. Gallen/Shanghai; Associate deep innovation, Munich, serial entrepreneur

Ron (Rani) Shifron, BSc, MBA, *General Manager Israel, Chief Marketing Officer*
International experience in Medical Device Development, Capital Equipment, Disposables, Accessories & Service business. Track record in start-up financing and implementing.

[stealth mode], PhD, MBA, *Chief Operating Officer*
VP of Innovation & IP Management at global pharmaceutical company. Business model, change management, and product strategy expert

[stealth mode], PhD, *Chief Scientific Officer*
Former CSO at German biopharmaceutical company. Drug discovery and inflammation expert. Expert knowledge in pre-clinical as well as clinical drug discovery and development; serial entrepreneur

Markus Fischer, *Head of Analytics and Bioinformatics*
Co-founder and former Head of Bioinformatics at Entelechon, Previously worked for global leaders and start-up companies, unique industry & partner network; serial entrepreneur

Dr. Axel Schumacher, PhD, *Head of Biobanking and Biomarker Discovery*
Epigenetics and Genomics Expert, Manager BIOBANK and BioKEP, Blood donation service of the Bavarian Red Cross

INOFEA AG

www.inofea.com

CONTACT
Dr Yves Dudal
CEO

ADDRESS
c/o Basel Inkubator
Hochbergerstrasse 60c
CH-4057 Basel
Switzerland

TELEPHONE
+41 61 633 30 19

YEAR FOUNDED
2011

SECTOR

- Biotechnology

COMPANY PROFILE

INOFEA empowers enzymes. We have developed a unique and patented platform technology to fit enzymes to in vivo and process conditions.

We are developing a wealth of applications from this platform technology in both Pharma and Consumer Healthcare market segments. We can either formulate enzymes as drugs efficient in in vivo conditions (digestive health products, pancreatic enzyme products, personal care products, medical textiles, etc.) or improve industrial biocatalytic processes.

MANAGEMENT

Dr Yves Dudal, *CEO*

Inventiva Pharma

www.inventivapharma.com

CONTACT
Frédéric Cren, MA/MBA,
CEO and Co-Founder

ADDRESS
50 rue de Dijon
21121 Daix
France

TELEPHONE
+33 3 80 44 75 00

EMAIL
info@inventivapharma.com

YEAR FOUNDED
2011

SECTOR

• Biotechnology • Consulting & Legal Services

COMPANY PROFILE

Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage whose objective is to develop and provide patients with new therapies. The focus of the company's R&D targets three promising areas, namely fibrotic diseases, the treatment of certain forms of lysosomal diseases and oncology with a priority for the development of indications for orphan diseases. The Company was founded in October 2011 by former executives of the French subsidiary of the American pharmaceutical group Abbott and started its operational activities after its acquisition of an integrated R&D platform and a portfolio of drug candidates. Inventiva has developed a recognized expertise in the field of nuclear receptors, transcription factors and epigenetic modulation. This expertise combined with the research platform, including biology teams, screening equipments, chemistry, ADME and pharmacology resources, as well as its own library of 240,000 compounds, enables the company to develop a regular flow of drug candidates. The product pipeline is rich and diversified with two products (IVA337 and IVA336) at clinical stage, a promising research partnership with AbbVie focusing on the treatment of several autoimmune diseases close to entering phase I, as well as several innovative projects at preclinical stage.

PRODUCT PIPELINE

IVAA337 : Phase IIb

Anti-fibrotic compound currently in Phase IIb in SSc (systemic sclerosis)

Phase IIb in NASH currently under preparation

IVAA336 : Phase I/II

Small molecule substrate reduction therapy approach to trat MPS I, MPS II and MPS VI patients

MPS VI Pahe I/II unver preparation

OPPORTUNITIES

Yap/Tead

Licensing

NSD2

NSD2 is a HKMT which triggers the expression of oncogenes and the oncogenic programming of multiple myeloma tumors. Knockdown of NSD2 leads to regression of multiple myeloma tumors carrying a specific gene translocation in mice, suggesting that NSD2 can be a therapeutic target for patients carrying this particular translocation.

Using SiRNA technologies, we have validated the role of NSD2 in human Multiple Myeloma cancer cells displaying the gene translocation and confirmed its potential as therapeutic target and identified in our library several compounds inhibiting NSD2 activity.

This program has received research grants from the European Community Eurostars.

We are contemplating either to set up a drug discovery partnership with a pharmaceutical company on a model similar to the ongoing AbbVie partnership or to out-license the program once proof of concept has been established in man.

MANAGEMENT

Frédéric Cren, MA/MBA, *CEO and Co-Founder*
Wide expertise within the areas of research, development, marketing, strategy and operations. Held senior positions at Abbott, Fournier, Solvay Pharma and the Boston Consulting Group. Former member of both Fournier and Solvay Pharma Executive Committees.

Pierre Broqua, Ph.D., *CSO and Co-Founder*
Has successfully managed numerous research programs leading to the discovery, development and commercialization of innovative compounds, including IVA337 and Ferring's GnRH antagonist Degarelix/ Firmagon®. Held several senior research positions at Fournier, Solvay Pharma and Abbott.

Karus Therapeutics Ltd.

www.karustherapeutics.com

CONTACT
Simon Kerry PhD MBA,
Chief Executive Officer

ADDRESS
93 Innovation Drive
Milton Park
Abingdon
Oxfordshire OX14 4RZ
United Kingdom

TELEPHONE
+44 (0)1235 829140

EMAIL
info@karustherapeutics.com

YEAR FOUNDED
1996

SECTOR

- Biotechnology

FINANCIAL SUMMARY

Karus has raised £29m to date, with the most recent investment froma syndicate of top-tier investors: SV Life Sciences, New Leaf Venture Partners, Novo A/S and IP Group

COMPANY PROFILE

Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers.

Karus is a leader in the design and development of innovative small-molecule drugs that combine targeted therapy and immunotherapy activity for the effective treatment of a diverse range of solid and hematological cancers.

PRODUCT PIPELINE

KA2237 - dual inhibitor of PI3K-p110b and p110d. First-in-man studies to start 2Q 2016.
Building on an unparalleled knowledge of the PI3K enzyme family's role in disease pathogenesis, Karus has designed and developed a new class of dual selective inhibitors of PI3K-p110ß and p110o. PI3K-p110ß is an oncogenic target in its wild-type and mutant forms, and drives cancer cell growth, including in tumors defective in the phosphatase PTEN. PI3K-p110o drives hematological tumor proliferation and survival, and has also emerged as a solid tumor immunotherapeutic target through its role in governing regulatory T cell function. Our orally-active molecules thus have significant therapeutic potential in the treatment of a diverse range of solid and hematological tumors through their combined ability to regulate T cell function and to directly inhibit cancer cell growth and metastasis..

KA2507 - selective HDAC6 inhibitor. In regulatory toxicology studies
Drawing on considerable experience in metalloenzyme inhibitor therapeutics, Karus has designed and developed a novel class of highly-selective inhibitors of HDAC6. This enzyme is a unique and functionally distinct member of the HDAC superfamily and is an important emerging drug target in cancer. Inhibition of HDAC6 drives tumor cells into apoptosis by blocking aggresome formation, and also reduces tumor cell-expression of programed death-ligand 1 (PD-L1). Expression of PD-L1 on cancer cells is positively correlated with tumor aggressiveness, and its presence camouflages tumors from attack by immune cells. Our HDAC6-selective inhibitors thus have significant therapeutic potential in solid and hematological tumor therapy through their combined pro-apoptotic and immunotherapeutic activity.

MANAGEMENT

Simon Kerry PhD MBA, *Chief Executive Officer*
Prof. Stephen J Shuttleworth PhD FRSC, *Chief Scientific Officer*
Dr Penny Ward, *Chief Medical Officer*
Simon Jones, *Chief Financial Officer*

Marinomed Biotechnologie GmbH

www.marinomed.at

CONTACT
Andreas Grassauer
CEO

ADDRESS
Veterinärplatz 1
1210 Vienna
Austria

TELEPHONE
+43 1 25077 4460

EMAIL
office@marinomed.com

YEAR FOUNDED
2006

SECTOR

• Drug Delivery • Pharmaceuticals/Licensing

COMPANY PROFILE

- Location: Campus of the University of Veterinary Medicine, Vienna
- Workforce: 22 FTEs
- Developed the proprietary MAVIREX, MARINOSOLV and IMMUVIREX platforms
- MAVIREX based on Carragelose®: Targeting 200 different respiratory virus strains – products are marketed worldwide via partnerships
- MARINOSOLV is a patent-protected technology platform enabling novel aqueous formulations of hardly soluble compounds.
- IMMUVIREX: comprises early programs targeting immunological or infectious diseases
- Excellent IP portfolio

OPPORTUNITY

Technology for insoluble locally applied drugs

What is MARINOSOLV

MARINOSOLV is a patent-protected technology platform enabling novel aqueous formulations of hardly soluble compounds. The different components are compatible with ocular and intranasal applications. MARINOSOLV was invented and developed by Marinomed scientists in the R&D laboratories of the company.

Key USP of the technology

MARINOSOLV permits the application of dissolved drugs that are otherwise insoluble to sensitive tissues such as the nasal mucosa, the laryngopharyngeal area, the respiratory tract, the tissues of the eye, and potentially joints.

First application of MARINOSOLV

Initial studies show that almost insoluble corticosteroids such as fluticasone propionate or budesonide are prime targets for a successful product development as eye drops or nasal sprays. Additionally, macrolide immunosuppressants have been successfully tested.

MANAGEMENT

Andreas Grassauer, *CEO*
Eva Prieschl-Grassauer, *CSO*
Helmut Baranyovszki, *Head Finance*
Angelika Bodenteich, *Head Development*
Renate Moser, *Head BD&L*

Medimetrics Personalized Medicine

www.medimetrics.com

CONTACT
Yves Decadt
CEO

ADDRESS
High Tech Campus Eindhoven
5600 JW Eindhoven
The Netherlands

TELEPHONE
+31 (0) 40 851 6451

EMAIL
yves.decadt@medimetrics.com

YEAR FOUNDED
2011

SECTOR

• Diagnostics • Drug Delivery • Medical Devices • Pharmaceuticals/Licensing

Other Sector • digital health

FINANCIAL SUMMARY

Private company. Main Shareholders are ZFHN Heilbronn and Philips.

COMPANY PROFILE

Medimetrics is creating "the pill beyond the pill", enabling smart pharmaceuticals for the digital health era.

Medimetrics is the pioneer and global leader in electronic oral drug delivery Medimetrics has created the world's first and only oral electronic drug delivery system or "electronic pill". Our technology integrates knowledge from the frontiers of different technological fields, such as pharmaceutical drug delivery, medical technology, information technology, advanced sensors and micro-electronics, resulting in a truly "smart pill". In our joint venture with Ligalli we are developing a special electronic drug delivery ring for women's health.

With our technology we can also sample GI fluids for the microbiom, metabolome or for instance cancer diagnostics.

PRODUCT PIPELINE

Devices :
– Intellicap oral device
– Ligally intravaginal ring

Services :
– absorption window studies
– microbiome studies

Smart Pharmaceuticals : connected drug device combinations
– oxybutinin in Ligally ring
– other smart pharma products under consideration (in hepatitis, oncology and parkinsons)

MANAGEMENT

Yves Decadt, *CEO*
Jeff Shimizu, *CTO*

MISSION Therapeutics Ltd.

www.missiontherapeutics.com

CONTACT
Dr Anker Lundemose
CEO

ADDRESS
Moneta (Building 280)
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom

TELEPHONE
+44 (0)1223 497 454

EMAIL
info@missiontherapeutics.com

YEAR FOUNDED
2011

SECTOR

- Biotechnology

FINANCIAL SUMMARY

MISSION has raised a total of $125M from investors Imperial Innovations Businesses LLP, Sofinnova Partners, SR One, Roche Venture Fund, Pfizer Venture Investments and Woodford Patient Capital Trust Plc. Latest round February 2016, $86M

COMPANY PROFILE

MISSION Therapeutics is a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases.

It has raised a total of $125M from investors Imperial Innovations Businesses LLP, Sofinnova Partners, SR One, Roche Venture Fund, Pfizer Venture Investments and Woodford Patient Capital Trust Plc.

MANAGEMENT

Dr Anker Lundemose, *CEO*
Mr David Luther, *CFO*
Dr Paul Wallace, *CBO*
Dr Michael Koslowski, *CMO*

MyoPowers Medical Technologies France SAS

www.myopowers.com

CONTACT
Eric Rambeaux
CEO

ADDRESS
13 rue de Village-Neuf
68300 Saint Louis
France

SECTOR

- Medtech

COMPANY PROFILE

MyoPowers Medical Technologies is a medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs.

The company focuses on the development of ARTUS, a new and unique implantable device for the treatment of severe stress urinary incontinence, an area where the unmet medical need is huge, especially in women where no solution is available.

PRODUCT PIPELINE

ARTUS - Preclinical Stage.

MANAGEMENT

Eric Rambeaux, *CEO*
Has a mix of industry (pharma & Device) and consulting background. Eric held various marketing and business development leadership positions in major pharma and medical devices companies. (Merck AG, Baxter, Abbott…) and across several therapeutic areas (urology, diabetes…)

Pierre Mainil-Varlet, MD, *CMO*
Previously CEO of Aginko research (CRO), managing numerous multicenter studies. Pierre had a strategic role in numerous scientific vendor and acquirer due diligences.

Christophe Aubert, *CTO*
Expert in Medical Devices R&D and Design Control. Held leadership R&D positions in the Medical Devices (Debio, J&J) and Pharma industries (Ipsen).

Numab AG

www.numab.com

CONTACTS
David Urech, PhD
Co-CEO, CSO

Oliver Middendorp, PhD,
Co-CEO, CBO

ADDRESS
Einsiedlerstrasse 34
CH-8820 Wädenswil
Switzerland

EMAIL
info@numab.com

YEAR FOUNDED
2011

SECTOR

• Investor - Other • Pharmaceuticals/Licensing • Bioinformatics

COMPANY PROFILE

Numab is a Swiss biotech company that innovates antibody-based therapeutics.

Numab's lead program ND007 targets autoimmune disease pand cancer. The therapeutic principle aims at eliminating the autoagressive, so-called Th17 effector and memmory cells by means of a bispecific anti-IL23RxCD3 antibody. Th17 cells are the main drivers of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and multiple sclerosis. Importantly, this approach also has potential as a 2nd generation immuno-checkpoint modulator for the therapy of cancer.

Numab's platform technology allows to reproducibly generate highly stable and potent antibody variable domain fragments that serve as building blocks for the engineering of mutli-specific antibody formats with entirely novel mechanisms of action

Numab entertains a pipeline of proprietary antibody-based programs and offers collaborations to discover innovative antibody-based therapeutics on behalf of its partners in the pharmaceutical industry.

PRODUCT PIPELINE

D007: The therapeutic principle of ND007 aims at eliminating the autoagressive, so-called Th17 effector and memmory cells by means of a bispecific anti-IL23RxCD3 antibody. Th17 cells are the main drivers of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and multiple sclerosis. As the the Th17 compartment comprises the auto-aggressive memory of many chronic inflammatory diseases, depletion of these cells is likely to result in a very long lasting effect.

Importantly, as Th17 cells create a pro-tumor microenvironment, ND007 has great potential also as a anti-cancer therapeutic. It acts through a dual mechanism, which locally depletes Th17 cells, reduces the infiltration of Tregs and stimulates CD8+ killer cells. Thus, ND007 holds the potential to be more effective and more safe as compared to conventional immuno-checkpoint modulators.

Numab has initiated the formal preclinical development of ND007 aiming at a CTA/IND filing by the end of 2016 and a FIM clinical trial early in 2017.

MANAGEMENT

David Urech, PhD, *Co-CEO, CSO*

David Urech is the CSO and co-CEO, as well as a founder of Numab. He holds an MSc in Molecular Biology and Neurosciences from the University of Zurich and a PhD in Biochemistry from the Biocenter in Basel. Before his engagement with Numab, David was Head of Research & Preclinical Development at Esbatech, where he was a member of the Senior Management. David's seeding scientific work on the pharmacokinetic properties of antibody fragments enabled the development of ESBA105, a TNF-inhibitory scFv that became the first antibody fragment to be applied topically by eye drops. David further conceived Esbatech's antibody discovery platform and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment age-related macular edema. The technologies and compounds developed by David and his team turned out to be a value driving factor for Esbatech's acquisition by ALCON in September 2009. David is an inventor on numerous patent applications and his scientific work has been published in peer-reviewed journals.

Oliver Middendorp, PhD, *Co-CEO, CBO*

Oliver Middendorp is the CBO and co-CEO, as well as a founder of Numab. Prior to this role, he served as Head of Alliance Management at Esbatech. In this function Oliver negotiated and concluded various collaboration and license agreements and managed the resulting alliances. Furthermore, he was responsible for managing Esbatech's patent portfolio, as well as for analyzing Esbatech's freedom to operate. After Esbatech was acquired by Alcon in September 2009, Oliver took over additional responsibilities in Alcon's R&D Alliance Group, where he became responsible for search, evaluation, negotiations and alliance management of collaborations in the fields of external diseases and drug delivery. Oliver studied molecular biology and immunology at the University of Zurich and received his PhD in biochemistry from the University of Basel in 2004. In the same year he was offered the position as Esbatech's business developer and became a member of the Esbatech Management.

OSE Pharma

www.osepharma.com/en

CONTACT
Dominique Costantini
CEO

ADDRESS
Pépinière Paris Santé Cochin
29 bis rue du Faubourg Saint Jacques
75014 Paris
France

TELEPHONE
+33 (0) 1 43 29 78 57

EMAIL
info@osepharma.com

YEAR FOUNDED
2012

SECTOR

- Biotechnology

COMPANY PROFILE

OSE Pharma is a immuno-oncology biotech developing a first-in-class T specific immunotherapy treatment proprietary platform against cancer for HLA A2+ responders.

Tedopi (OSE2101), a neo-epitopes T specific treatment is in Phase 3 in Non Small Cell Lung cancer (NSCLC)

A strong rationale is established for combining checkpoint-inhibitors and Tedopi (OSE 2101) fighting "neo epitopes" selected on HLA-A2 and TCR.

Other indications with Phase 2 status are available for partnership (Colon, Ovarian, Breast triple negative), as the same tumor antigens and the HLA A2 status are involved in the prognosis of such cancers.

Our patented T specific immunotherapy is strongly innovative due to the 5 tumor antigens selected in the same combination of 10 neo-epitopes increasing for each epitope the binding to key receptors for T cytotoxic response in order to fight tolerance issues.

On February 25th OSE Pharma announced its proposed merger with Effimune to create an international immunotherapy player.

The two companies bring together a balanced portfolio with a Phase 3 on-going in NSCLC with Tedopi our T specific immunotherapy, a phase 2 in preparation combining Tedopi with a Check-Point inhibitor PD1/PD-L1, and for instance Effi-dem a check-point of second generation with very interesting pre-clinical results especially in combination with PD-1/PD-L1 products.

We will build together a significant immunotherapy player focused on Immune Activation and Regulation.

PIPELINE

TEDOPI in PIVOTAL PHASE III CLINICAL TRIAL (EUROPE/US)

Tedopi® is currently under a Phase 3 registration trial in Europe and the U.S. in the treatment of NSCLC.

Tedopi® is a new "off-the-shelf" cancer immunotherapy approach based on OSE Pharma's proprietary Memopi® technology. This technology is based on "neo-epitopes" (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which activate a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected to obtain a therapeutic universal T vaccine.

Tedopi® combines 10 optimized "neo-epitopes" simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 "neo-epitopes" have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger cytotoxic T-cell response and lead the immune system to destroy cancer cells expressing the HLA-A2 antigen or one of the targeted cancer antigens.

Tedopi® can also be developed in Phase 2 in combination with other immunotherapeutic products or targeted therapies. It is also considered for other oncology indications (ovary, colon, breast) for HLA-A2 positive patients.

MANAGEMENT

Dominique Costantini, *CEO*
Alexis Peyroles, *CFO, BD*

Oxford BioMedica Plc.

www.oxfordbiomedica.co.uk

CONTACT
Dr. Jason Slingsby
Head of Business Development

ADDRESS
Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom

TELEPHONE
+44 (0) 1865 783 000

EMAIL
enquiries@oxfordbiomedica.co.uk

YEAR FOUNDED
1995

SECTOR

- Biotechnology

COMPANY PROFILE

OXB Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners including Novartis, Immune Design and GSK. Further information is available at www.oxfordbiomedica.co.uk.

PIPELINE

OXB-102: Late preclinical development. A Phase 1/2 study will be initiated later in 2016.
OXB-102 is a gene therapy product for Parkinson's disease. OXB's third generation minimal lentiviral vector is configured to deliver three enzymes involved in the conversion of tyrosine (and L-DOPA) into dopamine: AADC, TH and CH1. This is in contrast to single enzyme gene therapies in development for Parkinson's disease by Voyager and Agilis.

A previous study of the company's first program in Parkinson's disease, ProSavin, has enrolled 15 patients with Parkinson's Disease. Both one year and three year follow-up data from this study has been published.

OXB-202: Preclinical development
OXB-202 is a gene modified tissue product in preclinical development for the prevention of corneal graft rejection. Corneal transplant is the most common organ transplant around the world and a subset of patients are at risk of sight-threatening rejection of the transplanted cornea. OXB-202 is a lentiviral vector-based treatment of the corneal plug, where the anti-angiogenic genes endostatin and angiostatin reduce the neovascularisation that leads to corneal graft rejection. A Phase 1/2 study will initiate in 2016/17.

OXB-302 is in pre-clinical development
OXB-302 is OXB's CAR-T 5T4 program for treatment of solid tumours expressing the tumour associated antigen, 5T4. It employs OXB's industry-leading LentiVector platform which is also partnered with Novartis in the CAR-T field, along with OXB's IP portfolio, know-how and clinical development expertise in the field of 5T4-related tumour biology. The program has demonstrated in vivo proof of concept efficacy and a Phase 1/2 trial is anticipated in 2017.

MANAGEMENT

Mr. John Dawson, *CEO*
Mr. Tim Watts, *CFO*
Mr. Peter Nolan, *CBO*
Dr. Kyri Mitrophanous, *CSO*
Dr. James Miskin, *CTO*
Dr. Paul Blake, *CDO*
Dr. Jason Slingsby, *Head of Business Development*

PRAGMA THERAPEUTICS

Innovative medicines for stress disorders

Pragma Therapeutics

www.pragmatherapeutics.com

CONTACT
Sylvain Celanire, PhD
Chief Executive Officer & co-founder

ADDRESS
92 rue Ada Byron
– Domaine de Chosal
Biopark Archamps Technopole
74166 Saint Julien en Genevois
Cedex

EMAIL
contact@pragmatherapeutics.com

YEAR FOUNDED
2015

SECTOR

• Biotechnology • Pharmaceuticals/Licensing

FINANCIAL SUMMARY

PRAGMA has successfully been awarded national and international grants totalizing €1 million euros from Research and Innovation Agencies, innovation bank and patients advocacy groups to support discovery research on its mGlu7 program targeting PTSD and additional therapeutic indications, totalizing $20 billion market size.

COMPANY PROFILE

PRAGMA Therapeutics is discovering and developing innovative medicines acting on the mGlu7 receptor for severe stress disorders with high unmet medical needs.

The mGlu7 receptor has shown to be uniquely located in specific brain regions dysregulated upon traumatic events. Blocking mGlu7 receptor would represent a breakthrough therapeutic approach for patients suffering from Post-Traumatic Stress disorders (PTSD).

PRAGMA team has designed and characterized several chemical series able to block mGlu7, highly tractable and highly drug-like, with tailored pharmacological and pharmacokinetics properties.

Proprietary lead candidate PGT117 is a first-in-class orally active small specific mGlu7 inhibitor molecule, exhibiting novel fear extinction in vivo profile, confirming its potential role for the treatment of PTSD.

PRAGMA top-ranked lead asset has been recently awarded twice by international research agencies and patients advocacy group, selected by European pharmaceutical companies and renowned neuroscience academic leaders.

PIPELINE

PGT117: preclinical development stage

PGT117 is a nanomolar, orally bioavailable, selective, specific, brain penetrant mGlu7 antagonist with clean in vitro safety profile (wrt genotoxicity and cardiac safety). Preclinical Proof-of-Concept has been established in a translational rodent model of PTSD.

Follow-up and back-up molecules have been identified.

European patent application has been filed (compositions of matter and therapeutic uses) with subsequent filing planned.

OPPORTUNITY

Investment

PRAGMA is seeking €9 million total to complete Phase2a proof-of concept clinical trial of its lead candidate.

A first round of €4 million will support regulatory preclinical development and Phase 1 clinical trial.

MANAGEMENT

Sylvain Celanire, PhD, *Chief Executive Officer & co-founder*
Neuroscience R&D leader with 15-year experience from large Pharmaceutical and Biotech companies. Former CNS Business Unit Director and Group Leader (managemennt of 20 scientists) with preclinical project leader and portfolio management experience.

Guillaume Duvey, PhD, *Chief Scientific Officer & co-founder*
Drug Development expert with 15-year experience in Neuroscience within Pharmaceutical industry and Biotech companies, with track record from candidate identification until Phase 2 clinical trials. Management experience of internal R&D teams and external CROs. Identification and establishment of strategical scientific partnerships to better support Drug Development with novel technological platforms.

ProAxsis Ltd.

www.proaxsis.com

CONTACT
Dr David Ribeiro
CEO

ADDRESS
63 University Road
Belfast
BT7 1NF
United Kingdom

TELEPHONE
+44 28 95 21 8400

EMAIL
info@proaxsis.com

YEAR FOUNDED
2013

SECTOR

- Biotechnology

COMPANY PROFILE

ProAxsis, is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

Our rapid and easy-to-use tests incorporate patented "ProteaseTags™"; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as cystic fibrosis and COPD.

MANAGEMENT

François Martelet, *Chairman*
Dr David Ribeiro, *CEO*
Brian Walker, *CSO*
Lorraine Martin, *CTO*
Ernest Schneider, *Commercial-Legal Director and Company Secretary*
Peter Thoms FCA
Kathryn Lee, *Board Director*

Provectus Biopharmaceuticals, Inc.

www.pvct.com

CONTACT
Peter R. Culpepper
Chief Financial Officer and Chief Operating Officer.

ADDRESS
7327 Oak Ridge Highway
Knoxville, TN 37931
USA

TELEPHONE
+1 (866) 594-5999

EMAIL
marlon@plrinvest.com

YEAR FOUNDED
2002

SECTOR

- Biopharmaceuticals

COMPANY PROFILE

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

MANAGEMENT

H. Craig Dees, Ph.D., *Chief Executive Officer*
Timothy C. Scott, Ph.D., *President*
Eric A. Wachter, Ph.D., *Chief Technology Officer*
Peter R. Culpepper, *Chief Financial Officer and Chief Operating Officer.*

Provista Diagnostics, Inc.

www.provistadx.com

CONTACT
David E. Reese, PhD,
Chief Executive Officer and President

ADDRESS
55 Broad Street, 18th Floor,
New York, NY 10004
USA

TELEPHONE
+1-855-552-7439

EMAIL
IR@ProvistaDx.com

YEAR FOUNDED
2011

SECTOR

- Diagnostics

COMPANY PROFILE

Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.

Provista's proteomic tests are designed to detect the presence or absence of cancer, as opposed to the risk of developing cancer in the future. A blood-based approach for cancer detection identifies biochemical signatures associated with cancer development and progression. When used in combination with current standard of care, Provista's diagnostics tests improve the accuracy of cancer detection. Provista's goal is to integrate actionable information into the current standard of care, providing greater clarity in clinical decision-making, thereby reducing over-diagnosis, lowering healthcare costs and most importantly, improving outcomes and saving lives.

Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP), and certified by the Centers for Medicare & Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

MANAGEMENT

David E. Reese, PhD, *Chief Executive Officer and President*
Dr. Reese was appointed President and CEO in 2011 for his background in cutting-edge biomedical organizational infrastructure and finance. Prior to joining Provista, Dr. Reese was a Managing Director at multiple healthcare investment funds. Dr. Reese received his PhD from Vanderbilt University and his BS from Arizona State University. He has completed multiple post-doctoral fellowships.

Rao V. Mulpuri, PhD, MBA, *Chief Operating Officer*
Dr. Mulpuri is responsible for the development of Provista's operating plan based on prior work in the esoteric diagnostics space. Previously, Dr. Mulpuri was Vice President, Laboratory Operations, where he was responsible for multi-site commercial laboratory testing at AssureRx Health. Dr. Mulpuri received a PhD in physiology and biochemistry from Vikram University and MBA from the University of North Carolina.

Joseph M. Eggler, *Chief Commercial Officer*
Mr. Eggler is responsible for the executive leadership and strategic direction of the company's clinical commercial business. Mr. Eggler has twenty two years of commercial Pharmaceutical and Diagnostic experience including, sales, marketing, reimbursement, strategic planning, sales operations, training and commercial team leadership. Prior to joining Provista, Mr. Eggler was the National Sales Director for Oncology at Prometheus Laboratories. He is a graduate of Edinboro University with a degree in Computer Science.

Uriel E. Kusiatin, MBA, *Chief Financial Officer*
Mr. Kusiatin joined Provista as CFO in June of 2015 after two years of dedicated service to develop more robust financial systems and controls as well as managing the budgeting, financial planning and analysis processes. Mr. Kusiatin brings over 25 years of strategy development, operational execution and financial management experience as a business consultant and operations executive. Mr. Kusiatin holds a BS in Industrial Engineering from the Technical Institute of Denmark and an MBA from the Wharton School of the University of Pennsylvania

seiratherm GmbH

www.seiratherm.com/en

CONTACT
Dr. Matthias Roth
CEO and Founder

ADDRESS
Beethovenstraße 10 · 91074
Herzogenaurach
Germany

TELEPHONE
+49 89 809 131 420

EMAIL
matthias.roth@seiratherm.de

YEAR FOUNDED
2010

SECTOR

- Medical Devices

FINANCIAL SUMMARY

- To date seiratherm has been financed through grants & venture capital (incl. HTGF and Bayern Kapital)
- Intention to raise 3,0+ Mio € in a Series C round in 2016 for additional clinical trials and ramp up of sales organisation
- Exciting M&A arena for innovative companies

Market size

- Market revenue Western Europe approx. 900 Mio €in 2018 according to Frost & Sullivan
- World-wide expected to reach up to $2.2B in 2018 according to Frost & Sullivan

Business model

- Customers: Hospitals with operating theatres and/or intensive-care-units
- Two revenue sources: device & disposable sales per patient
- Competitive pricing in terms of costs per patient application
- Market launch in EU with hybrid sales structure in Q3/2016

COMPANY PROFILE

seiratherm GmbH is a clinical-stage medical device company focused on the development, production and marketing of innovative medical devices in the area of Targeted Temperature Management

PRODUCT PIPELINE

tempedy ®/ Clinic, CE mark, FDA clearance ongoing

Device & disposable for the regulation of the body core temperature combined with an integrated fluid-balance-management

CE approval since 2014, FDA clearance ongoing

Infusion of balanced fluids (NaCl, Ringer etc.) with appropriate flow rate (1 - 250 ml/min) and temperature (4°C – 42°C) in order to regulate the body-core-temperature (cool down, hold/maintain a specific level, rewarm)

Physiological feedback control combined with patient adaptive algorithm enable fully automatic & safe application

Clinically proven and accepted principle/method (e.g. rapid infusion of ice cold saline to induce hypothermia & infusion of warm fluids)

Broad successful clinical application data for various indications & currently enrolling into 4 studies

Fast, easy and non-additionally invasive application



Continued...

seiratherm GmbH

www.seiratherm.com/en

CONTACT
Dr. Matthias Roth
CEO and Founder

ADDRESS
Beethovenstraße 10 · 91074
Herzogenaurach
Germany

TELEPHONE
+49 89 809 131 420

EMAIL
matthias.roth@seiratherm.de

YEAR FOUNDED
2010

...continued

OPPORTUNITIES

tempedy
Intention to raise 3,0+ Mio €in a Series C round in 2016 for additional clinical trials and ramp up of sales organisation. In addition, strategic partners and/or distribution partners are being sought.
Business strategy
– Financing operations until break-even through another venture round and sales/licensing income
– Significant past acquisitions clearly indicate that globally, patient temperature management is expected to witness significant growth over the next years.
For further information also see Financial Summary.

MANAGEMENT

Interdisciplinary team of physicians, engineers and managers
Dr. Matthias Roth, *CEO and Founder*
Dr.-Ing. Thomas Reichthalhammer, *Technical Director,*
Frank Gottwald, *Sales Director,*
Superior Senior Medical Advisory Board with leading KOLs
Prof. Dr. Kollmar, *Chairman*:

SOPHIA GENETICS

Sophia Genetics

www.sophiagenetics.com

CONTACT
Jurgi Camblong
CEO and Co-founder

ADDRESS
Rue du Centre 172
CH-1025 Saint Sulpice
Switzerland

TELEPHONE
+41 21 694 10 60

YEAR FOUNDED
2011

SECTOR

- Biotechnology

COMPANY PROFILE

Sophia Genetics was founded in 2011 to make Data Driven Medicine a reality. With the adoption of digital technologies, such as Next Generation DNA Sequencing, the healthcare industry entered the Big Data world raising new challenges in data protection and data analytics. We are today the only company in the field of genomics with both, ISO 13485 (medical device) and ISO 27001 (data security) certifications.

With over 135 hospitals using our Sophia DDM® analytics platform, we have created the World's Largest Clinical Genomics Community. Every week, we contribute in better diagnosing thousands of patients in various areas including oncology, metabolism, pediatrics, cardiology and hereditary cancer.

PRODUCT PIPELINE

Sophia DDM® is a so ware-as-a- service platform. It integrates modules enabling analysis and protection of clinical NGS data. Our core technologies process and analyse raw genomic data to help hospitals be er and faster diagnose patients in the five following areas: Oncology, Metabolism, Pediatrics, Cardiology and Hereditary Cancer.

Besides the sequence data analysis, including alignment up to annotated facilitated variants, the Sophia DDM® comes with many other important functionalities for diagnosing your patients. From multiple panels of selected genes, genomes or exomes from sequenced patient DNA, up to variant report.

MANAGEMENT

Jurgi Camblong, *CEO and Co-founder*
Dr. Jurgi Camblong is one of the most visionary entrepreneurs in the fast growing domain of clinical genomics. After a successful academic career in Molecular Biology he moved to the Start-up scene with the objective of making genomics a reality for improved patients' diagnosis and care. After acting as the CEO of Gene Predictis, he founded Sophia Genetics in 2011 with Dr. Pierre Hutter and Prof. Lars Steinmetz. Since then Dr. Camblong has been successfully leading the development of the company, recruiting the right talents and executing innovative business models. Today, he is considered as one of the most successful Swiss entrepreneurs. Jurgi Camblong holds a PhD in Life Sciences (University of Geneva) and an EMBA in Management of Technology (EPFL-HEC Lausanne).

Marylin Mermod Schule, *CFO*
Marylin Mermod Schule is a senior financial officer. She joined Sophia Genetics in May 2015 and brings with her a strong financial acumen and accounting background as well as a track record in healthcare. Prior to joining Sophia Genetics, she worked for the Group Edmond de Rothschild where she held several key roles in corporate finance and private equity, including the co-development of a new private equity division. She started her career as an external audit manager at EY before joining the Swiss clinic La Metairie (Capio's group) where she has held the position of CEO and CFO. She holds an M.S. in Finance from the HEC Lausanne School of Business and is a Swiss Certified Accountant. She is a member of the boards of MedC Partners, a medtech consulting firm and Electro-kit, an electrical equipment engineering and manufacturing firm.

Zhenya Xu, *CTO*
Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. He holds a Master's degree from Cambridge University in computational biology, and obtained his PhD at the European Molecular Biology Laboratory (EMBL) where he focused on the transcriptome landscape of yeast. His PhD work systematically characterised the non-coding transcripts in yeast which lead to the unveiling that in a majority of cases, transcriptions are bidirectional. Dr. Xu is among the most experienced bioinformaticians worldwide in clinical NGS data analysis. He joined Sophia Genetics in 2012 and is the leader of the technology team who developed the clinical grade NGS data analytic solution. The resulting technologies such as PEPPER™, MUSKAT™ and MOKA™ are based on pattern recognition and machine learning techniques and validated by thousands of clinical samples. These technologies have become the core of Sophia DDM® backend, recognised and widely used in hundreds of hospitals across Europe.

Didier Pitton, *VP of Sales*
Didier Pitton is a senior business technology executive with extensive experience in Sales, Marketing, Product Management, Business Development and Strategy. Prior to joining Sophia in September 2012 he held global sales and business development roles at Odyssey Financial Technologies and Avaloq Evolution AG (leading providers of integrated technology and comprehensive solutions for wealth management, universal and retail banks).

Continued...

SOPHIA GENETICS

Sophia Genetics

www.sophiagenetics.com

CONTACT
Jurgi Camblong
CEO and Co-founder

ADDRESS
Rue du Centre 172
CH-1025 Saint Sulpice
Switzerland

TELEPHONE
+41 21 694 10 60

YEAR FOUNDED
2011

...continued

Adam Molyneaux, Director of IT
Dr. Adam Molyneaux is a senior software engineer. He obtained his initial degree at Imperial College and after a period developing software for structural analysis he moved to EPFL where he obtained his PhD in 2002. Since then he has been involved extensively with complex application development, spending 5 years as a Senior Developer / Project Leader for a biotech company, SmartGene SA, where he was responsible for the development of several flagship products, including a sequence proofreader and a HLA matching tool. He joined Sophia Genetics in July 2012 after 4 years as an independent consultant working on various SaaS, science based projects.

Pierre Hutter, *CSO and Co-founder*
Dr. Pierre Hutter is one of the most renowned medical geneticists in Switzerland. He completed his PhD in genetics in Edinburgh and his postdoctoral work in Cambridge (UK). He discovered the landmark speciation gene Hmr (Hybrid male rescue) in Drosophila, which has become the most studied gene in the field of reproductive isolation. Between 2005 and 2011 he was co-director of the Geneva University laboratory of Predictive Oncology, one of the two reference laboratories for the study of cancer predisposition. As head of the Medical Genetics Service of the Valais hospital, Dr. Hutter is currently involved in the development of genetic diagnoses based on high-throughput sequencing, works as a consultant for a private laboratory, and is an expert of accreditation of molecular genetics laboratories. He represents the Swiss Society of Medical Genetics at the FAMH commission of the Swiss Academy of Medical Sciences.

Stratpharma AG

www.stratpharma.com

CONTACT
Mr Darren Ker
CEO

ADDRESS
Centralbahnplatz 8
CH-4051 Basel
Switzerland

TELEPHONE
+41 61 691 12 80

EMAIL
inquiries@stratpharma.com

YEAR FOUNDED
2005

SECTOR

• Medical Devices • Pharmaceuticals/Licensing

COMPANY PROFILE

Stratpharma AG is an ISO 13485 certified company for the design, development and manufacture of medical devices for use in Cosmetic Dermatology, Plastic Surgery, Burns, Wounds & Scar management. Stratpharma sells 4 products in 40 countries with 8 products under development and has obtained marketing authorisation in 70 countries.

Stratpharma's products are novel and are revolutionising the treatment of wound indications including:

- Strataderm for treatment and prevention of abnormal scarring (Class I Medical Device)
- Stratamark for prevention and treatment of stretchmarks (Class I Medical Device)
- Stratamed for flexible wound dressing for open wounds (Class II Medical Device)
- StrataXRT for the prevention and treatment of Radiation Dermatitis (Class II Medical Device)

Stratpharma is growing rapidly due to the sales success in existing markets, new country launches and new product launches. This annual revenue growth of between 200% to 300% is forecast to continue and sales to exceed CHF 100 million in the next 2 to 3 years. Stratpharma will continue to drive this profitable growth through investment in distribution, marketing, clinical trials, new product development and organisation capability.

During 2015 Stratpharma will release another round of equity and is seeking an investor to share in our success.

Stratpharma is domiciled in Basel Switzerland and was founded in 2005.

OPPORTUNITY

Equity Investment

Stratpharma will release a round of Equity during 2016. The equity investment will be used to accelerate the existing growth of the Stratpharma business via investment in sales & marketing, new product development and organisational capacity.

MANAGEMENT

Mr Darren Ker, *CEO*
Mr Richard Koch, *CFO*
Mr Luka Valas, *General Counsel*
Mr Chris Unwin, *Director Supply Chain*

Strekin AG

www.strekin.com

CONTACT
Dr. Alexander Bausch
CEO

ADDRESS
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel
Switzerland

TELEPHONE
+41 616 332 971

YEAR FOUNDED
2014

SECTOR

- Pharmaceuticals/Licensing

FINANCIAL SUMMARY

After successful SEED A and SEED B with several millions sufficiently funded until end of first clinical Phase 2 study for STR001 in Hearing loss

Strategic SEED B2 financing round in 2016 under consideration

COMPANY PROFILE

Strekin focuses on discovering the untapped therapeutic potential in existing molecules to transform the lives of patients with diseases of cell stress-related inflammatory pathways.

Our approach uses new scientific knowledge to discover previously unknown mechanisms of action for existing compounds, or new importance for an existing target in a different disease area. We start only with molecules that have been effectively optimized as drugs, with proven clinical safety records from either mid to late stage clinical trials, or real-world medical use. We find opportunities and generate the preclinical evidence to support the novel potential of the therapy. Since our molecules have extensive biological data, well-characterized formulation and manufacturing routes, and established safety records, we can move quickly into clinical testing. The first product STR001 is developed in the area of hearing loss

The company is sufficiently funded through private investment to achieve the next major corporate milestones.

PRODUCT PIPELINE

STR001 clinical development

Str001 is a small molecule with an extensive clinical safety database systemically administered.

STR001 is currently in development for treatment of hearing loss with the first indication in protection of residual hearing during Cochlear Implant Surgery with intra tympanic administration.

STR002 under licensing negotioation

STR002 is a clinical asset with a clinical safety database of several hundred patients for 3 Month currently under negotiation to be licenced in. Further details to be communicated after deal closure.

MANAGEMENT

Dr. Alexander Bausch, *CEO*
Dr. Jacques Gaudreault, *COO*
Dr. Viktor Boerlin, *CMO*
Dr. Matthew Wright, *Vice Director Head of Research*
Dr. Urs Breitenstein, *CFO*
Claudia Berger, *Head Clinical Operations*

TaiwanJ Pharmaceuticals

www.taiwanj.com

CONTACT
Ying-Chu Shih, Ph.D.
CEO/Co-Founder

ADDRESS
No.2,Sec.2,ShengYi Rd.,
Zhubei City,
Hsinchu County 30261,
Taiwan(R.O.C)

TELEPHONE
+886 03-6587721

EMAIL
info@taiwanj.com

YEAR FOUNDED
2011

SECTOR

- Pharmaceuticals/Licensing

COMPANY PROFILE

TaiwanJ is a pharmaceutical company dedicated to the development and commercialization of first-in-class small molecules for unmet medical needs. The Company's drug development strategy is to reduce time-to-market, lower clinical risks, and minimize development costs by re-profiling approved drugs and adapt the fast regulatory path. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapy to address chronic liver disease, inflammatory bowel disease, and rheumatoid arthritis, as well as organ damage to the kidney and the lung. Specific diseases targeted include liver inflammation, liver fibrosis, NASH, NALFD, and autoimmune diseases including rheumatoid arthritis and Crohn's Disease. TaiwanJ seeks product development collaborations and strategic alliances to develop its pipeline of products into the market. The company plans to float an IPO by 2017 on the Taiwan stock market.

OPPORTUNITIES

JKB-122 licensing out

JKB-122 is the lead compound in the pipeline of TaiwanJ and is currently in the patient recruiting stage of its Phase II clinical trial in Taiwan under an IND approved by both the Taiwan FDA and the US FDA. JKB-122 is also granted an orphan disease designation as well as a Phase II IND for treating autoimmune hepatitis by US FDA. JKB-122 is an off-patent drug that has newly demonstrated properties in animal models of anti-fibrotic, immuno-modulating and anti-inflammatory activities that can prevent or reduce inflammation-associated liver damage.

JKB-121 licensing out

JKB-121 has exhibited efficacy in fatty liver inflammation in animal studies. A physician-initiated Phase II IND is currently in the patient recruiting stage in US on NASH (non-alcoholic steatohepatitis) treatment.

JKB-122 licensing out or partnering

For Crohn's disease, JKB-122 has 2 pilot trial showed high response rate in active patients. TaiwanJ seeks for phase2/3 development partner.

MANAGEMENT

Edwin Wu, Ph.D., *Founder/Chairman*
With over 20 years of experience in pharmaceutical R&D, Dr. Wu has served in various senior research and management positions for several pharmaceutical companies, including Pennwalt Pharmaceuticals, Fisons Pharmaceuticals, Astra Arcus (part of Astra Pharmaceuticals), ScinoPharm Taiwan and Jenken Biosciences.

Ying-Chu Shih, Ph.D., *CEO/Co-Founder*
Dr. Shih is specialized in the pharmaceutical research and early drug development in immunology, for diseases such as asthma, rheumatoid arthritis, liver diseases, and related areas. She worked as a research fellow, project leader, and project manager and as a director overseeing a team of 25 staff at ITRI, a leading biomedical R&D institution in Taiwan. Her experience also includes regulatory affairs and clinical trials.

Peter J.S. Chiu, Ph.D., *CSO*
Dr. Chiu's career in drug discovery area progressed from Schering-Plough Corporation as a senior scientist, to Pfizer as the Manager of the Department of General Pharmacology, and then at MDS Pharma Services (Seattle, Washington) as Pharmacology Director/Research Fellow/Chief Scientific Officer. While he is specialized in renal, gastrointestinal and cardiovascular pharmacology, Dr. Chiu has a broad-based knowledge and experience in pharmacology relating to new drug discovery.

Jerry Ting-Shun Chan, CPA and CVA, *CFO,*
Mr. Chan has license of C.P.A., Taiwan and C.V.A.(IACVA,USA) and has well knowledge and work experience of Corporate law, Securities and Exchange, Tax of Taiwan. He worked for Deloitte & Touche for 10 years and in those years he was the lecturer of internal training, in charge of IPO application process

Loren Miller, Ph.D., *VP of Clinical Development*
Dr. Miller has more than 20 years of experience in clinical regulatory affairs. He has served in several executive positions at PPD Development, including Vice President, Scientific and Regulatory Affairs.

Targovax ASA

www.targovax.com

CONTACT
Gunnar Gårdemyr
CEO

ADDRESS
Lilleakerveien 2 C
NO-0283 Oslo
Norway

TELEPHONE
+47 21 39 88 10

EMAIL
contact@targovax.com

YEAR FOUNDED
2010

SECTOR

- Biotechnology

FINANCIAL SUMMARY

In July 2015, in relation to the merger between Targovax ASA and the Finnish company Oncos Therapeutics, Targovax performed a successful private placement.

EUR 20m was raised, ensuring the first stage of an extensive clinical development program with 8 read-outs over the next two years.

With the planned upcoming IPO , Targovax will complete funding for its clinical development program consisting of six ph I/II studies in different indications.

Two of six studies are externally sponsored.

COMPANY PROFILE

Targovax: harnessing the immune system to fight cancer.

Targovax is a clinical stage immuno-oncology company dedicated to the development of targeted immunotherapy treatments for cancer patients.

Targovax is a leader in the immuno-oncology field born out of the merger in July 2015 of Targovax of Norway and Oncos Therapeutics of Finland. Targovax is headquartered in Oslo with offices also in Helsinki.

The new company is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient's own immune system to fight the cancer.

Targovax's lead peptide-based targeted immunotherapy, TG01, is currently in a phase II clinical study in resected pancreatic cancer, following a Phase I study which demonstrated immune responses in all patients (6). Its lead adenoviral product, ONCOS-102, has also successfully completed Phase I clinical studies and confirmed its tumor specific and systemic activity. ONCOS-102 will enter further clinical studies in the near future for the treatment of solid tumors such as melanoma, malignant pleural mesothelioma, and ovarian cancer.

Targovax has Orphan Drug Designation with the FDA and EMA for TG01 in pancreatic cancer and ONCOS-102 in mesothelioma, ovarian cancer and soft tissue sarcoma.

Targovax remains committed to the discovery, development and delivery to patients of its first-in-class therapeutic cancer treatments.

PRODUCT PIPELINE

TG01 Phase I/II Pancreatic Cancer

TG01 is evaluated in an ongoing open label, phase I/II of TG01/GM-CSF treatment and gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas. In a first cohort, 19 patients have received the combined treatment and of the 18 patients eligible for immune response assessment, 15 (83%) have established a detectable immune response.

ONCOS-102 Phase I/II Mesothelioma

This trial will be a randomized phase I/II open label study with a Phase Ib safety lead-in of ONCOS-102 and standard of care chemotherapy in patients with unresectable malignant pleural mesothelioma. The study is planned to include 6 patients in the safety cohort and approximately 24 patients in the randomized phase II part. In February 2016, Targovax announced the submission of the study protocol to the regulatory authorities in Spain in January. According to plan, the trial is planned to commence during the first half of 2016.

Continued...

Targovax ASA

www.targovax.com

CONTACT
Gunnar Gårdemyr
CEO

ADDRESS
Lilleakerveien 2 C
NO-0283 Oslo
Norway

TELEPHONE
+47 21 39 88 10

EMAIL
contact@targovax.com

YEAR FOUNDED
2010

...continued

ONCOS-102 Pase I/II Melanoma
This trial will be an explorative open-label study to determine anti-tumor immune activation and clinical response of ONCOS-102 given with pembrolizumab, a checkpoint inhibitor (human programmed PD-1-blocking antibody) in patients with advanced melanoma who have stopped responding to prior treatment with check point inhibitors. The goal of the study is to investigate whether these patients will start responding again to a checkpoint inhibitor after ONCOS-102 treatment. The trial is planned to include approximately 12 patients in the US and will commence in the second half of 2016.

OPPORTUNITIES

TG01

Oncos 102

TG02

MANAGEMENT

Gunnar Gårdemyr, *CEO*
Øystein Soug, *CFO*
Jon Amund Eriksen, *COO*
Magnus Jäderberg, *CMO*
Antti Voulanto, *EVP*
Tina Madsen, *VP QA*
Peter Skorpil, *VP BD*
Nikolaj Knudtzon
Ann-Kirsti Aksnes, *Head HR, VP*

Therabron Therapeutics

Therabron Therapeutics, Inc.

www.therabron.com

CONTACT
Thomas F. Miller
President & CEO

ADDRESS
9430 Key West Avenue
Suite 150
Rockville, MD 20850
USA

TELEPHONE
+1 240-205-7275

YEAR FOUNDED
1997

SECTOR

- Biotechnology

FINANCIAL SUMMARY

- $14 M raised to Date (VC)

Grants: 1. FDA Orphan Rx grant -- funding current P2 program
2. US ARMY Grant -- funding early stage program

COMPANY PROFILE

At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage, biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins which includes the CC10 protein -- a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class, biologic therapeutics. For additional information, please visit www.therabron.com

PRODUCT PIPELINE

CG100 – P2 – Peditaric critical care

PROGRAM NAME	DELIVERY ROUTE	TARGET INDICATIONS	US/EU MKT. OPPORTUNITY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	BLA
rhCC10 PROGRAMS								
CG100	Intratracheal	Prevention of Neonatal Chronic Respiratory Morbidities	$500 M+					
CG201	Intranasal	Chronic Rhinosinusitis	$1 B+					
CG367	Intravenous	Pediatric Acute Respiratory Failure; Severe influenza-like illness	$1 B+					
rhCC10 ANALOGUE PROGRAM								
CG459	Inhaled	COPD; Asthma	$2 B+					
rhUGRP1 PROGRAM								
CG1011	Inhaled	IPF; Fibrotic Lung Disease	$500 M+					

OPPORTUNITIES

EU rights – lead P2 program

MANAGEMENT

Thomas F. Miller, *President & CEO*
Alan Cohen, *SVP, CMO*
Linda Chang, *SVP, CFO*
Aprile Pilon, *Founder, EVP, CSO*

Tissue Regenix Group Plc.

www.tissueregenix.com

CONTACT
Mr Antony Odell
Chief Executive Officer

ADDRESS
The Biocentre
Innovation Way
Heslington
York, YO10 5NY
United Kingdom

TELEPHONE
+44 (0)1904 567609

EMAIL
enquiries@tissueregenix.com

YEAR FOUNDED
2006

SECTOR

• Medical Devices • Regenerative Medicine

COMPANY PROFILE

Tissue Regenix is a pioneering, international medical technology company, leading the development of regenerative products to make replacement body parts using biological (human & animal) materials.

The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from tissue leaving an acellular scaffold which is not rejected by the patient's body. The potential applications of dCELL® are diverse and address critical clinical needs such as wound care, heart valve replacement and knee repair

MANAGEMENT

Mr Antony Odell, *Chief Executive Officer*

Vaxart, Inc.

www.vaxart.com

CONTACT
Wouter Latour
Chief Executive Officer and Director

ADDRESS
385 Oyster Point Blvd., Suite 9A
South San Francisco, CA 94080
USA

TELEPHONE
+1 650 550 3500

EMAIL
info@vaxart.com

YEAR FOUNDED
2004

SECTOR

- Biotechnology

COMPANY PROFILE

Vaxart is a clinical-stage company developing oral recombinant vaccines based on its proprietary oral vaccine platform. All Vaxart vaccines are administered using a convenient room temperature-stable tablet. The platform is suitable for a wide range of recombinant vaccine antigens. Lead programs are targeting RSV, norovirus and influenza.

PIPELINE

Vaxart Pipeline

Three high value vaccine candidates are currently in the clinic, or advancing into the clinic in 2015:
– Seasonal Influenza
– Norovirus
– RSV

Impact

Seasonal influenza is currently a $3 Billion Market worldwide. In the US, the largest market, only 45% of all those for who vaccine is recommended are actually vaccinated in any given year. In adults age 18 – 64 vaccination rates are much lower, just over 30%. A tablet vaccine could dramatically impact vaccination rates, particularly in the 18 – 64 age group, the largest segment of the population.

RSV causes significant morbidity and mortality in children as well as in elderly. Annually some 150,000 – 200,000 adults and elderly are hospitalized due to RSV infection.

Norovirus is a highly prevalent viral intestinal infection, affecting some 20 million people annually in the US alone. It is best known as the "cruise-ship" bug, but is causing significant morbidity among the population. Travelers, health care workers, food industry workers, military and first responders would all greatly benefit from vaccination, particularly by convenient tablet that can be self-administered.

All three indications will likely require annual vaccination campaigns offering significant synergies. A portfolio consisting of tablet vaccines for flu, RSV and norovirus will be ideal to address these high volume – high value markets, and offer a formidable competitive advantage vis a vis other products currently in development.

MANAGEMENT

Wouter Latour, *Chief Executive Officer and Director*
Sean Tucker, *Founder, Chief Scientific Officer and Director*
David Liebowitz, *Chief Medical Officer*
John Harland, *Chief Financial Officer*
David Ingamells, *Vice President of Manufacturing*
Samir Singh, *Senior Vice President Corporate Development & Strategy*

Vaximm GmbH

www.vaximm.com

CONTACT
Dr. Heinz Lubenau,
Managing Director,

ADDRESS
MAFINEX Building
Julius-Hatry-Strasse 1
68163 Mannheim
Germany

EMAIL
info@vaximm.com

YEAR FOUNDED
2008

SECTOR

- Biotechnology

COMPANY PROFILE

VAXIMM is a Swiss- and Germany-based biotech company that is developing oral T-cell vaccines as immunotherapy for patients suffering from cancer.

Our oral T- VAXIMM's oral T-cell vaccine platform is based on an approved, live attenuated bacterial vaccine, which has been applied in millions of times, and which is safe and well tolerated.

To yield our oral T-cell vaccines, the bacteria are modified to deliver a eukaryotic expression plasmid, which encodes the genetic information of a specific target antigen. After ingestion of the vaccine, patients develop a cellular immune response (specific cytotoxic T-cells) against those targets. The so-generated killer cells may then seek and destroy tumor or tumor stromal cells in the patients' body.

PRODUCT PIPELINE

VXM01 Phase IIa

VXM01 targets the tumor vasculature and certain immunosuppressive cells, and improves the capability of the patients' own immune system to fight their tumors and related metastasis. VXM01 has already been tested in a first clinical trial in patients with advanced pancreatic cancer. Further clinical studies in colorectal cancer and glioblastoma are underway.

VXM04 Phase I ready

VXM04 targets a tumor-associated antigen that is expressed in pancreatic cancer cells and several other solid tumor types. VXM04 is developed in combination with VXM01 as an immunotherapy for the treatment of patients suffering from pancreatic cancer.

VXM06 Phase I ready

VXM06 targets a tumor-associated antigen that is expressed in haematological malignacies and several other solid tumor types. VXM06 is developed as an immunotherapy for the treatment of patients suffering from haematological malignancies.

MANAGEMENT

Dr. Heinz Lubenau, *Managing Director, Vaximm GmbH*
Dr. Klaus Breiner, *BB Biotech Ventures, Executive Chairman*
Dr. Jasper Bos, *Director*
Patrick Burgermeister, *Director*
Dr. Jean-Paul Prieels, *Director*
Dr. Sten Verland, *Director*

Virometix AG

www.virometix.com

CONTACT
Arin Ghasparian
CEO and co-founder

ADDRESS
Wagisstrasse 14
CH-8952 Schlieren
Switzerland

TELEPHONE
+41 (0) 43 433 86 60

EMAIL
info@virometix.com

YEAR FOUNDED
2009

SECTOR

• Biotechnology • Drug Delivery • Pharmaceuticals/Licensing

COMPANY PROFILE

Virometix AG is a privately held biotechnology company developing breakthrough synthetic nanoparticle-based vaccines and immunotherapeutic drugs for respiratory diseases and cancer. Lead product is a synthetic nanoparticle vaccine against Respiratory Syncytial Virus (RSV), the most common cause of lower respiratory tract infections among young children and older people worldwide, for which effective therapeutic interventions or vaccines are not yet available.

MANAGEMENT

Arin Ghasparian, *CEO and co-founder*
Dr. Armando Zuniga, *Chief Scientific Officer*
Dr. Urs Breitenstein, *Chief Financial Officer*

Xeltis AG

www.xeltis.com

CONTACT
Laurent Grandidier
Chief Executive Officer

ADDRESS
Mühlebachstrasse 26
CH-8008 Zurich
Switzerland

TELEPHONE
+41 44 269 79 79

EMAIL
info@xeltis.com

YEAR FOUNDED
2006

SECTOR

- Medical Devices

COMPANY PROFILE

Xeltis is a medical device company spearheading a revolutionary approach to regenerative medicine. Its technology is designed to harness the body's natural healing process, enabling spontaneous restoration of complex anatomical parts, such as cardiovascular valves. This approach may represent a way forward for cardiovascular interventions and the future of medicine.

Xeltis' technology is based on Nobel prize-awarded science of supramolecular chemistry. Its bioabsorbable devices are porous matrices designed to enable Endogenous Tissue Restoration, as the body's natural healing process pervades them with new healthy tissue. Each matrix is designed to get bioabsorbed overtime, leaving patients with new, healthy, functioning valves.

Xeltis is developing the first-ever bioabsorbable cardiovascular valves and vessels designed to allow Endogenous Tissue Restoration (ETR), a new transformational therapeutic approach in cardiovascular treatment.

- Xeltis is aiming to bring its first product to market, a pulmonary valve, within a few years
- Xeltis is also exploring a number of additional applications, including a bioabsorbable aortic valve

MANAGEMENT

Laurent Grandidier, *Chief Executive Officer*
Boris Warnack, *Chief Operations Officer*
Paul van Hagen, *Chief Financial Officer*
Martijn Cox, *Chief Technology Officer*
Eliane Schutte, *Chief Development Officer*
Oleg Sbanidze, *Chief Midical Officer*

Zytoprotec GmbH

www.zytoprotec.com

CONTACT
Bernd Seibel
Managing Director

ADDRESS
Mariannengasse 28/2
1090 Wien
Austria

TELEPHONE
+43 1 406 20 02

EMAIL
office@zytoprotec.com

YEAR FOUNDED
2007

SECTOR

- Biotechnology

FINANCIAL SUMMARY

No revenues, classic biotech financials, additional 2.5-3.5 million EUR necessary to get to end of Phase II

COMPANY PROFILE

Zytoprotec is a biotech company in Vienna/Austria based on reserch about cytoprotective effects of fluids on human cells. The first product PD-protec is a fluid to be used in peritoneal dialysis. It is currently in clinical phase II which is planned to be finsihed end of 2016 (75% of patients enrolled at this point). The size of the global market for PD solutions is US$ 2.6 billion. Since long time there has been no innovation in this market. As we believe PD-protec has the potential to replace the existing best in class PD solutions in the market, we see the long term peak sales potential of PD-protec in the range of US$ 600-900 million p.a. PD-protec is expected to overcome certain limitations of all glucose-based PD solutions (90% of the market): damage of peritoneal cells (resulting in peritonitis) and damage of membranes.

Zytoprotec has raised a total of EUR 16.6 million since 2007 and plans to raise an additional EUR 2.5-3.5 million in equity to complete Phase II trial.

PIPELINE

PD-protec : Phase II clinical trial
PD fluid (peritoneal dialysis), in Phase II clinical trial, 75% of patients enrolled, cross-over study-design, Austrian wide clinical trial with 6+ dialysis centers. last patient expected to be enrolled in May/June 2016 and treatment finished in Oct, data available end of 2016, final study report early 2017. Phase III likely to be under orphan drug status.

ICO-protec : pre-clinical stage
PD fluid for non-glucose based products in peritoneal dialysis; pre-clinical stage; expected to finalize pre-cllinical stage end of 2016 to be ready for first use in man

MANAGEMENT

Bernd Seibel, *Managing Director*
VC veteran with >20years biotech investment experience including >100 transactions managed

Bernhard Zinner, *Managing Director*
Former Business Head & General Manager in Austria for Baxter/Gambro, >20 years experience in Healthcare-, Hospital and Renal Business, PD market expert

Drooms AG

www.drooms.com

CONTACTS
Miss Luisa Henk
Senior Manager Business Development

Jan Hoffmeister
Managing Director

ADDRESS
Eschersheimer Landstraße 6
60322 Frankfurt
Germany

TELEPHONE
+49 69 478 640 0

EMAIL
office@drooms.com

YEAR FOUNDED
2001

SECTOR

- Biotechnology

COMPANY PROFILE

Drooms is a leading European provider of secure cloud solutions. The software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as due diligence for funding rounds, license negotiations, M&A activities or protection of intellectual property are handled securely, transparently and efficiently with Drooms.

Headquartered in Frankfurt, Drooms is expanding its global market presence with offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is has deep experience facilitating large-scale local and multi-jurisdictional transactions. Their expertise, combined with innovative processes and relentless customer focus have laid the groundwork for Drooms' excellent reputation.

PIPELINE

Drooms

Drooms' core competence is the configuration and administration of virtual data rooms, which gives users secure 24/7 online access to confidential documents. State-of-the-art security technology provides a powerful platform for sensitive and closely-controlled document exchange between internal and external resources, e.g. during online due diligence processes. Digital rights management determines who can review, print or save selected documents. Recording of all data room activities through detailed real-time reporting allows for monitoring of all activity in the data room. This functionality supports strategic decision making as well as supporting a company's compliance and risk management policies.

MANAGEMENT

Jan Hoffmeister, *Managing Director*
Alexandre Grellier, *Managing Director*

GeneCode Ltd.

www.genecode.com

CONTACT
Dr. Mati Karelson
Senior Partner

ADDRESS
Ahtri 8,
Tallinn 10151
Estonia

EMAIL
Info@genecode.com

YEAR FOUNDED
1993

SECTOR

- Biotechnology

COMPANY PROFILE

Genecode Ltd is an R&D company focusing on the discovery and development of disease-modifying drug candidates for the treatment of neurodegenerative diseases and viral infections. The company has identified small molecule mimetics of neurotrophic factors and artemin and proved theirs efficacy in animal models of Parkinson's disease and neuropathic pain. In another direction, Genecode, Ltd. has introduced a novel modified nucleotide-based antisense technology for gene silencing and using this technology developed antisense compounds targeting hepatitis C virus genome in picomolar concentrations in experimental animals. Presently, the company is looking for partners to complete the preclinical development and enter the clinical trials.

MANAGEMENT

Katrin Idla, *Managing Director*
Paavo Pilv, *Executive Director*
Kaupo Karelson, *Executive Director*
Andres Merits, *Scientific Team Leader*
Tõnis Timmusk, *Scientific Team Leader*
Mart Saarma, *Scientific Team Leader*
Mati Karelson, *Senior Partner*
Mehis Pilv, *Non-Executive Director*
Thomas Björn Waldin, *Non-Executive Director*

Provectus Biopharmaceuticals, Inc.

www.pvct.com

CONTACT
Peter R. Culpepper
Chief Financial Officer and Chief Operating Officer.

ADDRESS
7327 Oak Ridge Highway
Knoxville, TN 37931
USA

TELEPHONE
+1 (866) 594-5999

EMAIL
marlon@plrinvest.com

YEAR FOUNDED
2002

SECTOR

- Biopharmaceuticals

COMPANY PROFILE

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

MANAGEMENT

H. Craig Dees, Ph.D., *Chief Executive Officer*
Timothy C. Scott, Ph.D., *President*
Eric A. Wachter, Ph.D., *Chief Technology Officer*
Peter R. Culpepper, *Chief Financial Officer and Chief Operating Officer.*

Silver Sponsors

Drooms AG

www.drooms.com

Drooms is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.

Silver Sponsors

Pierre Fabre Fund for Innovation

www.pierre-fabre.com/en/pierre-fabre-fund-innovation

Pierre Fabre Fund for Innovation accompanies biotech companies, startups and research laboratories specialized in oncology, onco-dermatology or dermatology, in order to speed up the development process of new products currently at advanced preclinical stage or at early clinical stage.

Open to any international partnership opportunity, the main goal for Pierre Fabre Fund for Innovation is to help innovative companies located in France or in Europe.

Silver Sponsors

Provectus Biopharmaceuticals, Inc.

www.pvct.com

Provectus Biopharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers - melanoma, liver and breast - while minimizing side effects.

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver.
The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

Silver Sponsors

TORREYA PARTNERS

Torreya Partners, LLP

www.torreyapartners.com

Torreya Partners LLP is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide.

Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

Supporting Organisations

Berlin Partner

www.berlinpartner.de

First choice: Berlin Partner for Business and Technology

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.

A unique public-private partnership, Berlin Partner for Business and Technology collaborates with the Berlin State Senate and over 200 companies dedicated to promoting their city. Berlin Partner is also responsible for marketing the German capital to the world, for example with the successful “be Berlin” campaign.

Supporting Organisations

BioPharm Insight
An Infinata intelligence solution

BioPharm Insight

www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive and customizable online interface, BioPharm Insight provides an unrivalled capability to segment and analyse the industry with detailed and searchable profiles.

Supporting Organisations

Biotech Gate

www.biotechgate.com

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.

Supporting Organisations

Citigate Dewe Rogerson

Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world's leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo – NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m).

Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A).

Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Supporting Organisations

Edison

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison's largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

Supporting Organisations

FREEMIND
Non-Dilutive Funding Specialists

FreeMind

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.FreeMind's knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Supporting Organisations

Going Public

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate

Supporting Organisations

HollandBIO

www.hollandbio.nl

HollandBIO is the Dutch biotech industry association connecting, supporting, and representing approximately 120 medical, agro-food, and industrial biotech companies. Our members are active in all phases of research and development and include all company sizes: start-ups, SMEs, listed companies and multinationals. Together, we strive for a society taking full advantage of the power of biotechnology in health, food and sustainability.

Supporting Organisations

INSTINCTIF PARTNERS

Instinctif Partners

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

Supporting Organisations

LaBiotech.eu

http://labiotech.eu

LaBiotech.eu is the free and extensive European biotechnology news website. Launched in September 2014, this young and dynamic media is the best way for you to keep a watch on the business and innovations of biotechnologies. Thanks to our partnerships with major european biotech events we are also your dedicated website for event summaries and agenda. You can also subscribe to our weekly newsletter to receive the latest news.

Supporting Organisations

Life Science Austria

www.lifescienceaustria.at

Life Science Austria, LISA, is the first point of contact for scientific collaboration, setting up an operation, or funding and sponsoring of projects and businesses in Austria regarding Life Sciences. Austria Wirtschaftsservice runs this focal program on behalf of the Federal Ministry of Science, Research and Economy. Cooperating partners are ecoplus (Lower Austria), Human Technology Styria (Styria), LISAvienna (Vienna), MedTech-Cluster (Upper Austria) and the Tyrolean Future Foundation/Cluster Life Sciences Tirol.

Supporting Organisations

One Nucleus

www.onenucleus.com

About One Nucleus

One Nucleus is an international membership organisation for life science and healthcare companies. We are based in Cambridge with the majority of our members across the Cambridge/London corridor – at the heart of Europe's largest life science and healthcare cluster.

Organisation History

Established in 1997, One Nucleus is a not-for-profit membership organisation located in Cambridge. We have over 470 organisations as members, including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus' mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means them being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people's lives around the world. For our business and professional services members, it means them delivering exceptional services that significantly enhance the business performance of their clients.

Supporting Organisations

PharmaVentures
Experts in deals and alliances

PharmaVentures

www.pharmaventures.com

PharmaVentures is a premier transaction advisory firm; a leader in partnering, M&A deals and strategic alliances. For over 23 years PharmaVentures has provided specialist knowledge, insight and strategic support, completing more than 700 assignments across 38 countries. These include several recent sell side and buy side deals. Our services include: M&A, Valuation, Licensing, Expert Testimony, Strategic Advice and more.

Supporting Organisations

Swiss Biotech

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland's profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.Swiss Biotechs' mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Supporting Organisations

Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Organisers

SACHS ASSOCIATES

Sachs Associates

www.sachsforum.com

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia Exposure
Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company's conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients.

Eminent Speakers
Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior political and economic personalities as speakers at its events.

Sponsorship and Marketing Opportunities for forthcoming events
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.

Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:

- Conference Sponsor – including workshops and social events
- Exhibition stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please call Silvia Kar on +44 203 463 4890.

We look forward to seeing you at:

2nd Annual

Immuno-Oncology: BD&L and Investment Forum

3rd June 2016 • Hyatt Chicago Magnificent Mile • USA

4th Annual

MedTech & Digital Health Forum

For Technology & Healthcare Innovation

26th September 2016 • Congress Center Basel • Switzerland

16th Annual

Biotech in Europe Forum

For Global Partnering & Investment

27th – 28th September 2016 • Congress Center Basel • Switzerland

For more information about all our events please visit **www.sachsforum.com**

SACHS ASSOCIATES

27 Belsize Lane
London NW3 5AS

Tel: +44 (0)203 463 4890
Fax: +44 (0)207 691 7919

Follow us on Twitter – @SachsAssociates

www.sachsforum.com